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Abstract 
 
     The aim of this work was to assess the suitability of vibrational spectroscopic 
techniques (Raman, FT-IR and FT-NIR spectroscopy) as a means for the solid-state 
structural analysis of pharmaceuticals. Budesonide, fluticasone propionate, salbutamol 
hemisulfate, terbutaline hemisulfate, ipratropium bromide, polymorphic forms of 
salmeterol xinafoate and two polymorphic forms of sulfathiazole were selected since 
they are used in the management of certain respiratory disorders and from different 
chemical and pharmacological entities along with some pharmaceutical excipients. 
Conventional visual examination is not sufficient to identify and differentiate spectra 
between different pharmaceuticals. To confirm the assignment of key molecular 
vibrational band signatures, quantum chemical calculations of the vibrational spectra 
were employed for better understanding of the first five selected drugs. The non-
destructive nature of the vibrational spectroscopic techniques and the success of 
quantum chemical calculations demonstrated in this work have indeed offered a new 
dimension for the rapid identification and characterisation of pharmaceuticals and 
essentially warrant further research.  
 
     The application of simultaneous in situ Raman spectroscopy and differential 
scanning calorimetry for the preliminary investigation of the polymorphic 
transformation of salmeterol xinafoate polymorphs and two polymorphic forms of 
sulfathiazole has also been explored in this work leading to the development of a new 
method for the solid-state estimation of the transition temperature of 
entantiotropically related pharmaceutical polymorphs which represents the first 
analytical record of the use of this approach for pharmaceutical polymorphs. 
 
Keywords: Raman; IR; NIR; DSC; in situ; quantum chemical calculations;   
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1.1. Introduction 
     Vibrational Raman and IR spectroscopic techniques have been rapidly revolutionised 
and widely applied in various disciplines, encompassing the chemical, physical, 
pharmaceutical, medical and natural sciences. The unique chemical fingerprinting 
capability of these techniques has led to extensive opportunity for fundamental 
applications in the pharmaceutical sciences. Both techniques are complementary, and 
play a significant role in providing specific information on the identification and 
characterisation of materials, as well as providing fundamental molecular spectroscopic 
information in the structural elucidation of unknown compounds. 
     The vibrational spectra of pharmaceutical materials are often complex and 
assignment of the multiple vibrational modes to definitive spectral features has hitherto 
been difficult to achieve with any confidence. However, with the emergence of quantum 
chemical calculations, Raman and infrared spectroscopy have been explored further for 
the identification and discrimination of the vibrational spectra of pharmaceutical 
compounds. This approach is crucial as it provides a basis for the applications of both 
quantum chemical calculations and vibrational spectroscopy in pharmaceutical analysis. 
     Several key research papers have successfully demonstrated the potential of Raman 
spectroscopy for studies in polymorphism, particularly in investigating the 
transformation of pharmaceuticals in various environments (Hu et al. 2007; Amado et 
al. 2007b; Aaltonen et al. 2007a and Anquetil et al. 2003). Thermal analysis methods 
provide information about the bulk temperature-dependent physical properties of 
materials. However, it is not always possible to gain information about the molecular 
chemical changes associated with changes in temperature by using standard thermal 
analysis equipment alone. The combination of thermal analysis with Raman 
spectroscopy presents a complete picture of the chemical and physical changes 
 1
occurring in thermal processes. This thesis also explores the application of in situ 
Raman spectroscopy and differential scanning calorimetry in the preliminary 
investigation of the polymorphic transformations of pharmaceutical systems.  
 
1.2. Aims 
The aims of this research project were: 
1- To assess the suitability of vibrational spectroscopy (Raman, FT-IR and FT-NIR) as 
a means of identifying and differentiating several drugs used in the management of 
respiratory disorders which include budesonide, fluticasone propionate, salbutamol 
hemisulfate, terbutaline hemisulfate, ipratropium bromide, the polymorphic forms of 
salmeterol xinafoate and two polymorphic forms of sulfathiazole. Differentiation of 
these materials is of great importance to the quality control analysis of pharmaceutical 
processes. 
2- To assess the potential application of quantum chemical calculations to provide a 
better understanding of the vibrational spectra of selected drugs and deduce a molecular 
approach for identification of key molecular vibrational band signatures. 
3- To investigate the dependence of the Raman spectra of salmeterol xinafoate 
polymorphs with laser excitation wavelengths ranging from the visible to the near 
infrared regions of the electromagnetic spectrum. 
4- To investigate the use of near-infrared spectroscopy for the non-invasive in situ 
identification of several pharmaceutical excipients which include potassium sorbate, 
sodium starch glycollate, calcium ascorbate, calcium carbonate, candelilla wax, 
maltosextrin and monohydrated and anhydrous lactose inside USP vials. 
5- To develop simultaneous in situ Raman spectroscopy and differential scanning 
calorimetry and apply the instrumentation to investigations of the polymorphic 
 2
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transformation of salmeterol xinafoate polymorphs and two polymorphic forms of 
sulfathiazole. 
 
1.3. Thesis structure 
     This thesis has been divided into eight chapters. This chapter (Chapter One) provides 
the context and aims of this project. Chapter Two introduces Raman and infrared 
spectroscopy and gives a brief introduction to the quantum chemical techniques used in 
this work. Chapter Three gives a comprehensive review on the pharmaceutical 
applications of Raman spectroscopy. Chapters Four to Seven are divided into two parts. 
Part I (Chapters Four to Six) presents a comprehensive study of the vibrational 
spectroscopy for the characterisation of selected drugs that are used in the management 
of respiratory disorders leading to full assignment of the spectra supported by quantum 
chemical calculations. Part I also includes the dependence of the Raman spectra of 
salmeterol xinafoate polymorphs upon laser excitation wavelength and an evaluation  of 
near-infrared spectroscopy for the non-invasive in situ identification of several 
pharmaceutical excipients. Part II (Chapter Seven) concerns the development of 
simultaneous in situ Raman spectroscopy and differential scanning calorimetry for the 
preliminary investigation of the polymorphic transformation of salmeterol xinafoate 
polymorphs and two polymorphic forms of sulfathiazole. Chapter eight provides the 
conclusions of this research and recommendations for further work.  
 
2.1. Vibrational spectroscopy 
     Raman and IR spectroscopy are techniques that yield complementary information in 
order to characterise and identify the molecular structure of materials. These vibrational 
spectroscopic techniques, however, are governed by different selection rules (Grasselli 
et al., 1981). An overview of the origin of both the Raman effect and infrared absorption 
will now be provided. 
 
2.2. Molecular vibrations  
     The position of a molecule in three-dimensional space can be described using x, y 
and z co-ordinates for each atom relating to the three mutually orthogonal independent 
axes in space. Thus, each molecule containing N atoms has 3N degrees of freedom. 
Molecular motions consist of combinations of translations, rotations and vibrations; 
three of these fundamentals are pure translations that involve moving atoms 
simultaneously in the same direction, hence there is no change in the shape of the 
molecule and its bond lengths. Linear molecules have two rotational fundamental 
motions around the three orthogonal axes of the molecules (again, not altering any 
distances between the atoms) and non-linear molecules have three. Thus, each non-
linear molecule has 3N-6 vibrational degrees of freedom and each linear molecule has 
3N-5, giving rise to the fundamental vibrations of the molecule (Hendra et al., 1991). 
The number of stretching modes is equal to the number of bonds in the molecule; since 
acyclic molecules have N-1 bonds, there will be N-1 bond stretching modes and the 
remaining vibrations are bending modes. The stretching and bending modes comprise 
the vibrational spectrum of the molecule and for which all atoms move in-phase and 
with the same vibrational frequency. The numbers of fundamental bands observed are 
dependent upon the degeneracy of the vibrations and their positions in the spectrum are 
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governed by the vibrational frequencies. Overtone and combination vibrations may 
produce bands which are less intense than the fundamental vibrations in the Raman and 
IR spectra (Jee, 2004).  
 
2.3. The Raman effect 
     When a sample is illuminated with a monochromatic beam of radiation (typically, 
from a laser), the radiation is transmitted, absorbed or scattered by the molecules (Tu, 
1982). The scattered radiation contains photons with the same frequency as the incident 
radiation. This form of scattering is referred to as elastic scattering or Rayleigh 
scattering. A very small proportion of photons (approximately one in 108 to 1010) are 
scattered inelastically with frequencies different to that of the incident radiation; the 
phenomenon of inelastic collisions between incident photons and the molecule is known 
as the Raman effect (Raman and Krishnan, 1928) and the wavelength-shifted frequency 
is called Raman scattering. The differences in frequencies between the incident and the 
inelastic scattered radiation correspond to the frequency of the molecular vibrations 
present in the molecules of the sample.  
     When electromagnetic radiation is incident on the system of atoms in a molecule, the 
interaction distorts the electron cloud of the molecule and induces an electric dipole 
moment. This induced dipole then radiates scattered light, with or without exchanging 
energy with vibrations in the molecule. 
     The magnitude of the induced polarization, P is proportional to the intensity of the 
electric field, E, of the electromagnetic wave and to the molecular polarizability, α, as 
given by: 
P = αE 
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     The molecular polarizability is related to properties of a molecule which depend on 
its structure, the nuclear positions in the molecule and on the nature and direction of its 
chemical bonds (Hendra et al., 1991). The time-dependent amplitude of the electric field 
varies according to the equation: 
E = E0cos2πυ0t 
     where E0 is the maximum electric field amplitude, υ0 is the frequency and t is the 
time. Hence; 
P = α E0cos2πυ0t 
     In the case of Rayleigh scattering, the induced dipole emits electromagnetic radiation 
at the same frequency as the incident radiation (i.e. υ0). However, if a molecular 
vibration causes a change in the molecular polarizability, the induced dipole and the 
magnitude of the emitted radiation will also change. The change is described by the 
polarizability derivative, δα/δq. According to the Raman selection rule, to be Raman-
active, only vibrations that change the polarizability will yield Raman scattering 
(Pelletier, 1999), Hence 
           δα    
 δq 
≠  0 
   
     where q is the normal-co-ordinate (bond length or bond angle) describing the 
motions of the atoms during a normal vibration. The Raman band intensity is a function 
of the magnitude of the change in the polarizability (Schrader, 1995). 
 
     The polariazability of electrons in the molecule will be modulated by the molecular 
vibration (υm) so that (McCreery, 2000), 
α = α0 + sin υm 
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2.3.1. Quantum theory 
     If a molecule interacts with an electromagnetic field, a transfer of energy from the 
field to the molecule can occur. According to quantum theory, molecular motion can 
only have certain discrete energy states, for which a change in state is accompanied by 
the gain or loss of one or more quanta of energy (Turrell, 1996). A quantum of energy is 
described by Planck’s equation, ∆E = hυ, where h is Planck’s constant and υ is the 
classical frequency of the molecular motion. 
     The interaction of a molecule with electromagnetic radiation can be analyzed in 
terms of an energy mechanism. A vibrating molecule will be instantaneously polarized 
as a photon of incident radiation collides with it and its energy will be raised by hυ0 (the 
energy being immediately lost again by scattering). The scattered radiation consists of 
two types; the Rayleigh scattering is strong and has the same frequency as the incident 
beam, υ0, with no net energy loss and the other type of scattering is called Raman 
scattering and very weak. 
     Molecules in the ground state give rise to Raman scattering at frequencies υ0-υvib, 
where υvib is the frequency at which the molecule vibrates, given that a change in 
polarizability occurs during the vibration. If the molecule happens to be in an excited 
vibrational state when an incident photon is irradiated, the photon may gain energy 
when scattered, giving a Raman effect at frequencies υ0+υvib. These are known as the 
Stokes and anti-Stokes Raman scattering, respectively (Pelletier, 1999). The differences 
between the incident frequency of radiation and inelastic scattered frequencies 
correspond to the frequency of molecular vibrations present in the molecules of the 
sample. The excited states are not real and are described as virtual. The Stokes and anti-
Stokes Raman peaks are symmetrically positioned about the Rayleigh peak but their 
 7
intensities are very different. The vibrational energy transitions that can occur and 
which give rise to fundamental modes of vibrations are presented in Figure 2.1.  
 
Figure 2.1.An energy level diagram showing transitions equivalent to Raman and 
Rayleigh scattering and IR absorption (Day, 2002). 
 
     The ratio of Stokes to anti-Stokes intensity is governed by the temperature. 
According to the Boltzmann distribution, at ambient temperature most molecules are in 
their vibrational ground state (Bugay and Smith, 2004). The anti-Stokes lines therefore 
are less intense than the Stokes line because these transitions arise from higher 
vibrational energy levels that contain fewer molecules. Hence, Stokes Raman scattering 
is generally used for the Raman spectrum. A Raman spectrum is normally represented 
as a plot of Raman scattering intensity versus wavenumber shift or Raman shift. The 
frequency of the exciting radiation is set to zero and the wavenumber of the Raman shift 
represents the shift in frequency of a photon from this point. Thus, the Raman shift is 
independent of the frequency of the incident exciting laser. 
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2.3.2. Raman intensity 
     The Raman band intensities are proportional to:  
υ4συIC 
     where υ is the frequency of the incident radiation, συ is the Raman cross section, I is 
the irradiance of the radiation (Wm-2) and C is the sample concentration. The intensity 
of Raman scattering, therefore, depends on several factors such as the laser power and 
the wavelength or frequency of the incident laser as well as the polarizability of the 
molecule (Schrader, 1995). 
 
2.4. Infrared spectroscopy 
     Infrared (IR) spectroscopy is a technique based on the absorption of the 
electromagnetic radiation in the infrared region (Figure 2.2). The IR spectrum can be 
divided into three sub-regions, namely near-IR (NIR; 12500 – 4000 cm-1), mid-IR (4000 
– 400 cm-1) and far-IR (400 – 10 cm-1). Photon energies of IR radiation are not high 
enough to excite electrons, but may excite molecular vibrations (and the associated 
molecular rotations) of covalently bonded atoms and groups. 
     At room temperature, a molecule is generally in its ground electronic state where it 
sits in its ground vibrational state. The absorption occurs when the energy of the 
incident photons exactly matches that of a vibrational energy transition in the molecule 
(Drake, 2004). The absorption of energy occurs to excite the molecule to a particular 
higher vibrational state. A change in the dipole moment of molecule during a vibration 
is also necessary to induce the absorption process, i.e. δμ/δq ≠ 0 (δμ/δq = change of the 
dipole moment μ with distortion of the normal co-ordinate q). 
     When a bond with an electric dipole moment is exposed to IR radiation, it will 
increase its amplitude of vibration. Bonds with a dipole moment that oscillate at discrete 
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resonant frequencies when exposed to IR radiation are called IR-active. If the resonant 
frequency of the bond matches the frequency of the incident radiation, interaction will 
occur leading to absorption. 
     An IR absorption spectrum of a sample is obtained by passing the IR radiation 
through the sample and the fraction of the radiation absorbed at each frequency is 
determined. The frequency at which any peak in the absorption spectrum appears 
corresponds to the frequency of a normal mode of bond vibration in the molecule 
(Banwell, 1972). The fundamental vibrational modes are most often observed in the 
mid-IR region of the spectrum (4000 – 400 cm-1). 
 
 
Figure 2.2. Electromagnetic spectrum (Lang, 1995). 
 
2.4.1. Infrared selection rules 
     An overall change in the dipole moment of the molecule must occur for it to be IR 
active. The dipole moment is determined by the magnitude of the difference of charge 
and the distance between two centres of charge. The absorption will be high if the 
dipole moment associated with the bond vibration is large (as with highly polar groups 
of atoms with different electronegativities) and vice versa. A vibration which retains the 
centre of symmetry of a non-vibrating molecule (e.g. that found in homonuclear species 
such as O2) is termed IR inactive. IR active vibrations are categorised into two types of 
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vibrations, namely bending and stretching vibrational modes, which are classified 
depending upon the change of the molecular shape during the vibration with respect to 
its centre of symmetry. A stretching mode involves a change in the bond length, 
whereas the bending modes are characterised by the change in the angle of the bond. 
     Anhamonicity of the vibrations in the IR can cause the occurrence of overtone and 
combination bands. Overtones (the excitation of a vibration to a double or higher 
frequency) and combinations that are the sum or difference of two or more fundamental 
bands are observed in the near-IR region of the spectrum (12500 – 4000 cm-1). These 
features however are less intense than the corresponding fundamental vibrational modes 
in the mid-IR region of the spectrum. 
 
2.4.2. Quantitative infrared measurements  
     The absorption of radiation can be calculated through the Beer-Lambert law (Drake, 
2004): 
A = log (I0/It) = ε.c.l 
where:  
A = Absorbance 
I0 = intensity of incident radiation 
It = intensity of radiation transmitted by the sample 
l = path length of the sample 
c = molar concentration 
ε = molar extinction coefficient/absorption coefficient 
The various vibrational modes have different tendencies to absorb with different molar 
extinction coefficients and therefore they have different intensities in the IR spectrum. 
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2.5. Raman versus IR spectroscopy 
     Both IR and Raman spectroscopic techniques are complementary rather than 
supplementary because of their different selection rules. They provide information on 
molecular structure with regard to molecular vibrations and rotations (for which 
observation is only possible in the gas phase). In IR spectroscopy, a sample is exposed 
to IR radiation which it absorbs at only specific energies (one-photon direct process). 
Raman spectroscopic excitation on the other hand is usually performed at a single 
wavelength (two-photon scattering process i.e. laser photon and Raman photon). 
Vibrational modes can be strong in the Raman and weak in the IR and vice versa. To be 
IR active, a change in the dipole moment of a molecule is required, whereas in Raman 
spectroscopy, a change in polarizability is necessary. Polar bonds such as carbonyl 
groups produce the most intense bands in an IR spectrum, whereas non-polar bonds 
such as C=C tend to be stronger in the Raman spectrum. 
     Raman spectroscopy has some distinct advantages over IR spectroscopy, mainly due 
to the fact that it is non-destructive and non-invasive which is particularly very suitable 
for pharmaceutical studies as it requires minimal or no sample preparation and hydrated 
specimens, for example, can be analysed without desiccation as normally required for 
IR spectroscopy. Water and glass are weak Raman scatterers, but they absorb in the IR 
which favours the use of Raman spectroscopy in the analysis of aqueous solutions and 
glass can be simply used as a sample container. This allows the analysis of a wide range 
of sample types (solids, liquids and gases). A Raman spectrometer can be coupled to a 
probe via an optical fibre for in situ and remote analyses.  
     Fluorescence is a major issue in Raman spectroscopy which frequently arises from 
the analyte or sample impurities. This phenomenon is associated with the absorption 
and subsequent emission (approximately 10-8s) of a photon with energy equal to the 
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difference between two electronic energy levels in the molecule. Non-radiative decay 
processes occur in the electronically excited state prior to emission. These processes 
result in a reduction of energy of the emitted photon, in which the frequency of 
fluorescence emission may coincide with that of the Raman Stokes scattering. Since 
fluorescence has a higher (x106) quantum yield than Raman scattering, the Raman 
signal can be easily swamped by a broad fluorescence background signal. Sample 
fluorescence can be reduced by a careful selection of the laser excitation wavelength 
used. 
     Attenuated total reflectance (ATR) IR spectroscopy is also a non-destructive and 
non-invasive technique but it requires contact with the sample. ATR-IR normally works 
well with specimens having flat surfaces, whereas Raman spectroscopy can be used to 
analyse samples with rough surfaces. 
     In pharmaceutical polymorphic studies, it is essential that the technique is robust and 
non-destructive to preserve the identity of the specimens. Raman spectroscopy, Fourier 
Transform ATR and near-IR (NIR) spectroscopy, therefore, were considered to be 
appropriate spectroscopic techniques for pharmaceuticals in this work.  
 
2.6. X-ray powder diffraction 
     X-rays lie in the electromagnetic spectrum between the UV and gamma radiation and 
have approximate wavelengths of 0.1-100 Å. They are generated when electrons are 
accelerated by an electric field and directed against a metal target, which slows them by 
multiple collisions. Most of the electrons are not brought to a total stop by a single 
collision and so a continuum of radiation is formed. X-rays are scattered in various 
directions by the atomic electrons in the material. 
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X-rays are reflected from crystals only when the angle between the X-ray and the planes 
in the crystal fulfil the Bragg equation (van Grieken and Markowicz, 1993) (Figure 2.3): 
nλ = 2d sin θ 
     Where d is the perpendicular spacing between the lattice planes, θ is the compliment 
of the angle of incidence of the X-ray beam, also known as Bragg angle and n is the 
order of diffraction. If n = 1, the difference is one wavelength and the diffraction is said 
to be of first order. If n = 2, the difference is two wavelengths and the diffraction is 
second order and so on (Figure 2.3).  
 
Figure 2.3.Diagram of Bragg theory of X-ray diffraction showing the Bragg angle 
θ. 
 
     There are many number of diffraction  planes possible through the crystal lattice, but 
only a limited number which give reflections within the range: 2 < θ/degrees < 180. 
Every molecular repetition will give a unique set of reflections and so generate a unique 
diffraction pattern. Therefore, any polymorph will give a distinctive X-ray powder 
pattern, making X-ray crystallography of great value for identifying and distinguishing 
polymorphs.  
 
2.7. Differential scanning calorimetry (DSC) 
     DSC is used to measure heat flow changes in materials as a function of temperature. 
As the temperature is raised, phase transformations occur which may be endothermic or 
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exothermic. The technique may be considered as complementary to TGA 
(thermogravimetric analysis, concerned with measuring the change in mass of a sample 
as it is heated, so it is a quantitative rather than a qualitative technique, determining 
weight loss profiles against temperature or time, in controlled atmospheres). Since many 
of the changes that are observed do not coincide with weight loss processes, e.g. 
crystallisation and melting. The industrial uses of DSC are extensive, particularly for 
polymers, polymorphism, degradation, sublimation and melting point characterisation. 
Experienced thermal analysts can correctly infer many changes taking place from the 
breadth, position and intensity of heat flow peaks. However, not all transitions are 
simple to interpret, and as will be mentioned later in section 2.8.5, complementary 
molecular information about the heat-induced transitions taking place in a sample 
should be available through the coupling of DSC with FT-IR and Raman spectroscopy.    
 
2.8. Instrumentation 
2.8.1. Raman spectrometers 
     In general, there are two types of Raman spectrometers, dispersive and non-
dispersive. Both differ in the way in which the Raman scattered radiation is analysed. A 
non-dispersive instrument analyses the Raman scattered radiation in an interferometer, 
where the beam is split into two components creating a path difference between the 
source and the signal beam, which interfere when recombined to create an 
interferogram. The interferogram is then subjected to a Fourier-transform operation to 
produce the Raman spectrum. In a dispersive instrument, the Raman scattered radiation 
is spatially separated and dispersed into its constituent wavelengths before reaching the 
detector. Both types of Raman spectrometers were used during the course of this project 
and these are discussed in the following sections.  
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2.8.1.1. Fourier-Transform (FT) Raman spectrometer  
     A Bruker Fourier-Transform IFS66 optical bench instrument with an FRA 106 
Raman module accessory was used in this work (Figures 2.4a and 2.4b). The Nd3+/YAG 
(neodymium-doped yttrium-aluminium-garnet) solid-state continuous wave laser 
produced a NIR source of excitation wavelength at 1064 nm. At this wavelength, the 
laser can produce the maximum output of 1 W. The components drawn in broken lines 
are used only for FT-IR spectroscopy and are not discussed. Spectra were obtained from 
macroscopic samples placed in the sample holder; an open aluminium sample cup was 
used for powdered and small-sized samples. The spectral resolution and number of 
scans required were selected using the instrument software package (Bruker OPUS). To 
ensure the optimal performance is achieved, the alignment and frequency scale of the 
instrument were checked before the experiment is undertaken by obtaining a spectrum 
of sulphur and also routinely corrected using white light produced by a tungsten lamp. 
Raman spectra were normally recorded in the range 3200 – 50 cm-1 
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Figure 2.4a. Optical diagram of the Bruker IFS66 spectrometer optical bench with 
FRA 106 Raman module accessory (Brody, 2000) (Modified from Bruker). 
 
 
 
Figure 2.4b. Diagram of the fore-optics-section A-B on Figure 2.4a (Brody, 2000), 
(Modified from Bruker). 
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2.8.1.1.1. Standard operation 
     The main components of a conventional FT-Raman instrument comprise the laser, 
collection optics and filters, interferometer and detection system (Chase and Rabolt, 
1994). The laser provides a beam of intense, monochromatic radiant energy, which is 
polarized and coherent (in-phase). In the macroscopic mode, the laser passes parallel to 
the fore- optics through the base of the FRA 106 bench. The fore-optics contain prisms 
which turn the laser beam through 180o (known as ‘backscattered’ collection), but since 
the system is flexible, the collection of 90o scattering from the sample is also 
permissible. The laser provides a focussed spot diameter of approximately 100 μm at 
the sample. The collected scattered radiation from the sample then passes through a 
filter module which removes the unshifted Rayleigh scattered radiation (i.e. that at 1064 
nm). The collection optics and filter are optimized to be optically efficient, as this will 
control the amount of scattered radiation that will reach the detector. 
     The filtered radiation passes to an interferometer (Michelson or modified Michelson) 
where it is modulated. The interferometer splits the radiation beam into paths, which 
travel different distances. When recombined, the two beams interfere, producing either a 
constructive or destructive interference pattern. The modulated radiation leaving the 
interferometer is reflected back into the FRA 106 Raman module and to the FT-Raman 
detector (a liquid-nitrogen cooled extended range germanium detector), which measures 
variations in the intensity of the emergent beam as a function of the difference in path 
lengths. The interferogram, which comprises a number of sinusoidal signals added 
together, is converted into a Raman spectrum of signal intensity against wavenumber 
shift by the Fourier-Transform operation. 
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2.8.1.2. Dispersive Raman spectrometers 
     Two types of dispersive Raman spectrometers were used in this research; a 
Renishaw In Via confocal Raman microscope and a Renishaw portable Raman analyzer 
(RX210). 
 
2.8.1.2.1. Renishaw In Via confocal Raman microscope 
     A Renishaw In Via confocal Raman microscope has a variety of laser excitation 
wavelengths, ranging from the UV to the NIR region of the electromagnetic spectrum, 
depending upon the installed grating and filters. The excitation sources used during the 
course of this research were an argon-ion (Ar+) gas laser (488 and 514 nm), a helium-
neon (He-Ne) gas laser (633 nm) and a gallium-aluminium-arsenide (GaAlAs) 
stabilised diode laser (785 nm). The alignment and frequency scale calibration of the 
instrument were checked before the experiment as a routine set-up by obtaining a 
spectrum of a silicon wafer (reference band at 520 cm-1 ± 1 cm-1). Samples on glass or 
steel slides were placed on the microscope stage and the area of interest was focused 
with the objective lens. Raman spectra were acquired at 2 cm-1 spectral resolution and 
recorded normally in the range 3200 – 100 cm-1. The required parameters such as 
spectral frequency range, exposure time of the charged coupled device (CCD) detector 
and number of spectra to be accumulated were selected using instrument software 
(Renishaw WiRETM). This software automatically switches the spectrometer to the 
required excitation wavelength. The filter wheel is rotated if saturation of the CCD 
detector occurred to reduce the laser intensity at the sample. The use of a confocal 
microscope can increase the spatial resolution up to 1 μm diameter, which is beneficial 
for the analysis of a small spot within the specimen. 
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2.8.1.2.2. Charge-coupled device (CCD) detection 
      In the early 1990s the charge-coupled device (CCD) detector was created (Pelletier, 
1999). This development greatly increased the speed at which a complete Raman 
spectrum could be collected but CCD detectors are most suited for lasers with 
wavelengths of less than 1000 nm, due to the silicon being essentially transparent above 
1100 nm. The detector is made up of thousands of pixels, each of which store charge 
proportional to the number of photons that hit it. Each pixel can only take a limited 
charge so sometimes the photons overflow, creating peak shape distortion in the 
spectrum. 
 
2.8.1.2.3. Standard operation 
     A schematic diagram of the instrument is shown in Figure 2.5. Laser radiation passes 
through a filter wheel (1), which can be used to minimise the incident laser power to 
50%, 25%, 10% or 1%. The beam is then spectrally (2) and spatially (3) filtered. Once 
filtered, the laser radiation is directed into the Olympus metallurgical microscope using 
mirrors (4 and 5) and two holographic notch filters (both labelled 6), as a beam splitter. 
The laser radiation is focused onto the sample through the objective lens (20x and 50x 
were used in this project, giving a spot diameter of approximately 3 and 2 μm, 
respectively, at the sample). The scattered radiation is collected by the objective lens 
(180o backscattered geometry) and the intense Rayleigh scattered radiation is rejected 
by two holographic notch filters (6) to prevent it from entering the spectrograph. 
     The Raman scattered radiation is analysed using a spectrograph, which contains a 
holographic grating (typically 1200 or 2400 grooves/mm). This scattered radiation is 
focused through the spectrograph entrance slit (7) and passed via a reflecting prism (8) 
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to a diffraction grating (9) which disperses the radiation into its constituent wavelengths 
before reflecting them back to the prism (8) and then onto the CCD detector (10). 
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Figure 2.5. A schematic diagram of Renishaw In Via confocal Raman microscope 
(Source: Renishaw Plc.) 
 
2.8.1.2.4. Portable Raman analyser 
     A Renishaw portable Raman Analyser (RX210) (Figure 2.6) gives a rapid, non-
destructive analysis by Raman spectroscopy in a compact portable unit. This instrument 
is also known as the prototype RIAS or ‘Raman In A Suitcase’. Because of its 
portability, versatility and real-time analysing capability it can be used in conjunction 
with other analytical instruments for pharmaceutical applications. The Renishaw RX210 
spectrometer operates at 785 nm in the NIR region, produced by a diode laser with a 
spectrograph coupled to a thermoelectrically cooled CCD detector and holographic 
grating (Figure 2.6). An attached fibre-optic probe was equipped with an x20 objective 
lens. The diffraction grating (1000 lines/mm) limits the spectral range to ~2100-100  
cm-1 with a spectral resolution of 10 cm-1. The maximum output power of the diode 
laser at the source is 500 mW and ~50 mW at the sample. Daily wavenumber 
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calibration is required and is achieved by recording the Raman spectrum of silicon (1 
accumulation, 10 s) for static mode. If necessary, an offset correction is performed to 
ensure that the position of the silicon band is 520.5 ± 0.10 cm-1. Spectra were recorded 
with a single scan, 10s exposure. To avoid the interference from white light (i.e. room 
light), the system was covered with a shroud. Spectra were not corrected for the 
instrument response. The spectrometer was controlled by a portable PC with 
commercial instrument control software (Renishaw WiRE 2 Service Pack 8). 
 
 
Figure 2.6. A schematic diagram of Renishaw portable Raman analyser (RX210) 
(Source: Renishaw Plc.) 
 
2.8.1.3. Dispersive versus non-dispersive Raman spectrometers 
     The use of either a dispersive or non-dispersive Raman spectrometer is not just a 
matter of choice since both instruments depend on many factors such as the nature of 
the sample to be analysed, e.g. fluorescent or non- fluorescent and the time scale for the 
analysis. Both systems fundamentally give the same spectrum from a given sample but 
may differ in the quality of the spectra obtained. The careful selection of the instrument 
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type which can give optimal performance therefore, is necessary prior to performing an 
experiment in order to obtain a high quality Raman spectrum.  
      A non-dispersive FT-Raman spectrometer normally uses 1064 nm laser excitation, 
whereas a dispersive Raman spectrometer uses multiple laser excitation wavelengths 
ranging from the UV to NIR. With 1064 nm excitation, the energy of the radiation is 
lower than that of electronic transitions from the ground state in most molecules; 
therefore the electronic excited state is rarely populated. In contrast, at the lower 
wavelengths of excitation used in dispersive instruments, the high energy of 
photon/radiation involved can initiate fluorescence, which is more intense than the 
Raman signal, as well as resulting in the possibility of sample photodegradation.  
Sample heating in the FT-Raman system may also interfere with the Raman spectrum 
but this normally occurs when higher laser power levels are used. 
     Higher Raman spectral intensities can be collected by decreasing the wavelength 
(increasing the frequency) since the band intensity is directly proportional to the fourth 
power of the frequency of the incident radiation.  Therefore, the more intense spectrum, 
i.e. larger Raman scattering, is generally obtained within shorter acquisition times using 
the dispersive Raman spectrometer. It also offers higher sensitivity with the use of low 
noise CCD detectors in contrast to the relatively high noise level and low sensitivity of 
the germanium detector. The scattered radiation is dispersed by the diffraction grating 
across an array of pixels on the CCD detector and the intensities of radiation incident at 
all frequencies on the CCD is analysed simultaneously (multichannel advantage). 
     In non-dispersive spectrometers, with no slits, fewer optical elements and the use of 
the interferometer, the scattered radiation is not spatially separated (multiplex/Fellgett 
advantage) as it is in dispersive instruments, in which a spectrograph with a diffraction 
grating separates the radiation into individual wavelengths. This allows a high 
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throughput of scattered radiation to the detector (known as the Jacquinot advantage) 
(Hendra et al., 1991). The simultaneous measurement offered over the whole spectral 
range results in an improved signal-to-noise ratio. The FT-system also offers a constant 
spectral resolution over the whole spectral range covered. 
     With dispersive instruments, frequency precision and accuracy depend on the 
calibration being effected with external standards and the ability of the 
electromechanical mechanisms to uniformly move gratings and slits during and between 
scans, where, during this process, displacement error can sometimes occur due to 
mechanical wear, resulting in band shape distortion and low signal-to-noise ratios. In 
contrast, the interferometer has an internal frequency standard provided. As a result, the 
wavenumber calibration of the interferometer is more accurate as well as having longer 
term stability than that of the dispersive instruments. This is known as the Connes 
advantage (Hendra et al., 1991). 
     Since, both types of spectrometers were available during the course of this research, 
a range of pharmaceutical samples were analysed using several instruments at various 
excitation wavelengths. 
 
2.8.2. Infrared spectroscopy 
     Two types of IR instruments were used in this research, namely a Scimitar series 
Digilab UMA-400 FT-IR spectrometer and Bruker Optics MPATM FT-NIR 
spectrometer. 
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2.8.2.1. Scimitar series Digilab UMA-400 FT-IR spectrometer 
      The Varian Scimitar series FT-mid-IR spectrometer’s components comprise the 
radiation source, interferometer and detector. The interferometer (Michelson) consists 
of three active components, a moving mirror, a fixed mirror and a beam splitter. 
Radiation from the broadband IR source is directed into the interferometer, and imaged 
on the beam splitter. At the beam splitter, half the IR beam is transmitted to the fixed 
mirror and the remaining half is reflected to the moving mirror. After the separated 
beams are reflected from the two mirrors, they are recombined at the beam splitter. Due 
to changes in the relative position of the moving mirror to the fixed mirror, an 
interference pattern is generated. The resulting beam then passes through the sample 
and is focused on the Mercury Cadmium Telluride (MCT) detector. 
     When the mirror is moved at constant velocity, the intensity of radiation reaching the 
detector varies in a sinusoidal manner to produce the interferogram. The interferogram 
is the record of the interference signal. If the sample happens to absorb at this 
frequency, the amplitude of the sinusoidal wave is reduced by an amount proportional 
to the amount of sample in the beam. The interferogram contains information over the 
entire IR region to which the detector is responsive. Fourier-transformation converts the 
interferogram into the final IR spectrum. 
     For attenuated total reflectance (ATR) measurements, the Varian 400 UMA 
microscope is attached to the spectrometer and Specac Siver GateTM single reflection 
germanium crystal ATR is used with the depth of penetration of 0.7 μm. ATR technique 
relies on total internal reflection which sample is brought into direct contact with the 
crystal (known as internal reflection element, IRE), which has a higher refractive index 
than that of the sample. When the angle of incidence of the light from the IRE to the 
sample exceeds the critical angle, total internal reflection takes place, allowing the light 
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to penetrate slightly into the sample, producing an absorbance-like spectrum. A 
simplified optical layout of a typical ATR-FTIR is represented in Figure 2.7. In this 
work, both transmission and ATR techniques were used and this system was controlled 
by the instrument software (Digilab Win-IR Pro 3.4). The software was set to remove 
the absorption peak of CO2 and a background spectrum was collected prior to the 
experiments being conducted. Spectra were recorded in the range 4000 – 400 cm-1. 
 
Figure 2.7. A simplified optical layout of a typical ATR-FTIR spectroscopy 
(modified from (Sherman Hsu, 1997)). 
 
2.8.2.2. Bruker Optics MPATM FT-NIR spectrometer 
     A Bruker Optics MPA (Figure 2.8) is a multi-purpose analyser, combining flexibility 
and the power of FT-NIR spectroscopy. The spectrometer allows both transmission and 
diffuse reflectance measurements to be carried out. It comprises filter, grating and 
interferometer, which is equipped with gold-coated optics and an indium gallium 
arsenide (InGaAs) detector. A thirty-position sample wheel can be can be used for 
automated sampling and an optical fibre probe is also available for remote analysis. For 
instrument calibration, the background spectrum was routinely collected before the 
experiment was undertaken. The spectral resolution and number of scans required were 
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optimized using the instrument software package (Bruker OPUS). In this work, samples 
were inside USP vials, placed on the sample stage and analysed in diffuse reflectance 
mode. Spectra were recorded in the range 12500 – 4000 cm-1 (2500 – 800 nm). 
 
 
 
Figure 2.8. Bruker optics MPATM FT-NIR spectrometer (Source: The Bruker 
Optics Inc.) 
 
2.8.3. X-ray powder diffractometer 
     Powder X-ray diffraction data were recorded with a Bruker D8 diffractometer 
(Figure 2.9) with Cu-Kα1,2 radiation (1.5418 Å) and a secondary curved graphite 
monochromator. The X-ray tube was operated at 40 kV and 30 mA. Samples were 
scanned in a vertical Bragg-Brentano (θ/2θ) geometry (flat reflection mode) from 5-40° 
(2θ) using a 0.005° step width and a 1.5 s count time at each step. The receiving slit was 
1°and the scattering slit was 0.2°. Data were analysed with Bruker AXS Topas 2.1 
software including a correction for axial divergence. Background coefficients, cell 
parameters, sample displacement error and phase fractions were optimised parameters. 
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 Figure 2.9. Schematic diagram of a typical X-ray powder diffractometer. 
 
2.8.4. Differential scanning calorimeter 
     DSC profiles were generated in the range of 50 to 220°C using a TA Instrument, 
DSC Q2000 apparatus operating in the PCA mode with an RSC90 cooling unit. 
Temperature calibration was performed using an indium metal standard at the respective 
heating rate. Accurately weighed samples (1.5 – 2.5 mg) were placed in Tzero 
aluminium pans using a similar empty pan as a reference. A scanning speed of 10 °C 
min.-1 was employed. 
 
2.8.5. The simultaneous in situ Raman –DSC set up 
     In this research work, an assembly of the fibre-optic coupled portable Raman 
spectrometer and DSC instrument was used (Figure 2.10) for the simultaneous in situ 
investigation of the solid-state polymorphic transformation of salmeterol xinafoate and 
sulfathiazole polymorphs. 
     For establishing thermal treatments, 1.5 – 2.5 mg of the samples was placed in Tzero 
aluminium pans. The sample and reference pans were run in an open configuration 
without the use of lids and the cell of the instrument was covered with specially 
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engineered lids and a quartz window to allow the acquisition of the Raman signals 
simultaneously. 
     Following thermal preparation, Raman spectra were collected with samples held 
isothermally for 1 minute at the temperatures of interest. DSC melting curves were run 
simultaneously with Raman spectral scanning. The probe laser radiation could have a 
heating effect on the sample but the emerging lower power of 25 mW laser beams from 
the fibre-optic probe is divergent, giving a greatly reduced power density spread over 
the sample surface. Raman spectra collected during the temperature-transformation 
experiments showed changes coincident with changes in DSC heating curves, 
confirming that any heating effect arises from the bulk of the sample and not from just 
the surface layer. 
 
 
 
Figure 2.10. An assembly of the fibre-optic coupled portable Raman and DSC. 
 
2.9. Spectral conversion and manipulation  
     Several spectral manipulation methods were employed to the vibrational spectra in 
this work. Spectral manipulation refers to mathematical transformation of the original 
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spectra by using specific software. All vibrational spectra were exported to the 
Galactic*.SPC format using GRAMS AI (Galactic Industries, Salem, NH, Version 8.0). 
Several techniques of spectral manipulation were used; the principal ones being baseline 
correction, smoothing, deconvolution and integration of peak areas which have been 
done using GRAMS AI package. 
 
2.9.1. Baseline correction 
     Background in vibrational spectra is common and arises from either luminescence 
processes (fluorescence), non-laser-induced emissive processes (room lights) or Raman 
scattering from optics or solvents (Shaver, 2001). The background can be removed by 
employing baseline correction, i.e. by selecting multiple points through which a straight 
line or curve is drawn. The resulting curve is then subtracted from the original 
spectrum. 
 
2.9.2. Smoothing 
     ‘Noise’ in a spectrum can be diminished by a smoothing process. After a spectrum is 
smoothed, it becomes similar to the result of an experiment carried out at a lower 
spectral resolution. A smoothing function is basically a convolution between the 
spectrum and a vector whose points are determined by the degree of smoothing applied. 
The Savitzky-Golay smoothing algorithm was used in this research with seven 
smoothing points and a second order polynomial. The algorithm is based on performing 
a least squares linear regression fit of a polynomial around each point in the spectrum to 
smooth the data. 
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2.9.3. Deconvolution 
     Deconvolution is the process of compensating for the intrinsic line widths of bands 
in order to resolve overlapping bands (Kauppinen et al., 1981).This technique yields 
spectra that have much narrower bands and is able to distinguish closely spaced 
features. The instrumental resolution is not increased, but the ability to differentiate 
spectral features can be significantly improved. 
 
2.9.4. Integration of peak areas  
     The band area integration is performed using the trapezoidal rules. The area under 
the peak is separated into trapezoids; the ends are made equal by the use of baseline 
correction. 
 
2.10. Computational chemistry 
     Computational chemistry encompasses not only quantum mechanics, but also 
molecular mechanics, minimisation, simulations, conformational analysis and other 
computer-based methods for understanding and predicting the behaviour of molecular 
systems (Leach, 2001). In this work, we are interested in molecular properties such as 
vibrational spectra so we will focus on the use of quantum chemical calculations 
applicable to these types of problems. 
     Hartree-Fock (HF) methods increase the accuracy of prediction for vibrational 
spectra but scale as a function of the number of electrons in the system and become 
unwieldy for large systems (Young, 2001). Density functional theory (DFT) 
calculations improve on the accuracy of HF methods but are similarly unwieldy for 
many-atom (>100 atoms) systems. 
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     Fundamentally, the calculations try to determine the energetics of the molecular 
conformations. HF is an ab initio method that accomplishes this by getting as close as 
possible to a solution of the Schrödinger equation for the molecular system of interest. 
The Schrödinger equation is given as: 
ĤΨ = EΨ 
     This equation states that the energy of the system (E) is derived from the operation 
of the Hamiltonian operator (Ĥ) on the wave function (Ψ), a function of the nuclei and 
electrons in the system. An advantage of the quantum methods is that they provide 
insight into electronic structure in the sense of electron distributions; these are often 
very important in terms of reactivity of the system of interest. The output of the 
calculations describes the electronic structure in terms of molecular orbitals. The 
orbitals are constructed from mathematical functions, called basis functions, which 
when grouped for the purposes of the calculation are called a basis set. The more 
functions present in the basis set the better the representation of the orbitals. However, 
the greater the number of functions in the calculation, the greater the resources required 
to accomplish the output. In fact, calculations scale as the number of basis functions to 
the fourth power – thus the more basis functions employed, the more resources the 
calculation requires (Jensen, 2007). The Hamiltonian operator (Ĥ) yields the energy by 
considering the energy in a molecule to be made up of a series of interactions: 
Ĥ = - Kinetic energy of electron 
       - Potential energy between electrons and nuclei 
       + Potential energy between electrons 
       + Potential energy between nuclei 
     The attractive forces are negative and the repulsive forces are positive in this 
equation. The HF method, however, has an intrinsic weakness in its approach. This lies 
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in the way in which the potential energy between electrons (a repulsive force) is 
determined. HF methods use the central field approximation, which takes an advantage 
for the electron-electron repulsion and uses that value in Ĥ and does not determine the 
specific electron-electron interactions. This is clearly not physically realistic. The 
situation where the electrons are far from each other should be more probable as the 
electron-electron repulsion is less; the consideration of the explicit interactions between 
electrons is called electron – electron correlation. The absence of this correlation means 
that HF methods always carry an intrinsic error.  
     A more practical approach to improving accuracy of calculations for the medium-to-
large systems is density functional theory (DFT) (Jensen, 2007). In such calculations 
some aspects of electron – electron correlation are included. DFT has come to dominate 
computational chemistry of medium-to-large molecules, including pharmaceuticals 
(Young, 2001) so it has been used throughout this work. 
     In determining geometries, the molecule is varied until a local or global energy 
minimum is obtained. Once the structure is calculated it is possible to test if the 
calculation is accurate. One way to do this is to compare the calculated structure with a 
known crystal structure. Generally, DFT and HF methods perform well in structural 
comparisons with experimental data. Another way is to use the information from the 
calculation to evaluate other observables, such as the dipole moment or vibrational 
spectra of the compound of interest. The vibrational spectra are useful observables 
because they are relatively easy to measure on samples for which crystallographic data 
may be absent (Foresman and Frisch, 1996). 
     Vibrational spectroscopy offers a good method of determining how accurate a 
calculation is for a number of reasons. Firstly, the values for the band frequencies are 
evaluated through the gradients of the energy (E) of the nuclear potential energy 
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surfaces (PES) for the vibrational modes of the molecule (q), which is δE/ δq. For this 
to correlate with experimental data, the calculation must reproduce the stiffness of the 
bonds in the molecule. Secondly, the relative intensities of vibrational spectra are 
related to the PES and its interaction with external electric fields and geometry changes 
caused by vibrational motion. For example the IR intensities are determined by the 
change in the dipole moment (μ) with vibrational mode (δμ/δq). To calculate this 
correctly the modelling must not only accurately predict the dipole but also how it 
changes with vibrational modes (e.g. bond stretching). For Raman spectroscopy, the 
Raman intensity is related to the change in polarizability (α) with vibrational mode 
(δα/δq). The polarizability of the molecule is related to the elasticity of the electron field 
in the system. These are related to the energy of the system in the following ways 
(Jensen, 2007). For IR intensity (δμ/δq)2 = (δ2E/δRδF)2, where R is the change in 
geometry and F is the electric field strength. For Raman intensity (δα/δq)2 = 
(δ3E/δRδF2)2, thus the Raman intensities require the energy of the system to be known 
with respect to geometry change and the effect of the external electric field. 
Importantly, if there is good correlation between the calculated properties, such as 
electronic potentials and molecular orbitals (MOs), may also be good representations 
and thus provide predictive power to the analyst examining these data. The nature of the 
MOs and electrostatic potentials are important parameters used to study pharmaceuticals 
and the properties of such compounds. 
 
3.1. Introduction 
     Raman spectroscopy is experiencing renewed interest in pharmaceutical applications, 
with a wide field of applications ranging from the characterization of drug formulations 
to on-line process analysis encompassing qualitative, quantitative and physical analysis. 
Physical analysis has involved the identification of polymorphism, hydrates and 
amorphous mixtures. Characterisation of simple powders has been extended to complex 
pharmaceutical formulations, including tablets, capsules, injection solutions and 
suspensions. Formulations have also been analysed through their packaging. The 
characteristics of the Raman spectroscopic technique make it ideal for process 
monitoring and it has been used to quantify changes in situ during pharmaceutical unit 
operations. These areas are described in the following subsections, with potential future 
uses of Raman spectroscopy also indicated. The literature contains several reviews on 
the uses of Raman spectroscopy in the pharmaceutical field (Angel et al., 1999; Bugay 
et al., 2007; Chalmers and Dent, 2006; Fini, 2004; Pfeffer-Hennig and Bellus, 2004; 
Pinzaru et al., 2004; Sandler et al., 2007; Vankeirsbilck et al., 2002; Wartewig and 
Neubert, 2005; Williams, 2001). 
 
3.2. Characterisation and detection of pharmaceuticals    
     A wide range of applications of Raman spectroscopy is evident for the 
characterisation of drug molecules either alone or in various dosage forms, in 
complexation with various metals and β-cyclodextrin derivatives, as co-crystals and 
using quantum chemical calculations have been presented in the literature.  
     The absence of the need for sample preparation and short spectral acquisition times 
make Raman spectroscopy particularly suitable for high-throughput identity verification 
of pharmaceutical compounds. Recently, quantum chemical calculations in conjunction 
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with Raman spectroscopy have been used in studying pharmaceutical systems. One 
reason to combine computational methods with spectroscopic data is that spectroscopy 
provides a method of testing the efficacy of the calculations. The accurate prediction of 
the frequency and intensity of vibrational bands suggests a well modelled potential 
energy surface. This in turn provides more confidence for the assignment of other 
predicted parameters. In this way it is possible for quantum chemical calculations to 
assist quality control development in the same way that it has facilitated drug discovery 
for many years. Table 3.1 presents a list of pharmaceutical systems studied by Raman 
spectroscopy and computational methods, within the Table, the pharmaceutical 
compound is presented along with the methods utilized, and a citation. 
     Raman spectra can be obtained noninvasively from solids and liquids inside vials or 
blister packs. McCreery et al. have reported the use of NIR Raman spectroscopy for 
identification of pharmaceuticals inside amber USP vials. Although the amber glass 
greatly attenuates the signal, spectra of sufficient quality were obtained for the 
determination of vial contents with 1-60 s integration. Identification was performed 
using a library of spectra and ranged in accuracy from 88% to 96%. Most of the errors 
were due to fluorescent emission in the samples. When these samples were omitted, a 
marked improvement in accuracy of the search algorithm resulted (McCreery et al., 
1998). This work has demonstrated the potential of Raman spectroscopy for on-line 
process monitoring. 
     The superior ability of Raman spectroscopy to characterize the stretching modes of 
the C-H bond compared with IR spectroscopy has been demonstrated for several 
compounds of pharmaceutical interest (Cutmore and Skett, 1993). Raman spectra can be 
recorded directly from TLC plates with no need for special treatment of either the 
samples or the plates (Petty and Cahoon, 1993). 
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     Raman spectroscopy has been used to investigate the metal complexes of ibuprofen, 
naproxen, tolmetin, diclofenac sodium (Trinchero et al., 2004), allopurinol (Torreggiani 
et al., 2003), suprofen (Williams, 2000), cimetidine (Baranska and Proniewicz, 1999), 
piroxicam (Santi et al., 1993; Wagner and Baran, 1999), insulin-mimetic complex 
(Muglia and Baran, 2000), the β-cyclodextrin inclusion complexes of tolbutamide 
(Ueda and Nagai, 1981; Veiga et al., 2001; Veiga et al., 1996) and the anti-
inflammatory drug loxoprofen (Choi et al., 2001) and the hydroxypropyl- β-
cyclodextrin inclusion complexes of sertaconazole (Rodriguez-Perez et al., 2006), and 
progesterone (Zoppetti et al., 2007). The characterisation of the indomethacin-saccharin 
(Basavoju et al., 2008), norfloxacin-isonicotinamide (Basavoju et al., 2006) and 
carbamazepine-nicotinamide (Rodriguez-Hornedo et al., 2006; Seefeldt et al., 2007) 
cocrystals by Raman spectroscopy have also been reported. 
 
3.3. Solid-state properties 
     One clear advantage of Raman spectroscopy for the study of the solid-state forms of 
pharmaceuticals is that the technique can probe the low frequency lattice vibrations (100 
to 150 cm-1) that are associated with molecules in the crystalline state. Many drugs 
exhibit polymorphism, different molecular arrangements within a crystal lattice. 
Different polymorphic forms have different lattice energies with consequent deviations 
in properties such as melting point, solubility, dissolution rate, and bioavailability. 
Thus, the characterisation of polymorphism in new chemical entities (and in some 
existing therapeutic agents) is of great importance. Although X-ray data remains the 
prime method for deducing the presence of polymorphs, Raman spectroscopy can 
provide rapidly some valuable complementary information. It is worth emphasizing that 
X-ray data are time-consuming to collect and are clearly is an off-line method, whereas 
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Raman spectroscopy has the potential of providing relevant information in situ or in at-
line analysis. Table 3.2 presents a list of polymorphic systems studied by Raman 
spectroscopy; within the Table, the pharmaceutical compound is presented along with a 
brief comment, and a citation.  
     With some crystalline solids, solvent in the surrounding medium may become 
incorporated into the crystal lattice of the compound in stoichiometric proportions. 
These molecular adducts are termed solvates. Hydrates are formed when water is the 
solvent of crystallization. Incorporation of the solvent molecules into the crystal lattice 
produces a new unit cell different from that of the anhydrate and, consequently, the 
physical properties of the solvate may differ from those of the anhydrate. To distinguish 
solvates from polymorphs, the term pseudopolymorphs has been applied to solvates 
(Giron, 1995). Raman spectroscopy has been used to identify and characterize the 
anhydrate and monohydrate forms of baclofen (Mirza et al., 2007), the anhydrate form 
of norfloxacin (Info et al., 2006),  paroxetine hydrochloride hemihydrate (Thorley et al., 
2006), the non-stoichiometric hydrates of ester type local anesthetics (Schmidt and 
Schwarz, 2006), the two anhydrous phases and water:DMSO solvate of olanzapine 
(Polla et al., 2005), the hydrated and anhydrous crystal forms of amlodipine besylate 
(Rollinger and Burger, 2002), amoxicillin trihydrate (Cutmore and Skett, 1993), five 
solvates of spironolactone (Beckstead et al., 1993), griseofulvin and its solvates (Bolton 
and Prasad, 1981), risedronate hemi-pentahydrate (Lester et al., 2006), and the mono 
and sesquihydrates of pantoprazole sodium (Zupancic et al., 2005). 
     Amorphous forms, where the drug molecules show minimal order, are also of 
considerable importance because these systems show more rapid dissolution than 
crystalline forms. Additionally, there are issues concerning stability where the 
amorphous system may be hygroscopic and the presence of moisture could induce re-
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crystallization of the material to provide a crystalline form of the drug. Raman 
spectroscopy has been used to study the amorphous forms of blends of paracetamol and 
citric acid (Pekka et al., 2007), indomethacin (Savolainen et al., 2007a) and lactose 
(Katainen et al., 2005). 
     Salt selection for a pharmaceutical compound is a critical component of drug 
development because the selection of the wrong salt can lead to chemical and physical 
stability issues as well as formulation problems. Raman spectroscopy has been used to 
study the molecular nature of the organic salts of norfloxacin with succinic acid, 
malonic acid and maleic acid (Basavoju et al., 2006) and the salts crystallized from a 
salbutamol base (Edwards et al., 1993a), where variations in vibrational frequencies due 
to electron withdrawing or donating substituents were clearly evident; for example, the 
C-C-O stretching vibration shifted from 776 cm-1 in the free base to 756 cm-1 in the 
benzoate salt. The C=C stretching frequency also shifted from 1610 to 1603 cm-1 with 
the benzoate ion but showed an increase to 1616 cm-1 with sulfate ion. Clearly the 
choice of salt affects the molecular nature of the drug with obvious implications for its 
physico-chemical properties. 
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3.4. Quantitative applications of Raman spectroscopy in various pharmaceutical 
systems 
     Raman scattering is proportional to the concentration of the scattering substance, and 
this provided the basis for quantitative Raman spectroscopy. The intensity of 
spontaneous Raman scattering in an ideal (non-absorbing) system during a particular 
vibration can be defined as: 
L = PDβDK 
     where L is the specific intensity of the Raman scattering (photons sr-1 cm-2 sec-1), PD 
is the power density of the incident laser radiation (photons cm-2 sec-1), β is the 
differential Raman scattering cross-section per cm3 and K is a geometric factor that 
depends on the observation geometry (incident and detection angles) (McCreery, 2000). 
The most important feature of the previous equation in this context is that the intensity 
of Raman scattering of a particular mode is directly proportional to the vibrating species 
concentration (described by D). Although the Raman scattering occurs over the 
bandwidth of the mode and hence a frequency range, proportionality is maintained at a 
single Raman shift as described by McCreery (McCreery, 2000). This relationship 
provides the basis for quantitative Raman spectroscopy. 
     In solid-state analysis, peak intensities, or peak areas were determined for 
quantification after baseline correction (Kontoyannis, 1995). When chemometric 
methods based on Partial Least Squares (PLS) regression and multivariate calibration 
were developed for quantitative determination, a better accuracy of prediction became 
possible. For multivariate calibration not only one data point but a complete spectral 
structure is used for calibration and modelling. Compared to univariate calibration 
characteristic peaks are dispensable. Thus, in recent years this technique has become 
popular (Dyrby et al., 2002; Szostak and Mazurek, 2004). Further advances were 
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achieved by Principal Component Analysis by which only reduced spectral information 
is used for calibration (Mazurek and Szostak, 2006b; Pratiwi et al., 2002; Szostak and 
Mazurek, 2002). 
     Quantitative Raman spectroscopy has been used in diverse applications in 
pharmaceutical analysis. An exhaustive review by Strachan et al (Strachan et al., 2007b) 
provided good survey of the quantitative Raman spectroscopic analysis of 
pharmaceutical solids. Table 3.3 presents a list of pharmaceutical compounds studied by 
quantitative Raman spectroscopy, within the Table, the pharmaceutical compound is 
presented along with a brief comment, and a citation. Chemical applications have 
mainly involved quantifying active pharmaceutical ingredients, while physical 
characterisation has covered polymorphism, hydrate formation and crystallinity. 
Initially, simple binary powder mixtures were quantified but this has since extended to 
complex formulations, including tablets, capsules, microspheres, ointments, injection 
solutions and suspensions as in Table 3.3.  
 
3.5. Process pharmaceutical applications 
     As far as industrial applications are concerned, the Raman spectroscopic technique is 
really promising because the spectrometers traditionally used in the laboratory may be 
displaced to the industrial environment in a remote manner through the use of fibre-
optic probes. In situ measurements can thus be ensured for a number of applications. 
Moreover, Raman techniques are well suited for measurements through glass or plastic 
media and can be performed within inhomogeneous media, which avoids difficulties 
and uncertainties related to sampling for off-line analysis. 
     Rantanen (Rantanen, 2007) has reviewed the process analytical applications of 
Raman spectroscopy, where different applications of Raman spectroscopy in the field of 
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process analysis of pharmaceutical solid dosage forms are summarized. In addition, the 
pitfalls associated with interfacing to the process environment and challenges within 
data management are discussed. Fe'votte (Févotte, 2007) has reviewed the real-time use 
of Raman spectroscopy for monitoring solid pharmaceutical elaboration processes with 
a particular attention on the in-line monitoring of crystallization processes.  
     NIR absorption spectroscopy is characterised by strong OH absorption so that solid 
state transitions cannot always easily be identified when using this technique in the 
presence of water. On the contrary, water is a weak Raman scatterer, which makes the 
technique attractive for many pharmaceutical applications involving aqueous media 
such as the monitoring of wet granulation of theophylline and caffeine (Jørgensen et al., 
2002), and the freeze drying processes of mannitol (Romero-Torres et al., 2007).  
     Spray coating is an important unit operation in the pharmaceutical industry. El 
Hagrasy et al. have utilized a noncontact Raman fibre-optic probe for the in-line 
monitoring of the progress of coating from process measurements (El-Hagrasy, 2006). 
Romero-Torres et al. have quantitatively characterized the coating variation in tablets 
using Raman spectroscopy with a revolving laser focus combined with PLS multivariate 
analysis (Romero-Torres et al., 2005) and created a predictive tablet coating thickness 
quantification models in the presence of a strong broad-band fluorescence interference 
(Romero-Torres et al., 2006). The Raman spectra of a set of coated acetaminophen 
tablets were analyzed for the purpose of calibrating the spectra to tablet coating 
thickness (Kauffman et al., 2007). 
     There is a very wide range of process pharmaceutical applications of Raman 
spectroscopy available in literature ranging from monitoring of solvent-mediated 
polymorphic transitions to quantitative reaction monitoring, in Table 3.4, the various 
pharmaceutical systems that have been studied by Raman spectroscopy as a PAT 
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technique with a brief comment on the special role achieved by Raman spectroscopy 
have been presented. 
 
3.6. Interactions 
     Interactions between drugs and excipients play an important role during the 
development of a new pharmaceutical formulation. The problem of chemical or physical 
interactions exists for all dosage forms. Raman spectroscopy has been proven to be an 
important tool in evaluating the drug and excipient interactions. Flemming and Picker-
Freyer have studied the compaction of spray dried lactose or anhydrous lactose with 
acetylsalicylic acid, nicotinamide and thiaminchloride hydrochloride (Flemming and 
Picker-Freyer, 2008). The drug-excipient interaction in ketoprofen with lactose and 
polyvinylpyrrolidone was reported, these interactions were found to involve mainly the 
central carbonyl group and the terminal methyl-carboxylic moieties of the ketoprofen 
molecule, this being reflected in particular vibrational  modes, such as the methyl 
torsion, the out-of-plane C-OH bending, and the inter-ring C=O stretching. (de Carvalho 
et al., 2006).A Raman spectroscopic study of diclofenac sodium and β-cyclodextrin 
interaction was also reported (Iliescu et al., 2004). 
     The use of Raman spectroscopy to study drug polymer interactions has been 
reported. The interactions of diclofenac sodium with ammonio methacrylate (Sipos et 
al., 2008), clotrimazole with polyethylene oxide (Todica et al., 2007), indomethacin 
with polyvinypyrrolidone (Taylor and Zografi, 1997), sulfthiazole with povidone 
(Bolton and Prasad, 1984) and probucol with polymers (Broman et al., 2001) have been 
presented. Hendra et al. have studied the interactions of diclofenac sodium and 
sympathomimetic amines with biomedical polymers (Hendra et al., 1990), and 
promethazine, diclofenac, theophylline and indomethacin in polymeric diluents based 
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on polyethylene oxide, sodium alginate and hydroxypropylmethyl cellulose (Davies et 
al., 1990). 
     Raman spectroscopy has been used to study the interactions of the antimalarial 
drugs, chloroquine and mefloquine with hematin (Cinta-Pinzaru et al., 2006), 
antimicrotubular agent with cysteine (Bouchaour, 1986), lecithin with cholesterol 
(Tantipolphan et al., 2006) and sugar ester and hydroxypropylmethyl cellulose with 
cefditoren pivoxil (Yokoi et al., 2005). 
     Raman spectroscopy has been used as method to probe the solid-state form of active 
substances present in various dosage forms. Taylor and Langkilde (Taylor and 
Langkilde, 2000) have obtained Raman spectra from intact tablets and capsules 
containing enalapril maleate, prednisolone, form I and II polymorphs of rantidine, 
anhydrous and monohydrated theophylline and warfrin sodium clathrate, phase 
transitions from anhydrous and monohydrate forms could be specially determined. 
Okumura and Otsuka have evaluated the microcrystallinity of indomethacin in a 
pharmaceutical model tablet based on FT-Raman spectroscopy (Okumura and Otsuka, 
2005). Severdia and Siek have identified and differentiated between dosage strengths of 
an active drug in white opaque hard gelatine capsules (Severdia and Siek, 2002). 
Compton and Compton have demonstrated that FT-Raman spectroscopy can be used to 
examine pharmaceutical preparations contained in polymeric packages (Compton and 
Compton, 1991).  Recently, Matousek and Parker have reported that, the largely 
neglected transmission Raman geometry is ideally suited for the non invasive probing 
of pharmaceutical capsules and tablets, reducing substantially capsule and tablet shell 
Raman and fluorescence signals that often hamper similar measurements in the 
conventional backscattering Raman geometry (Matousek and Parker, 2006; Matousek 
and Parker, 2007). 
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     Pharmaceutical counterfeiting is becoming a serious problem in developed and 
developing countries. Because of its ability to record spectra without sample preparation 
with short collection times, Raman spectroscopy is a useful method to detect counterfeit 
drugs. The use of Raman spectroscopy to study pharmaceutical counterfeiting has been 
reviewed (Deisingh, 2005; Olsen and Kiehl, 2006). Raman spectroscopy is proposed as 
a fast and reliable method for the detection of counterfeit Viagra tablets (de Veij et al., 
2008) and artesunate anti-malarial tablets, (de Veij et al., 2007; Hall et al., 2006; Ricci 
et al., 2007). Eliasson and Matousek described the application of spatially offset Raman 
spectroscopy (SORS) in the identification of counterfeit pharmaceutical tablets and 
capsules through different types of packaging (Eliasson and Matousek, 2007). SORS 
uses conventional Raman spectroscopy, but rather than detect the Raman signal directly 
at the point of laser illumination, SORS detects the signal at a distance from the incident 
position. 
     Raman spectroscopy has been used to study the composition of pharmaceutically 
relevant medicinal plants. Edwards et al have reported that FT-Raman spectroscopy has 
the ability to discriminate between ginseng specimens according to the country of origin 
(Edwards et al., 2007). Raman spectroscopy has been used in the identification of 
Chinese traditional medicines (Mao and Xu, 2006) and medicinal and aromatic plants 
(Schulz, 2005). The determination of alkaloids in capsules, milk and ethanolic extracts 
of poppy by FT-Raman spectroscopy was also reported (Schulz et al., 2004).  
     Edwards et al. have studied extensively skin and the drug-skin interactions. They 
have reported the interactions between the human stratum corneum and the penetration 
enhancer (DMSO) (Edwards et al., 1995a; Edwards et al., 2002), verrucae and salicylic 
acid (Edwards et al., 1998), oxybenzone oxidation following solar irradiation of the skin 
(Edwards et al., 1996b), and the drug distribution in a transdermal drug delivery device 
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(Edwards et al., 1996a). They have also reported the FT-Raman spectra of mammalian, 
reptilian (Edwards et al., 1994), human skin (Edwards et al., 1992), and human stratum 
corneum in vitro and in vivo (Edwards et al., 1993b) for pharmaceutical drug delivery 
experiments on diffusion across the skin membranes. Caspers et al. have also presented 
in vitro and in vivo Raman spectra of human skin (Caspers et al., 1998). Zhang et al. 
have utilized confocal Raman spectroscopy to track dephosphorylation of resveratrol 
triphaosphat in skin (Zhang et al., 2007a) and image the prodrug-to-drug transformation 
of a 5-fluorouracil derivative in skin (Zhang et al., 2007b). A confocal Raman 
microprobe has been used in the screening of glycerol-based hydration cream of human 
skin (Chrit et al., 2006). Raman spectroscopy has been used to study the crystallization 
of β-estradiol in acrylic transdermal drug delivery system (Variankaval et al., 1999) and 
to investigate the bioadhesive tetracaine local anaesthetic formulations (Dennis et al., 
2004). Raman spectra of the human lens in relation to the anticataract effect of 
bendaline have been reported (Bertoluzza et al., 1986). 
 
3.7. Chemical imaging and mapping 
     Chemical imaging is an emerging platform technology that integrates conventional 
imaging and spectroscopy to attain both spatial and spectral information from an object. 
Vibrational spectroscopic methods, such as near-IR and Raman spectroscopy, combined 
with imaging are particularly useful for analysis of pharmaceutical forms (Bell et al., 
2008).  
     Chemical images are made up of hundreds of contiguous wavebands for each spatial 
position of a target studied. Consequently, each pixel in a chemical image contains the 
spectrum of that specific position. The resulting spectrum acts like a fingerprint, which 
can be used to characterise the composition of that particular pixel. The spectroscopic 
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chemical imaging technique relies on the interface of an optical microscope equipped 
with a motorized stage to a Raman spectrometer. The operator is able to visually focus 
upon a sample of interest and optical observations about the sample are made. 
Subsequently, the same visual area (two-dimensional) is defined for spectroscopic 
analysis. Utilizing a raster pattern involving the stepwise movement of the motorized 
stage along the x- and y-axes, individual spectra are acquired for each spatial location 
within the two dimensional area. Spatial resolution is typically defined by the technique 
as about ~1 μm. Once the individual spectra are obtained for the two-dimensional area, 
the intensity of a specific spectral feature within each spectrum can be plotted versus the 
spatial position. In this manner, one is able to obtain a contour plot showing the spatial 
position of a chemical entity. 
 
     Bell et al (Bell et al., 2008), recently published a review documenting the 
applications of chemical imaging to pharmaceutical process monitoring and quality 
control. Belu et al. (Belu et al., 2008) have utilized scanning confocal Raman 
microscopy for chemical imaging of rapamycin eluting coatings. Šašic has reported the 
application of Raman imaging technique for determining the spatial distribution of all 
components in a common type of pharmaceutical tablet manufactured in two different 
ways (Šašic, 2007a), chemical imaging of pharmaceutical granules (Šašic, 2008) and 
alprazolam in alprazolam/xanax tablets (Šašic, 2007b). Multivariate data analysis for 
Raman imaging of a model pharmaceutical tablet (Zhang et al., 2005), comparison of 
Raman chemical images produced by univariate and multivariate data processing (Šašic 
et al., 2004), confocal Raman microimaging of coated pellets of remoxipride 
hydrochloride monohydrate (Ringqvist et al., 2003), Raman imaging for the study of the 
subcellular distribution of the anticancer agent paclitaxel in living breast cancer cells 
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(Ling et al., 2002) and emulsion systems (Andrew et al., 1998) have been presented in 
the literature. Confocal Raman spectroscopy was successfully applied to determine the 
state of ibuprofen in a solid matrix showing equivalence to physical solution 
(Breitenbach et al., 1999). 
     Raman micro-spectroscopic mapping is utilized to investigate pharmaceutical tablets 
containing a low concentration of active pharmaceutical ingredient (Henson and Zhang, 
2006), tablets containing chloramphenicol palmitate polymorphs (Lin et al., 2006), 
pharmaceutical bead formulations (Šašic et al., 2005b), pharmaceutical products by 
sample-sample two-dimensional correlation (Šašic et al., 2005a), in vitro deposition of 
combination pressurized metered-dose inhalers containing salbutamol and 
beclometasone dipropionate (Steele et al., 2004), the subcellular distribution of zinc 
phthalocyanines (Freeman et al., 1998), pharmaceutical tablets and powder blends 
(Šašic and Clark, 2006) and surface domains of amorphous sorbitol (Ward et al., 2005). 
Clarke et al. have applied the chemical image fusion approach which is the development 
of a novel sample referencing approach that allows data to be acquired from exactly the 
same area of the sample using both Raman and FT-NIR microscopies, the optimum 
images for the components are then overlaid which gives rise to a combined chemical 
image that visually describes the entire formulation, for a more complete visualization 
of pharmaceutical formulations (Clarke et al., 2001a; Clarke et al., 2001b). 
 
3.8. Hyphenated techniques   
     Aaltonen et al. (Aaltonen et al., 2007b) have utilized Hyphenated NIR/Raman 
spectroscopy combined with principal component analysis as fast and comprehensive 
method of solid phase analysis. NIR spectroscopy was effective in separating the 
hydrate form (II) from the hydrates (α and β) of nitrofurantoin, while Raman 
 48
spectroscopy provided accurate information from the differences between the 
anhydrates (Aaltonen et al., 2007b). Taylor and Gift have reported the hyphenation of 
Raman spectroscopy with gravimetric analysis to interrogate water solid interaction in 
pharmaceutical systems containing sulfaguanidine, cromolyn sodium, amorphous 
sucrose, rantidine HCl, and silica gel (Gift and Taylor, 2007). Cimpoiu et al. have 
separated and identified eight hydrophilic vitamins using TLC and Raman spectroscopy 
without using standards of vitamins (Cimpoiu et al., 2005). 
 
3.9. Future pharmaceutical uses of Raman spectroscopy 
     Raman spectroscopy continues to grow in popularity both among analytical chemists 
and in other fields and it has become a standard method for the characterisation of drugs 
and for industrial process monitoring. Raman spectroscopy is being developed as a 
detection mechanism in many hyphenated techniques, and it is expected that this field 
will continue to develop in the next few years. 
     While Raman spectroscopy in the backscattering collection mode is limited to 
probing shallow, semitransparent media, the spatial offset Raman spectroscopy (SORS) 
improves the penetration depth (Matousek, 2006). The SORS method is based on the 
collection of Raman spectra from spatially offset region away from the point of 
illumination on the sample surface. The laterally offset Raman spectra contain different 
relative contributions from sample layers located at different depths. This difference is 
brought about by a wider lateral diffusion of photons emerging from greater depths. The 
offset spectra can either contain acceptably low Raman contributions from the surface 
layer, or if a considerable signal is still present then this can be further removed using a 
scaled subtraction of spectra obtained at different spatial offsets. Alternatively, the 
separation of Raman signals originating from different layers in the sample can be 
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accomplished using multivariate data analysis applied to a set of spatially offset Raman 
spectra. The SORS approach is also capable of effectively suppressing the interfering 
fluorescence if it originates from the surface layer of the probed medium. Clearly, 
SORS will broaden the pharmaceutical application of Raman spectroscopy. 
     The future for Raman spectroscopy within the pharmaceutical field appears bright. 
The technique has developed rapidly, with instrumental advances providing flexible 
equipment that is capable of obtaining good quality rapid data from a variety of sample 
forms and states. 
 
Table 3.1. Listing of different pharmaceutical compounds characterised by Raman spectroscopy and computational methods. 
 
Pharmaceutical compound Raman 
spectroscopy 
Computational 
method 
References 
Fluticasone propionate X X (Ali et al., 2009a) 
Artemisinin X X (Moroni et al., 2008) 
Ibuprofen X X (Bondesson et al., 2007; Vueba et al., 2008) 
Thalidomide X X (Cipriani and Smith, 2008) 
Paracetamol,oxcarbazepine, 
chloropropamide and olanzapine 
X X (Ayala, 2007) 
Platinum II anticancer drug (Cimpoiu et 
al., 2005) 
X X (Amado et al., 2007a) 
Uracilyl-pyridinium mesomeric betaine X X (Schmidt et al., 2007) 
Budesonide X X (Ali et al., 2007) 
γ-crystalline and amorphous 
indomethacin 
X X (Strachan et al., 2007a) 
Isoniazid X X (Akalin and Akyuz, 2007; Gunasekaran, 2005a) 
Clavulanic acid X X (Miani et al., 2007) 
Nevirapine X X (Ayala et al., 2007) 
Aspirin, caffeine and ibuprofen X X (Bondesson et al., 2007) 
Atorvastatin calcium X  (Gunasekaran et al., 2007a) 
Diazepam,phenytoin, phenobarbitone X X (Gunasekaran et al., 2006b) 
Indomethacin-cyclodextrin inclusion 
complex 
X X (Rossi et al., 2006) 
Glibendamide, rosiglitazone maleate X  (Gunasekaran et al., 2007b) 
Metformin X X (Gunasekaran et al., 2006a) 
Salmeterol xinafoate and fluticasone 
propionate 
X   
(Theophilus et al., 2006) 
4-Thiocarbamoylpyridine X X (Wysokinski et al., 2006b) 
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Table 3.1. (Continued) 
 
Pharmaceutical compound Raman 
spectroscopy 
Computational 
method 
References 
5-para-fluoro-benzilidine-thiazolidine-2-
thione-4-one 
X X  
(Baias, 2006) 
Pyrazinamide, atenolol, metoprolol, 
pindolol and verapamil 
X X  
(Cozar et al., 2006) 
Carboplatin X X (Wysokinski et al., 2006a) 
Non steroidal anti-inflammatory drugs 
(ibuprofen, naproxen and tolmetin) 
X X  
(Jubert et al., 2006) 
Cyanocobalamin (vitamin B12) X  (Gunsekaran and Sankari, 2005) 
5-Fluorouracil X X (Pavel et al., 2005; Rastogi et al., 2000) 
Sulfonamides X  (Rama et al., 2005) 
Falicaine HCl and isomorphic dyclonine 
HCl 
X   
(Schmidt, 2005c) 
Benzocaine X X (Gunasekaran, 2005b) 
Fluoroquinolones (naldixix acid, 
oxolinicacid, cinoxacin, flumequine, 
norfloxacin,ciprofloxacin, lomefloxacin, 
ofloxacin, enoxacin, sarafloxacin and 
moxifloxacin 
X X  
 
 
 
(Neugebauer et al., 2005) 
Caffeine, theobromine and theophylline X  (Edwards et al., 2005) 
Platinum II anticancer drugs X X (Michalska and Wysokinski, 2005) 
Plumbagin X X (Sajan et al., 2005) 
Combretastatin-A4 X X (Binoy et al., 2004) 
Carbamazepine polymorphs X X (Strachan et al., 2004a) 
Carvedilol X X (Marques et al., 2002) 
9-β-D-arabinofuranosyladenine-5\-
monophosphate 
X X (Hernandez et al., 2002) 
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Table 3.1. (Continued) 
 
Pharmaceutical compound Raman 
spectroscopy 
Computational 
method 
References 
Cimetidine X X (Baranska and Proniewicz, 1999) 
Amantadine X X (Rivas et al., 1999) 
5-iodo-2\-deoxyuridine X X (Bailey et al., 1999) 
Aminoglutethimide X X (Glice et al., 1998) 
Arabino nucleoside X X (Hernandez et al., 1998) 
Frozen glucose solution X  (Taylor et al., 1997) 
Lansoprazole X  (Curin, 1997) 
Sanocrysin X  (Tobön-Zapata et al., 1997) 
Heparin X X (Atha et al., 1995; Atha et al., 1996) 
Salbutamol base and salts X X (Ali et al., 2009b; Edwards et al., 1993a; Ticehurst 
et al., 1994) 
Aged flurazepam mono and 
dihydrochloride salts 
X   
(Neville et al., 1994) 
A promising drug in AIDS therapy X  (Baran, 1993) 
Fluccloxacillin and sodium cephalothin X  (Cutmore and Skett, 1993) 
Acridine X X (Butler and Cooney, 1993) 
Antineoplaston A10 X X (Michalska, 1993) 
Phenethylamine,tyramine, dopamine 
and tyrosine 
X X  
(Choi and Lubman, 1992) 
Primaquine diphosphate and its cation 
radical 
X   
(De Faria and Santos, 1991) 
Sulfa drug molecules X  (Prabakaran and Mohan, 1990) 
Dapsone X  (D'Cunha, 1983) 
New anticancer inorganic ring systems X  (Manfait et al., 1982a; Manfait et al., 1982b) 
Barium sulphate in parenteral solution X  (Boddapati et al., 1980) 
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Table3.1. (Continued) 
 
Pharmaceutical compound Raman 
spectroscopy 
Computational 
method 
References 
Benzodiazepines X  (Bass, 1978a) 
Sympathomimetic amines X  (Bass, 1978b) 
Phenothiazines X  (Hosomi et al., 2004; Kure and Morris, 1976) 
Palladium-5-nitofurylthiosemicarbazone 
complex 
X X  
(Gambino et al., 2007) 
Lamivudine X X (Pereira et al., 2007) 
Deflazacort X  (Cuffini et al., 2007) 
Microcrystalline cellulose and powder 
cellulose 
X   
(Fechner et al., 2003) 
Krypton solution X X (Durig et al., 2004) 
Iodixanol X  (Priebe et al., 1995) 
Complex for magnesium 
supplementation 
X   
(Wagner et al., 1999) 
Nystatin X  (Colline et al., 1985) 
Anthopleurin A X  (Ishizaki et al., 1979) 
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Table 3.2. Listing of different pharmaceutical polymorphic systems studied by Raman spectroscopy. 
 
Pharmaceutical 
polymorph 
Comments References 
Salmeterol xinafoate Characterisation and polymorphic transformation by 
simultaneous in situ Raman spectroscopy and DSC 
(Ali et al., 2008) 
Nimodipine In its solid dispersions in polyethylene glycol (Docoslis et al., 2007) 
Carbamazepine Cocrystals with nicotinamide and saccharin 
The influence of various excipients on its conversion 
kinetics in aqueous suspensions 
Quantitative analysis of polymorphic mixtures 
(Porter, 2008)  
 
(Tian et al., 2007) 
(Strachan et al., 2004b) 
Oxybuprocaine HCl Three polymorphic forms (Info et al., 2008) 
Tamoxifen citrate Three polymorphic foms (Gamberini et al., 2007) 
Salicylanilide Three forms (polymorph I,II and the amorphous form (De Spiegeleer et al., 2007) 
Risperidone In tablets (Karabas et al., 2007) 
Bicalutamide Two crystal forms and an amorphous phase (Vega et al., 2007) 
Sulphathiazole Five polymorphic forms (Zeitler et al., 2006) 
Norfloxacin Enantiotropic relationship between polymorphs A and 
B 
 
(Barbas et al., 2006) 
Chloramphenicol 
palmitate 
Three polymorphic forms (Gamberini et al., 2006) 
Celecoxib A novel polymorphic form (form IV) (Lu et al., 2006) 
Rantidine Form I and II (Thorley et al., 2006) 
Paracetamol Form II 
Monoclinic and orthorhombic forms 
(Thorley et al., 2006) 
(Moynihan and O’Hare, 2002) 
Local anaesthetic drugs 24 local anaesthetics have been characterized (Schmidt, 2005a) 
Chloroprocaine HCl Two polymorphic crystal forms (Schmidt, 2005b) 
Felodipine and 
nitrendipine 
 (Vassou et al., 2005) 
Benzimidazole drug In complex finished formulation (De Spiegeleer et al., 2005) 
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Table 3.2. (Continued) 
 
Pharmaceutical 
polymorph 
Comments References 
Chlorpropamide, 
diflunisal, furosemide, 
piroxicam, ritonavir and 
other 9 pharmaceutical 
compounds 
Statistical analysis of differences in Raman spectra of 
polymorphs 
 
(Mehrens et al., 2005) 
Hydroxyprocaine HCl Two polymorphic and a pseudopolymorphic crystal 
form 
( 
Schmidt and Schwarz, 2005) 
Prilocaine HCl Two polymorphic forms, a dioxane solvate and the 
amorphous form 
 
(Schmidt et al., 2004) 
Nifedipine One amorphous and three crystalline phases (Chan et al., 2004) 
A novel sodium ion 
channel blocker 
Two polymorphic forms A and B (Cheung et al., 2003) 
Pramocaine base and 
HCl 
Two crystal forms of the Base and three crystal 
modifications of the salt 
 
(Schmidt et al., 2003a) 
Various drugs and 
excipients 
Potential of carrageenans to protect drugs from 
polymorphic transformation 
 
(Schmidt et al., 2003b) 
Roxifiban Two polymorphic forms (Maurin et al., 2002) 
Cilostazol Three forms A, B and C (Stowell et al., 2002) 
CNS active drug Org 
13011 
Four forms A, B, C and D (van Hoof et al., 2002) 
17β-estradiol In transdermal drug delivery system 
Four different crystal forms (EA, EC, ED and EM) 
(Variankaval, 2002)  
(Variankaval et al., 2000) 
D-mannitol Three modifications 
In binary mixture with NaCl 
(Burger et al., 2000)  
(Telang et al., 2003) 
Diprophylline Two polymorphic forms (Griesser, 1999) 
Acetazolamide Two modifications I and II (Griesserx, 1997) 
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Table 3.2. (Continued) 
 
Pharmaceutical 
polymorph 
Comments References 
Nimodipine Two polymorphic forms (Grunenberg et al., 1995) 
Spironolactone Differentiation of polymorphic samples (Neville et al., 1992) 
Ampilcillin and 
griseofulvin 
Two polymorphs and a trihydrate form (Bellows et al., 1977) 
Lactose A definitive guide to polymorph determination (Kirk et al., 2007) 
Buspirone HCl Two forms 1 and 2 (Sheikhzadeh et al., 2006) 
Salicaine base and HCl  (Schmidt et al., 2006) 
Benzocaine, butambene 
and isobutambene 
Each drug exists in two polymorphic crystal forms (Schmidt, 2005d) 
Acetaminophen, 
sulfamethoxazole, 
carbamazepine and a 
pharmaceutical 
intermediate 
Control of crystal polymorphism through the use of 
polymer heteronuclei 
 
(Price et al., 2005) 
Tranilast Five polymorphic forms (Vogt et al., 2005) 
Torasemide Three crystal forms I and II and a pseudopolymorphic 
crystal form (form A) 
 
(Rollinger et al., 2002) 
Piroxicam Three different forms (alpha, beta and monohydrate) (Taddei et al., 2001) 
Stavudine Three forms I, II and III (Gandhi et al., 2000) 
DuP 747 Two polymorphic forms (Raghavan et al., 1994) 
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Table 3.3. Listing of different pharmaceutical compounds studied by quantitative Raman spectroscopy. 
Pharmaceutical compound Comments References 
Ticlopidine HCl In tablets (Markopoulou et al., 2008) 
Sulfathiazole and 
sulfanilamide 
As a pharmaceutical powder using a simple 
univariate calibration model 
(López-Sánchez et al., 2008) 
Phenacetin and salophen In solid binary mixtures with caffeine (Koleva et al., 2008) 
Atorvastatin calcium Polymorph in tablets (Skorda and Kontoyannis, 2008) 
Pharmaceutical tablets and 
capsules 
Using transmission Raman spectroscopy (Johansson et al., 2007) 
Ambroxol In an intact capsule formulation 
In tablets 
(Kim et al., 2007a)  
(Hwang et al., 2005; Szostak and Mazurek, 
2004) 
Amiodarone HCl In Angoron liquid formulation (Orkoula et al., 2007) 
Acetaminophen In a turbid pharmaceutical suspension (Park et al., 2007) 
Medroxyprogesterone 
acetate 
In a pharmaceutical suspension (De Beer et al., 2007b; De Beer et al., 2004) 
Povidone In a commercial eyewash solution by direct 
measurement through a plastic bottle  
 
(Kim et al., 2007b) 
Salicylic acid Influence of particle size on its quantitative 
determination in a pharmaceutical ointment  
 
(De Beer et al., 2007a) 
Spray dried lactose Determination of the amorphous content (Lehto et al., 2006) 
Diclofenac sodium and 
aminophylline 
In injection solutions (Mazurek and Szostak, 2006b) 
Captopril and prednisolone In tablets (Mazurek and Szostak, 2006a) 
Illicit drug mixtures On paper currency  (Noonan et al., 2005) 
Ahydrate/hydrate powder 
mixtures 
Using nitrofurantoin, theophylline, caffeine and 
carbamazepine  
 
(Rantanen et al., 2005) 
Carbamazepine Polymorphic mixtures (Strachan et al., 2004b) 
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Table 3.3. (Continued) 
 
Pharmaceutical compound Comments References 
Corn starch and lactose 
monohydrate 
Two-component powders and tableted mixtures (Virágh, 2003) 
Sorbitol, mannitol, 
famotidine, acemetacin, 
carbamazepine, 
meprobamate and 
phenylbutazone 
Polymorphic forms in drug formulations (Auer et al., 2003) 
Dipyrone In tablets (Izolani et al., 2003) 
Acyclovir In pharmaceutical solid dosage forms through their 
poly(vinyl chloride) blister package 
 
(Skoulika and Georgiou, 2003) 
Rantidine HCl Polymorphic mixtures (Pratiwi et al., 2002) 
Vitamin C In food and pharmaceutical products (Yang and Irudayaraj, 2002) 
Diltiazem HCl In tablets (Vergote et al., 2002) 
Active substance 
(containing CN) 
In a pharmaceutical tablet (Dyrby et al., 2002) 
Mannitol polymorphs Binary mixtures containing beta and delta mannitol (Campbell Roberts et al., 2002) 
Acetylsalicylic acid and 
acetaminophen 
In tablets (Szostak and Mazurek, 2002) 
Ciprofloxacin In solid pharmaceutical dosage forms (Skoulika and Georgiou, 2001) 
A radiosensitizer, 5-iodo-2\-
deoxyuridine 
Within biodegradable polymeric microspheres (Geze et al., 1999) 
Isosorbide-5-mononitrate In a tablet (Jedvert et al., 1998) 
Bucindolol In intact gel capsules (Niemczyk et al., 1998a; Niemczyk et al., 
1998b) 
Two crystal forms of a 
pharmaceutical compound 
 (Langkilde et al., 1997) 
Cortisone acetate Polymorphs (Deeley, 1991) 
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Table 3.3. (Continued) 
 
Pharmaceutical compound Comments References 
Sulfasalazine-containing 
polymeric microspheres 
 (Watts et al., 1991) 
Phenylpropanolamine HCl 
and acetaminophen 
In pharmaceutical preparations (King et al., 1985) 
Indomethacin Ternary mixtures of different solid-state forms (Heinz et al., 2007) 
Diphenhydramine HCl In liquid formulations (Orkoula et al., 2006) 
Etoricoxib Investigating the hydrate conversion propensity (Dalton et al., 2006) 
Vitamin A Degradation (Failloux et al., 2003) 
Monoclinic and 
orthorhombic paracetamol 
In powder mixtures (Al-Zoubi et al., 2002) 
Aspirin Tablets (Wang et al., 1997) 
Calcium carbonate and 
glycine 
In antacid tablets (Kontoyannis, 1995) 
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Table 3.4. Listing of different process pharmaceutical applications of Raman spectroscopy.  
 
Pharmaceutical system Comments References 
Flufenamic acid Estimation of the transition temperature for the 
enantiotropic polymorphic system from the 
transformation kinetics 
 
 
(Hu et al., 2007) 
Magnesium stearate Monitoring in blends and tablets (Aguirre-Mendez, 2007) 
Active pharmaceutical 
ingredient’s hydrate form 
Online Raman spectroscopy in a complex wet 
drying process 
 
(Liang, 2007) 
Potential pharmaceutical 
materials 
Fluidised bed characterization (Bell et al., 2007) 
Theophylline Probing pseudomorphic transitions in 
pharmaceutical solids 
Effect of excipients on hydrate formation in wet 
masses 
 
(Amado et al., 2007b) 
 
(Airaksinen et al., 2003) 
α-lactose monohydrate and 
amorphous lactose and 
trehalose 
Determination of amorphous content in the 
pharmaceutical process environment 
 
(Savolainen et al., 2007b) 
Theophylline and 
nitrofurantoin 
In situ measurement of solvent-mediated phase 
transformations during dissolution testing 
 
(Aaltonen et al., 2006) 
Theophylline monohydrate In-line monitoring of solid-state transitions during 
fluidisation 
 
(Aaltonen et al., 2007a) 
Ibuprofen and xanthan gum Quantitative in-line monitoring of the 
homogenization process of a pharmaceutical 
suspension 
 
 
(De Beer et al., 2006) 
Taltirelin and timepidium 
bromide 
Monitoring of solvent-mediated polymorphic 
transitions 
 
(Kobayashi et al., 2006) 
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Table 3.4. (Continued) 
 
Pharmaceutical system Comments References 
Carbamazepine Solvent-mediated phase transformations kinetics of 
an anhydrate/dehydrate system 
 In situ Raman spectroscopic polymorphic analysis 
of optically trapped microcrystals in a microliter 
fluid volumes 
In situ FT-Raman spectroscopy to study the 
kinetics of the polymorphic transformation 
Monitoring the solubility and stability of 
anhydrate/hydrate in ethanol-water mixtures  
 
(Qu et al., 2006b) 
 
 
(Anquetil et al., 2003) 
 
(O’Brien et al., 2004) 
 
(Qu et al., 2006a) 
Pharmaceutical tablet On-line content uniformity determination of tablets 
using low-resolution Raman spectroscopy 
 
(Wikström et al., 2006) 
Erythromycin A dihydarte Thermally induced phase transformations (Miroshnyk et al., 2006) 
Risedronate 
 
 
Use of a TG/DTA/Raman system to monitor 
dehydration and phase conversions 
On-line Raman spectroscopy for characterizing 
relationships between drug hydration state and 
tablet physical stability  
 
 
(Kern et al., 2005) 
 
 
(Hausman et al., 2005a) 
Powder blends Comparison of sampling techniques for in-line 
monitoring  
 
(Wikström et al., 2005) 
Theophylline anhydrous In-line monitoring of hydrate formation during wet 
granulation  
 
(Wikstroem et al., 2005) 
Diltiazem HCl In-line monitoring of a pharmaceutical blending 
process 
 
(Vergote et al., 2004) 
Pharmaceutical polymorph Robust polymorph isolation using in situ Raman 
spectroscopy 
 
(Zhou et al., 2002) 
 
 62
 63
Table 3.4. (Continued) 
 
Pharmaceutical system Comments References 
Carbopol ultrez and tefose Raman spectroscopy as a PAT during formulations 
of topical gels and emulsions 
 
(Islam et al., 2004) 
Compound A Evaluation of drug physical form during 
granulation, tabletting and storage 
 
(Williams et al., 2004) 
A multipolymorphic 
compound (MK-A) 
The use of in situ Raman spectroscopy to determine 
the rate of polymorph turnover 
 
(Starbuck et al., 2002) 
Theophylline and caffeine Monitoring of hydrate formation during wet 
granulation 
 
(Jørgensen et al., 2002) 
Ibuprofen In situ study of impregnation of ibuprofen into PVP (Kazarian and Martirosyan, 2002) 
Muro 128 (dehydrating 
agent) 
Drug induced corneal hydration changes monitored 
in vivo by confocal Raman spectroscopy 
 
(Erckens et al., 2001) 
Ethyl acetate and 
acetylsalicylic acid 
Quantitative  reaction monitoring (Shackman et al., 2000) 
Paracetamol and lufenuron In situ characterization of polymorphic forms (Szelagiewicz et al., 1999) 
Polycyanoacrylates Raman spectroscopic monitoring of the 
polymerization of cyanoacrylate 
 
(Urlaub, 1998) 
Acetaminophen In situ identification in a fatal overdose case (Pestaner et al., 1996) 
Hydrate forms of Piroxicam 
and carbamazepine 
In situ analysis to reveal the multiple solid-state 
forms that appear during isothermal dehydration 
 
(Kogermann et al., 2007) 
Mannitol Monitoring of phase behaviour during freeze-
drying 
 
(Romero-Torres et al., 2007) 
Azimilide dihydrochloride On-line monitoring of low dose blend uniformity (Hausman et al., 2005b) 
Lovastatin Monitoring the stability in solid state in the 
presence of gallic acid 
 
(Orkoula et al., 2004) 
Metoprolol 
 
Monitoring of the synthesis (Svensson et al., 2000) 
 
4.1. Introduction 
     The purpose of this study is to provide a group of case studies that illustrate how 
quantum chemistry may be used in studying pharmaceutical systems to provide viable 
structural information when considering the complexation, interactions and solid-state 
analysis of a number of commonly used respiratory drugs, namely, budesonide, 
fluticasone propionate, salbutamol hemisulphate, terbutaline hemisulphate and 
ipratropium bromide, and how they have been studied using quantum chemistry. 
Importantly, the focus is on existing and well-established quantum methods to support 
vibrational spectroscopic molecular assignments. 
     We are particularly interested in trying to model the properties of molecules, such as 
structure and vibrational spectra; for these properties there are an array of methods and 
commercial programme packages available to researchers (Young, 2001). For example, 
there are comparatively simple molecular mechanics and semi-empirical methods that 
may be applied to large molecular systems. These methods have been successful in 
many areas, e.g., a review by Taskinen and Yliruusi (Taskinen and Yliruusi, 2003) 
highlighted the use of semi-empirical calculations to predict the octanol-water partition 
coefficients for a variety of compounds. Calculations may be used to screen tens of 
thousands of compounds for the purpose of drug design as exemplified in the study of 
ligands for the retinoic acid receptor by Silva et al (Silva et al., 2005). However, as we 
are interested in molecular properties such as vibrational spectra it is often necessary to 
use more sophisticated and more limited computational methods than those offered by 
semi-empirical approaches. For this reason we will focus on the use of quantum 
chemical calculations applicable to these types of problems. 
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4.1.1. Budesonide 
     Budesonide (BUD) is a relatively new non-halogenated potent glucocorticoid that 
has been designed to express high topical activity with reduced systemic side effects. 
This has been achieved by incorporating features into the drug molecule that generate a 
pronounced hepatic metabolism resulting in low oral bioavailability and high hepatic 
clearance (Spencer and McTavish, 1995). Because of these design features, BUD has 
been very successful in the topical treatment of asthma via inhalation administration 
(Hvizdos and Jarvis, 2000). The use of BUD has also been extended to the local therapy 
of other diseases. It is evaluated in the treatment of chronic inflammatory bowel disease 
in the form of enteric-coated pellets insoluble in gastric juice, rectal foams and enemas 
(Hamedani et al., 1997). 
     Structurally, BUD is a 16α, 17α-acetal prepared by reaction of the 16α, 17α-
dihydroxysteroid (16α-hydroxyprednisolone) with n-butyraldehyde. Due to the 
introduction of the alkyl chain at the C22 atom, BUD is a mixture of two epimers (22R 
and 22S) (Figure 4.1) (Albertsson et al., 1978). Both epimers appear to have similar 
pharmacological effects; however, in vitro studies have suggested that the R-epimer is 
two to three times more potent with respect to its anti-inflammatory effects (Brattsand et 
al., 1982). The only pharmacopoeial monograph for BUD appears in the British and 
European Pharmacopoeias (Pharmacopoeia, 2001; Pharmacopoeia, 1997) which state 
that the R/S epimer ratio should be within the range of 60 ~ 49/40 ~ 51. 
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Figure 4.1. The chemical structure of epimer 22R of BUD. The S epimer inverts 
the position of the proton and the propyl grouping on C-22. 
 
4.1.2. Fluticasone propionate 
     Fluticasone propionate (FP) is a highly potent, triflourinated glucocorticoid. Unlike 
most other corticosteroids, the structure is based on androstane, rather than a pregnane 
corticosteroid nucleus (Figure 4.2). The molecule is designed to maximize topical anti-
inflammatory activity and minimise the unwanted systemic side effects associated with 
other glucocorticoids; this is because FP is rapidly metabolised to the inactive 17β-
carboxylic acid metabolite (Bain et al., 1993; Martindale, 2005; Phillipps et al., 1994). 
The combination of potent topical anti-inflammatory and a low systemic side effect 
profile makes FP an ideal compound to treat asthma, seasonal and perennial rhinitis 
(Fuller et al., 1995; Scadding et al., 1995). 
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Figure 4.2. The chemical structure of FP. 
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4.1.3. Salbutamol hemisulfate 
     Salbutamol hemisulfate (SB) (synonym: albuterol hemisulfate) is a relatively 
selective β2-adrenergic agonist and is used as a bronchodilator. The chemical name of 
SB (Figure 4.3) (Ganjali et al., 2005; Oliva et al., 2005; Yamini et al., 2006) is 1-(4-
hydroxy-3-hydroxymethylphenyl)-2-(tert-butylamino) ethanol sulphate (2:1) (salt). SB 
is indicated for the prevention and relief of bronchospasm with reversible obstructive 
airway disease (asthma), and for the prevention of exercise induced bronchospasm. SB 
acts by stimulating the adenyl cyclase enzyme, which catalyzes the formation of cyclic-
3/, 5/-adenosine monophosphate (cyclic AMP) from adenosine triphosphate (ATP). The 
cyclic AMP thus formed, mediates the cellular responses. The increased cyclic AMP 
levels are associated with relaxation of bronchial smooth muscles. SB is effective by 
both oral and inhalation routes of administration so it has been used in tablets, syrups, 
metered dose inhalers, and nebulised inhalation solutions.  
NH2 C
CH3
CH3
CH3
CH2OH
OH
HO
+
 
Figure 4.3. The chemical structure of SB. 
      
     SB, like other β2- agonists are misused by athletes for their potential to improve 
muscular strength via their significant anabolic effects (Clarkson and Thompson, 1997). 
SB is often illegally used as feed additives for their potential role in increasing muscular 
mass and reducing body fat in animal species (Moloney et al., 2003). However, SB is a 
steady substance, so it can be easily deposited in both human and the edible animal 
tissues. When used at higher or long-term dose, it is found to have severe poisoning side 
effects (Vale, 2003). The misuse of SB by athletes has been demonstrated and banned 
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by the World Anti-Doping Agency (WADA). Its usage as feed additives for growth 
promotion in livestock growth, which has resulted in a number of reports of human food 
poisoning (Ramos et al., 2003) has also been prohibited in many countries. 
 
4.1.4. Terbutaline hemisulfate 
   Terbutaline hemisulfate (TBS),1-(3,5-dihydroxyphenyl)-2-(tertbutylamino) ethanol 
sulphate (2:1) (salt) (Figure 4.4) belongs to the class of β2-agonist drugs as SB and used 
for the treatment of pulmonary disorders particularly in the treatment of  bronchial 
asthma in humans (Ramos et al., 2003). As a therapeutic agent, low doses of TBS can 
be administered directly to the lung airways via inhalation in order to minimize negative 
side effects and maximize efficiency (Votion et al., 1997). It has been 
pharmacologically proven to be able to increase muscle protein, reduce total body fat 
due to lipid removal from fat deposits, and promote muscle growth. In animals, in 
addition to its regulatory role in veterinary medicine as a bronchodilator and tocolytic 
agents, increases the ratio of lean meat to fat (re-partitioning) and improve feed 
conversion efficiency (Kuiper et al., 1998). 
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Figure 4.4. The chemical structure of TBS. 
 
     TBS is known to exist in at least two anhydrous modifications (A and B), a 
monohydrate and an acetic acid solvate. A higher hydrate, supposedly a trihydrate 
(which has also been denoted as terbutaline hemisulfate sesquihydrate), has also been 
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reported (Hickel et al., 1982). All five modifications have been structurally 
characterized by thermogravimetric analysis, differential scanning calorimetry, X-ray 
powder diffraction and solid-state NMR (Harris et al., 2008).  
 
     The crystal structures of anhydrate B and the acetic acid solvate are known (Harris et 
al., 2008; Sengupta and Dattagupta, 1996) and are contained in the Cambridge Crystal 
Structure Database (CSD) with codes ZIVKAQ and ZIVKAQ01, respectively. The 
crystal structure of terbutaline hemisulfate sesquihydrate also appears in the CSD, under 
code BECVIO. 
 
4.1.5. Ipratropium bromide 
     Ipratropium bromide (IPRA), chemically known as, 8-isopropyl-nor-atropine-
methylbromide, a quaternary ammonium compound with antimuscarinic properties, is 
used as a bronchodilator for the maintenance and treatment of bronchospasms 
associated with chronic obstructive pulmonary disease (Martindale, 2005) (Figure 4.5). 
 
N
+
O
O
OH
Br-
 
 
 
Figure 4.5. The chemical structure of IPRA. 
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4.2. Experimental 
4.2.1. Materials 
      A specimen of BUD was obtained from Mallincrodkt and specimens of FP, SB, 
IPRA and TBS were obtained from Sigma-Aldrich. All specimens were used without 
further purification.  
 
4.2.2. Raman spectroscopy 
     Fourier-transform Raman spectroscopy for all the drugs studied was carried out 
using a Bruker IFS 66 instrument with an FRA 106 Raman module attachment and a 
Nd3+ /YAG laser operating at 1064 nm in the near infrared. The powdered specimens 
were examined in aluminium cups. The spectra were recorded at 4 cm-1 spectral 
resolution and 500 spectral scans accumulated to improve signal-to-noise ratios. Laser 
powers were maintained at 100 mW at the sample in case of FP, SB and TBS and at 200 
mW in case of BUD and IPRA. 
 
4.2.3. Infrared spectroscopy 
     The IR spectra of the all studied drugs were recorded as KBr discs (1:200) using a 
Digilab Scimitar Series spectrometer. The spectra were recorded in the range of 400-
4000 cm-1 at 4 cm-1 spectral resolution with the accumulation of 512 spectral scans. 
 
4.2.4. X-ray powder diffractometry  
     Powder X-ray diffraction (PXRD) data for BUD and TBS were recorded with a 
Bruker D8 diffractometer with Cu-Kα1,2 radiation (1.5418 Å) and a secondary curved 
graphite monochromator. The X-ray tube was operated at 40 kV and 30 mA. Samples 
were scanned in vertical Bragg-Brentano (θ/2θ) geometry (flat reflection mode) from 5-
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40° (2θ) using a 0.005° step width and a 1.5 s count time at each step in the case of 
BUD and from 5-50° (2θ) using a 0.01° step width and a 1.0 s count time at each step in 
the case of TBS . The receiving slit was 1° and the scattering slit was 0.2°. Data were 
analysed with Bruker AXS Topas 2.1 software including a correction for axial 
divergence. Background coefficients, cell parameters, sample displacement error and 
phase fractions were optimised parameters. 
 
4.2.5. Calculation details 
     Calculations for all the drugs studied were performed using GAMESS-UK (Guest et 
al., 2005) and ORCA programmes (Neese, 2004). Geometry optimisation was initially 
performed using a semi-empirical PM3 Hamiltonian and then further refined using 
BLYP density functional theory with a 6-31G* basis set (Becke, 1988; Lee et al., 1988; 
Neese, 2004). IR and Raman spectra were calculated using the quasi-harmonic 
approximation, through diagonalisation of the mass-weighted Hessian matrix. 
Intensities were calculated using the dipole-moment derivatives and the polarisability 
derivates of the normal modes. 
 
4.3. Results and discussion 
     Prior to the vibrational spectroscopic analysis, it is worth noting that the computed 
vibrational frequencies are sensitive to the theoretical method used and are generally 
shifted with respect to the experimental values. The hybrid BLYP functional has been 
used throughout this work because it shows the best performance with a minimum error 
(Jensen, 2007). At the basis set limit, the deviations from the experimental harmonic 
frequencies are 20-30 cm-1.  
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     The crystal structures, conformations and comparisons between the experimental and 
the calculated vibrational spectra of certain drugs will be presented as representative 
examples. 
     The IR and Raman spectra of the all studied drugs have been recorded over the 
wavenumber range 4000-400 cm-1 and 3600-100 cm-1, respectively, using both 
transmission and attenuated total reflectance modes of operation for the former and 
1064 nm laser wavelength for the later technique.      
     The OH stretching modes observed near 3500 cm-1 in the IR spectra are not observed 
in the Raman spectra, whereas bands in the low wavenumber region that are normally 
characteristic of polymorphic crystalline pharmaceutical forms are not recorded in the 
IR spectra of the all studied drugs. 
 
4.3.1. Budesonide 
4.3.1.1. X ray powder Diffractometry  
     The crystal structures of BUD were taken from the Cambridge Structure Database 
(CDS) as collection codes RHBUXP10 and SHBUXP10 for R- and S-epimers, 
respectively. 
     The composition of BUD sample was investigated by PXRD. All peaks in the pattern 
coincided with theoretical patterns for R- and S-epimer forms generated from single 
crystal studies (Figure 4.6) (Albertsson et al., 1978). Notably, no halo attributable to 
amorphous content in the sample was apparent. Peaks in the pattern were significantly 
broadened and pattern-fitting using the Rietveld approach indicated the presence of only 
two components underpinning the major peaks in the pattern. The broadening was 
hence attributed to the mixture of epimers in the sample. Quantitative Rietveld analysis, 
based on the single crystal structures, indicated the mixture to be composed of epimers 
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in the ratio R:S of 36:64. The two epimers of BUD are known to form solid solutions in 
the mixtures over the composition range 0-95%. (Albertsson et al., 1978). Inclusion of 
both epimers in the same crystal is likely to induce significant disorder which manifests 
as peak broadening in the diffraction pattern (James, 1982). Refinement of cell 
dimensions in conjunction with quantitative Rietveltd analysis resulted in cell 
parameters (R-form: a = 8.510(2), b = 9.175(2), c = 29.027(9) Å; S-form: a =  8.552(2), 
b =  9.228(2), c = 29.1106(9) Å) corresponding to those reported for epimer mixtures 
with a predominance of the S-epimer, again these observations suggest that the material 
corresponds with the range of continuous solid solutions described by Albertsson et al 
(Albertsson et al., 1978). 
 
 
2Theta 
Figure 4.6. PXRD pattern of BUD epimers (the red is 22R and the blue is 22S). 
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4.3.1.2. Infrared and Raman Spectroscopy 
The BUD conformation (Figure 4.7) has been used in the calculation of its vibrational 
spectra. 
 
   Figure 4.7. The BUD conformation   
     The IR and FT-Raman spectra of BUD are shown in Figures 4.8- 4.13; these spectra 
illustrate clearly the complexity of structural information that is provided from IR and 
Raman analysis.  
 
4.3.1.2.1. 4000– 2600 cm-1 region 
     Although the IR spectrum of BUD is reported in the FDM, Electronic Handbook of 
FTIR Spectra, (FDM), this does not identify the epimeric content and does not provide 
spectral band assignments. Bandi et al (Bandi et al., 2004) have reported the IR 
spectrum of BUD and its complex with hydroxypropyl-β-cyclodextrin (HPBCD) citing 
the spectral  band assignments to indicate  the possibility of the molecular interaction 
with excipients, other additives and combinations of drugs. However, no recognition is 
made in this paper of the BUD epimers and a detailed analysis of the υ (C=O) stretching 
region of its complex with HPBCD does not clarify the molecular interaction between 
the BUD and the HPBCD. 
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     The υ (OH) stretching band (Figure 4.8) in the IR spectrum at 3488 cm-1 suggests 
that external hydrogen bonding occurs in the crystalline BUD.  The CH stretching 
region comprises several features in the wavenumber range 3100-2800 cm-1 (Figures 4.8 
and 4.9 for the IR and Raman spectra, respectively); the CH stretching bands of the 
unsaturated, aromatic component of BUD are more clearly shown in the Raman 
spectrum rather than in the IR spectrum (Table 4.1) and can be assigned to bands at 
3043 and 3010 cm-1 in the Raman spectrum. The CH aliphatic stretching bands 
comprise both CH3 and CH2 symmetric and asymmetric stretching modes assigned to 
the medium-strong features between 2990 and 2871 cm-1. A weak feature at 2755 cm-1 
in the IR spectrum (Figure 4.8) is assignable to a combination band arising from the 
CH3CH2 – end group of the aliphatic chain attached to the heterocyclic five-membered 
ring (Edwards et al., 1995b). 
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Figure 4.8. The IR spectrum of BUD, 2600 – 4000 cm-1 region. 
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Figure 4.9. The Raman spectrum of BUD, 2600 – 3200 cm-1 region. 
4.3.1.2.2. 1780 – 1580 cm-1 region 
     This is a very important spectroscopic region for structural studies, particularly for 
the C=O and C=C groups in this molecule. Expanded wavenumber regions of the IR 
and Raman spectra are shown in Figures 4.10 and 4.11, respectively. The IR spectrum 
has two very strong bands at 1721 and 1668 cm-1 compared with a single strong Raman 
band at 1656 cm-1. Close inspection of Figures 4.10 and 4.11 reveals that the strong IR 
band at 1721 cm-1 has a weak shoulder at 1715 cm-1 and that at 1668 cm-1 has a weak 
shoulder at 1656 cm-1; whereas the Raman band at 1656 cm-1 has a weak shoulder at 
1668 cm-1 and two components are identifiable for a weak broad band at 1714 and 1721 
cm-1. There are two other bands clearly seen in this spectral region at 1625, 1603 and 
1627, 1602 cm-1 in the IR and Raman spectra, respectively. The strong band at 1721  
cm -1 in the IR can be attributed to the carbonyl attached to the aliphatic ring (cf. 
literature values for 5-membered aliphatic ring at 1750–1700 cm-1, and dimethyl ketone 
at 1715 cm-1) (Colthup et al., 1975) whereas that at 1668 cm-1 can be attributed to the 
quinonoid aromatic C=O (cf. benzophenone at 1660 cm-1). para –Substitution in an 
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aromatic ring decreases their mode further in wavenumber. In contrast, the  strong 
Raman spectral feature at 1656 cm-1 can be attributed to C=C stretching in the 
quinonoid aromatic ring. Figure 4.10 and 4.11 also show the curve-resolved spectral 
region accomplished using the GRAMS8 package which contain the components of the 
C=O and C=C modes discussed above.     
     The 1714 cm-1 band in the doublet is reliably assigned to the intramolecular 
hydrogen bonded C=O group which with the evidence from the OH stretching region, 
can be associated with the OH group on the side chain of the 5-membered aliphatic ring. 
Another possible assignment of the carbonyl bands at 1720 and 1714 cm-1 is a 
monomer/dimer structure but this can be excluded here on the basis of the PXRD 
evidence. Considerable spectroscopic attention focuses on the closeness in wavenumber 
between the aromatic C=O at 1668 cm-1 (strong in the IR and weak in the Raman) and 
the C=C band at 1656 cm-1 (strong in the Raman and weak in the IR); close coupling 
between the conjugated C=C and C=O in the aromatic ring is suggested and the 
quantum chemical calculations confirm this. 
     The remaining two vibrational bands in this wavenumber region at 1627 and 1602  
cm-1 (Raman), 1625 and 1603 cm-1 (IR) can be assigned on the basis of the quantum 
chemical calculations to molecular vibrations that involve both C=C and C=O groups in 
an   asymmetric ring vibrations. 
     It is appropriate here to consider the results from our interpretation of the C=O and   
C=C stretching region of BUD in comparison with the previously reported IR spectrum 
(FDM). Firstly, Bandi et al (Bandi et al., 2004) did not consider the R&S epimers of 
BUD. Secondly, they have calculated that the molecular interaction between BUD and 
HPBCD should have produced a  band wavenumber shift in the IR of 11 cm-1, from 
which they proposed that there is a possible change in the environment of the BUD 
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band of the quinonoid C=O group. They observed that there is a change in the spectrum 
with a shift from 1673 to 1662 cm-1. Our Raman and IR structural analysis here can now 
be applied to the data of Bandi et al. and we can confirm the assignment of 1668 cm-1 
band as a quinonoid structure. It is interesting also that the 11 cm-1 shift reported on 
molecular complexation by Bandi et al now brings their modes into almost exact 
coincidence with the C=C  Raman mode , when the close ring coupling between the 
C=C and C=O is supported from our calculations.  
 
  
Figure 4.10. Expanded wavenumber region of the IR spectrum of BUD (1580 – 
1780 cm-1), showing observed (-) and curve resolved (□) component spectra. 
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Figure 4.11. Expanded wavenumber region of the Raman spectrum of BUD (1580 
– 1780 cm-1), showing observed (-) and curve resolved (□) component spectra.   
 
4.3.1.2.3. 1800 – 100 cm-1 region 
     The IR and Raman spectra over this wavenumber range are shown in Figures 4.12 
and 4.13, respectively; the IR comprises a rich spectrum from the C=O and C=C 
functionalities, which have already been discussed in some detail above, along with 
many bands of medium and strong intensities, whereas the Raman spectrum consists 
mainly of the strong C=C features and relatively few, weaker features.  In the range 
1450 – 1300 cm-1 we expect CH3 and CH2 aliphatic bending vibrations to occur with 
CHO deformations around 1375 – 1410 cm-1. Lower in wavenumber, we expect to find 
the COC ether stretching modes at 1140/1130 cm-1 and 1050/1040 cm-1 strong in the IR, 
and at 870/850 cm-1 of medium intensity in the Raman spectrum. CCO stretching occurs 
between 1150-1075 and 1075-1000 cm-1 for primary and secondary alcohols, with 
strong bands in the IR spectrum and medium bands in the Raman spectrum. COH 
bending occurs over a wide range between 1430 and 1200 cm-1, weak in intensity in the 
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IR spectrum and of medium weak intensity in the Raman spectrum. The CH2 scissoring 
and wagging modes occur near 1250 cm-1. 
     Then, in the 1100 – 900 cm-1 region we can expect modes arising from CCH bending 
and C–O stretches in primary and secondary alcohols near 1060 cm-1 and C–C 
stretching modes in the aliphatic chains and alicyclic moieties. Methyl rocking and CH2 
rocking modes extend over the region 970 – 760 cm-1. 
     Finally, complex ring modes of CCO and COCOC vibrations and deformations in 
the range between 660 and 500 cm-1 occur in the low wavenumber region; in this 
region, we should expect the aromatic quinonoid ring deformations near 600 cm-1. In 
the weak bands observed in the Raman spectrum below 400 cm-1, the methyl torsional 
mode at 265 cm-1 of medium weak intensity can be noted. 
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Figure 4.12. Expanded wavenumber region of the IR spectrum of BUD (100 – 1800 
cm-1). 
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Figure 4.13. Expanded wavenumber region of the Raman spectrum of BUD (100 – 
1800 cm-1). 
 
     The key Raman spectral features of BUD are the aromatic υ(CH) band at 3043 cm-1, 
the υas(CH2) band at 2940 cm-1, the υ(CH2) bands at 2914 and 2871 cm-1 and the 
υ(C=C) band at 1656 cm-1, while its key IR spectral features are the hydrogen bonded 
υ(OH) band at 3488 cm-1, the υas(CH2) band at 2936 cm-1, the υ(CH2) band at 2873 cm-
1, the υ (C=O) band at 1721 cm-1, the υ(C=C) band at 1668 cm-1, the in-plane δ(CH) 
band at 1407 cm-1, the υ(C–C) band at 1292 cm-1, the υ(C-OH) bands at 1051 and 1014 
cm-1 and the CCH aromatic deformation band at 888 cm-1.  
 
     Molecular vibrational assignments for the observed IR and Raman bands are given in 
Table 4.1. 
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Table 4.1. Vibrational wavenumbers/cm-1 of BUD. 
 
 
Observed 
 
Raman 
 
IR 
 
Calculated
 
Proposed Assignment 
- 3488, br, s 3419 OH stretching, H-bonded 
3043 m 3040 w 3032 aromatic CH stretching 
3010 mw 3009 w 3007 (C=CH) stretching 
2990 mw - 2994 υas CH3 stretching 
- 2958 2964 υas CH3, υas CH2 stretching 
2940 s 2936 s 2946 υas CH2 stretching 
2914 s 2915 m, sh 2929 υ CH2 stretching 
2902 w, sh 2900 w, sh 2900 υ CH3 stretching 
2871 s 2873 s 2875 υ CH2 stretching 
2755 mw 2755 w  (CH3-CH2-) end group; combination band 
1721 w, sh 1721 s 1687 υ (C=O) 
1714 mw, br 1715 w, sh  υ (C=O) 
1668 w, sh 1668 s 1665 υ (C=O) 
1656 vs 1656 mw, sh  υ (C=C) 
1627 mw 1625 ms 1632  
1602 mw 1603 ms 1597  
1451 mw 1450 mw, sh  CH3 symmetric deformation 
 1440 m 1429  
 1407 ms 1403 CH deformation/ in plane 
 1394 ms 1401  
 1369 mw 1367  
1352 w 1353 mw 1354  
1329 mw 1327 mw 1330  
1296 w 1292 m 1285 υ(C–C) 
1240 w 1239 m 1239  
 1217 w 1225  
1162 w 1166 1152  
1130 w 1133 m 1141  
1109 mw 1110 m 1112  
 1092 m 1097  
1029 w 1051 m 1067 C–OH stretching 
  1030  
 1014 m 1018 C–OH stretching 
970 w 982 mw 987 CH3 rocking 
 956 mw 957 CH3 rocking 
 932 w 933  
 910 w 916  
 888 ms 892 CCH aromatic deformation 
 872 mw 866 CCH aromatic deformation 
 849 m, br 847  
823 w 821 m 821  
768 w 769 mw  CH2 rocking 
 739 w   
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Table 4.1. (Continued) 
 
 
Observed 
 
Raman 
 
IR 
 
Calculated
 
Proposed Assignment 
 696 mw  CH wagging 
671 w    
643 mw    
531 mw  538  
414 w    
312 w    
265 mw   CH3τ 
 
4.3.2. Fluticasone propionate 
     An initial structure (code DAXYUX) (Figure 4.14) for the geometry optimisation 
was taken from the CSD optimised using BLYP density functional theory (Becke, 1988; 
Lee et al., 1988). 
 
 
 
Figure 4.14. The crystal structure of FP (code DAXYUX).     
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     The IR and FT-Raman spectra are shown in Figures 4.15-4.17. A complete 
assignment of the experimental vibrational features was carried out (Table 4.2) in the 
light of both the theoretical results presently performed and the vibrational 
spectroscopic data. Several calculated modes have been matched with the 
experimentally observed bands in the IR and Raman spectra, and these modes have been 
described. The vibrational spectra illustrate clearly the complexity of structural 
information that is provided from the IR and Raman analysis. 
 
4.3.2.1. 3700 – 2600 cm-1 region  
     Although the IR and Raman spectra have been reported previously (Guo-feng et al., 
2007; Theophilus et al., 2006), but these reports provide neither spectral band 
assignments nor vibrational spectroscopic characterisation in conjunction with the 
quantum chemical calculations. 
     The profile of the υ (OH) stretching band (Figure 4.15) in the IR spectrum at 3336 
cm-1 suggests that external hydrogen bonding occurs in the crystalline FP. The CH 
stretching region comprises several features in the wavenumber range 3100 – 2800 cm-1 
(Figure 4.15) for the IR and Raman spectra; the CH stretching bands of the unsaturated, 
component of FP are shown more clearly in the Raman spectrum rather than in the IR 
spectrum (Table 4.2) and can be assigned to the bands at 3075 and 3058 cm-1 in the 
Raman spectrum in addition to, the CH stretching band of the five membered ring at 
3023 cm-1. The CH aliphatic stretching bands comprise both CH3 and CH2 symmetric 
and asymmetric stretching modes which have been assigned to the medium intensity 
features between 2878 and 2965 cm-1. 
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Figure 4.15. FT-Raman and IR spectral stackplot of FP in the 2600 – 3700 cm-1 
region. 
 
4.3.2.2. 1800 – 1550 cm-1 region 
     This is a very important spectroscopic region for structural studies, particularly for 
the C=O and C=C groups in the molecule. Expanded wavenumber regions of the IR and 
Raman spectra are shown in Figure 4.16. The IR spectrum has one very strong band at 
1661 cm-1 and four strong bands at 1744, 1699,1616 and 1611 cm-1 compared to one 
very strong band at 1663 cm-1, one medium band at 1606 cm-1, medium shoulder band 
at 1611 cm-1 and two weak bands at 1742 and 1698 cm-1 in the Raman spectrum. The 
strong bands at 1744 and 1699 cm-1 in the IR spectrum and the weak Raman spectral 
features at 1742 and 1698 cm-1 can be attributed to the carbonyl attached to the aliphatic 
ring (cf. literature values for a five membered aliphatic ring at 1750 – 1700 cm-1, and 
dimethyl ketone at 1715 cm-1) (Colthup et al., 1975) and carbonyl attached to sulfur 
respectively, this shift occurs because of force constant changes in the carbonyl bond 
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(Lin-Vien et al., 1991), whereas that at 1661 and 1616 cm-1 can be attributed to the C=O 
and C=C stretching vibration in the quinonoid aromatic ring (cf. benzophenone at 1660 
cm-1), which couples together in the same moiety.  This coupling explains the observed 
strength in both Raman and IR bands at 1663 and 1661 cm-1 respectively.  
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Figure 4.16. FT-Raman and IR spectral stackplot of FP in the 1550 – 1800 cm-1 
region. 
 
4.3.2.3. 1800 – 100 cm-1 region 
     The IR and Raman spectra over this wavenumber region are shown in Figure 4.17; 
the IR region comprises a rich spectrum from the C=O and C=C functionalities, which 
have been already discussed in some detail above, along with several bands of medium 
and strong intensities, whereas the Raman spectrum consists mainly of the strong C=C 
features and other weaker features. In the range 1530 – 1330 cm-1, we expect CH3, CH2 
and CH aliphatic deformation vibrations to occur. Lower in wavenumber, we expect to 
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find the aliphatic C-F stretching vibrations at 1271 and 1233 cm-1,  of medium intensity 
in the IR spectrum and of weak intensity in the Raman spectrum. The in-plane δ(CH) 
vibration occurs at  1226 cm -1 in the IR spectrum of medium intensity and at 1194 cm-1 
in the Raman spectrum of medium weak intensity and the υ(F-C-S) band occurs at 1027 
cm-1 in the IR spectrum of medium intensity and at 1023 cm-1  in the Raman spectrum 
of weak intensity. 
     Methyl rocking and CH2 rocking modes extend over the range 970 – 995 cm-1, the 
CCH aromatic deformation mode extends over the range 870 – 900 cm-1, the (O=C-O-
C) stretching mode occurs at 843 cm-1 , the CH wagging mode occurs near 700 cm-1 and 
the C-S stretching mode occurs in the range of 616 – 650 cm-1.  
     Finally, the complex ring modes of CCO and COCOC vibrations and deformations 
in the range between 600 and 500 cm-1 occur. In the low wavenumber region the methyl 
torsional mode at 234 and 264 cm-1 of weak intensity can be noted. 
Figure 4.17. FT-Raman and IR spectral stackplot of FP in the 100 – 1800 cm-1 
region. 
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     The key Raman spectral features of FP are the υas (CH2) band at 2935 cm-1, the  
υ(C=O) band at 1663 cm-1 and the δ(CH3) band at 1606 cm-1, while the key IR spectral 
features are the υ(OH)  band at 3336 cm-1, the υ(C=CH) band at 2975 cm-1, the υas 
(CH3), υas (CH2)  bands at 2964, 2942 and 2881 cm-1, the υ (C=O) bands at 1744 and 
1661 cm-1, the υ (S-C=O) band at 1699 cm-1, the υ (C=C) band at 1616 cm-1, the δ(CH3) 
band at 1455 cm-1, the υ(C-C) band at 1304 cm-1, the υ(C-F) band at 1271 cm-1, the in-
plane δ(CH) band at 1226 cm-1, the υ(F-C-S) band at 1027 cm-1, the r(CH3) band at 993 
cm-1, the δ(C-C-C) band at 944 cm-1 and the CCH aromatic deformation bands at 895, 
884 and 873 cm-1.  
Table 4.2. The observed and calculated vibrational wavenumbers/cm-1 of FP. The 
calculated Raman and IR intensities (IRaman and IIR) are relative to that of υ (C=O) 
at 1667 cm-1, set arbitrarily equal to 1.  
 
 
Observed 
 
 
Calculated 
Raman 
(cm-1) 
IR 
(cm-1) 
 
υ 
 
IRaman 
 
IIR 
 
 
Proposed Assignment 
 3336 m 3567 0.513 0.030 υ(OH)  
3075 w 3069 vw 3123 0.186 0.035 υ(CH) 
3058 mw 3051 vw 3082 0.465 0.069 υ(CH)  
3023 mw 3024 vw 3027 0.229 0.120 υ(CH) of the five membered ring  
3005 mw 2975 m 2999 0.291 0.119 υ(C=CH)  
2965 mw 2964 m 2968 0.138 0.080 υas (CH3), υas (CH2) 
2935 m 2942 m 2944 0.308 0.155 υas (CH2) 
2878 mw 2881 m 2933 0.356 0.102 υs (CH2) 
1742 w 1744 s 1737 0.684 0.047 υ (C=O)  
1698 w 1699 s 1695 0.118 0.525 υ (S-C=O) 
1663 vs 1661 vs 1667 1.000 1.000 υ (C=C) 
 1616 s 1639 0.036 0.155 υ (C=C) 
1611 sh,m 1611 s     
1606 m  1607 0.054 0.039 δ(CH3) 
1492 mw 1530 vw 1493 0.071 0.019 δ(CH3)  
1453 mw 1455 m 1445 0.027 0.058 δ(CH3) 
1422 w 1421 mw 1425 0.004 0.024 Ring stretching 
1387 w 1395 mw 1399 0.041 0.017 δ(CH2) 
1369 w 1376 mw 1372 0.028 0.045  
1334 w 1365 mw 1357 0.019 0.002 δ(CH) 
1321 m 1319 m 1323 0.074 0.034  
1281 w 1304 m 1298 0.081 0.059 υ (C-C) 
1233 mw 1271 m 1267 0.035 0.074 υ (C-F) 
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Table 4.2. (Continued) 
 
Observed 
 
 
Calculated 
Raman 
(cm-1) 
IR 
(cm-1) 
 
υ 
 
IRaman 
 
IIR 
 
 
Proposed Assignment 
 1248 m 1244 0.018 0.055  
1194 mw 1226 m 1223 0.097 0.052 In-plane δ(CH) 
 1214 m 1217 0.015 0.016  
1168 mw 1188 m 1177 0.017 0.022  
1146 mw 1147 w 1147 0.004 0.397  
1126 w 1124 m 1124 0.167 0.046  
1106 w  1109 0.021 0.016  
1067 w 1064 s 1070 0.039 0.090  
1058 w  1058 0.018 0.055  
1023 w 1027 m 1020 0.023 0.480 υ(F-C-S)  
992 w 993 s 993 0.097 0.196 r(CH3)  
970 w  972 0.004 0.053 r(CH3) 
953 w 944 m 953 0.047 0.257 δ(C-C-C) 
931 w 933 m 936 0.015 0.124  
887 w 895 ms 904 0.028 0.135 CCH aromatic deformation 
 884 ms 877 0.011 0.094 CCH aromatic deformation 
869 w 873 m 863 0.016 0.110 CCH aromatic deformation 
843 w  835 0.033 0.028 υ(O=C-O-C) 
 816 w 816 0.022 0.046  
799 vw 797 w 802 0.002 0.014  
773 vw 782 w 776 0.021 0.032 r(CH2) 
733 m 734 mw 751 0.008 0.009  
698 vw 707 w 706 0.003 0.013 CH wagging 
650 vw  655 0.005 0.037 υ(C-S) 
616 vw  626 0.015 0.012 υ(C-S) 
584 w  581 0.005 0.016  
562 w  558 0.034 0.015  
549 w  541 0.004 0.084  
532 w  524 0.022 0.009  
519 w  512 0.019 0.012 Out-of-plane δ(CC)  
505 w  508 0.002 0.014  
470 vw  484 0.019 0.016  
448 vw  448 0.008 0.004  
435 vw  425 0.009 0.007  
409 w  408 0.013 0.033  
387 vw  387 0.014 0.018  
370 w  372 0.015 0.025  
348 vw  348 0.013 0.014  
330 vw  324 0.007 0.203  
308 w  311 0.019 0.008  
286 vw  282 0.011 0.08  
264 w  264 9.6e-4 0.018 CH3τ 
234 w  237 0.013 0.026 CH3τ 
159 w  156 0.010 0.011  
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4.3.3. Salbutamol hemisulfate 
     Calculations were performed on the SB cation (Figure 4.18)  and its molecular 
structure used for geometry optimisation, using the BLYP density functional with a 6-
31G* basis set (Becke, 1988; Lee et al., 1988), was taken from Cambridge Crystal 
Structure Database (CSD) with code SALBUT, Figure 4.19. 
 
Figure 4.18. The SB conformation 
 
 
 
Figure 4.19. The crystal structure of SB (code SALBUT).     
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     The observed IR and Raman spectroscopic wavenumbers are listed in Table 4.3 
along with the calculated values; assignment of the major experimental vibrational 
features was carried out in the light of the theoretical results and the vibrational 
spectroscopic data previously reported (Corrigan et al., 2006; Edwards et al., 1993a; 
FDM; Ticehurst et al., 1994). Several calculated modes have been matched with 
experimentally observed bands in the IR and Raman spectra, and these modes have been 
described; very weak features in the observed spectra cannot be reliably assigned on the 
basis of the quantum chemical calculations.   
 
4.3.3.1. 3800 – 2200 cm-1 region 
     The broad rather diffuse υ (OH) stretching band (Figure 4.20) in the IR spectrum at 
3474 cm-1 suggests that hydrogen bonding occurs in the crystalline SB. The υ (NH) 
stretching band is observed in the IR spectrum in the range 3280 – 3160 cm-1 (Figure 
4.16). The CH stretching region comprises several features in the wavenumber range 
3130 – 2800 cm-1 (Figure 4.20) for the IR and Raman spectra; the CH stretching bands 
of the aromatic component of SB are shown in the Raman spectrum (Table 4.3) and can 
be assigned to the bands at 3127, 3107 and 3093 cm-1. The CH aliphatic stretching 
bands of CH3 symmetric and asymmetric stretching modes are shown in the both 
Raman and IR spectra, and can be assigned to the medium strong features at 3025 and 
2982 cm-1 and the medium feature at 2954 cm-1 in the IR spectrum, the weak feature at 
3027 cm-1, the medium strong feature at 2985 cm-1, the medium shoulder feature at 
2973 cm-1 and the medium feature at 2880 cm-1 in the Raman spectrum. The broad 
medium band at 2927 cm-1 and the medium band at 2899 cm-1 in the Raman spectrum 
can be attributed to υ (CH) and υ (CH2) attached to aliphatic (OH), respectively, and the 
weak feature at 2623 cm-1 can be assigned to υ (CC) ring. 
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Figure 4.20. FT-Raman and IR spectral stack plot of SB in the 2200 – 3800 cm-1 
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region. 
 
4.3.3.2. 1800 – 1100 cm-1 region 
     This is a very important spectroscopic region for structural studies, particularly for 
the C=C group in this molecule. Expanded wavenumber regions of the IR and Raman 
spectra are shown in Figure 4.21. It is worth noting that, the calculated band of δ (NH2+) 
at 1643 cm-1 was observed in neither IR nor Raman spectra and this may be attributed to 
the presence of sulfate anion which may hinder this feature. The IR region comprises a 
rich spectrum from the C=C functionality, along with several bands of medium and 
strong intensities, whereas the Raman spectrum consists mainly of the strong C=C 
features and several other weaker features. The υ(C=C) band occurs at 1616 cm-1, of 
medium strong intensity in both the Raman and IR spectra. The bands at 1616 and 1205 
cm-1 in both Raman and IR spectra and the band at 1558 cm-1 in the IR spectrum can be 
assigned on the basis of quantum chemical calculations as hydrogen bonded C-OH 
angle coupled to a phenyl ring vibration. Again, it is worth noting that the calculated 
methyl deformation vibrational bands at 1569, 1563 and 1552 cm-1 have not been 
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observed in the experimental vibrational spectra which may be due to the presence of 
the sulfate anion which may hinder the observation of some of the methyl deformation 
features. The very weak feature at 1539 cm-1 and the medium strong feature at 1507  
cm-1 in the IR spectrum can be assigned to υ(CC)ring and δ(CH2)(sciss.) modes, 
respectively. The medium intensity band in the Raman spectrum and the medium weak 
band in the IR spectrum at 1468 cm-1 can be assigned to δ (CH2-N). In the 1360 – 1390 
cm-1 range in the IR spectrum we have observed three bands at 1386, 1379 and 1362  
cm-1 which can be assigned on the basis of quantum chemical calculations as mixed 
modes associated with δ(NH2+), δ(CH2) and δ(CHOH) groups.  In the range 1470 – 
1250 cm-1, we expect CH3, CH2 and CH aliphatic bending vibrations bands to occur. 
Lower in wavenumber we have observed the υ(S=O) band at 1156 cm-1 in the Raman 
spectrum and the δ(COH) and δ(CH2OH) bands at 1126 cm-1 and the very strong band 
at 1112 cm-1 in the IR spectrum which can be assigned on the basis of quantum 
chemical calculations to hydrogen bonded CH-OH angle coupled to the phenyl ring 
vibration. 
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 Figure 4.21. FT-Raman and IR spectral stack plot of SB in the 1100 – 1800 cm-1 
region. 
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4.3.3.3. 1100 – 50 cm-1 region 
     IR and Raman spectra over this wavenumber range are presented in Figure 4.22. The 
strong band in the IR spectrum at 1084 cm-1 can be assigned on the basis of quantum 
chemical calculation to hydrogen bonded CH-OH & CH2OH angle coupled to phenyl 
ring vibration and the very strong band at 1029 cm-1 can be assigned to r (CH3) mode. 
The three υas(C-OH) bands of the three OH groups of SB are more clearly shown in the 
IR spectrum of medium intensity at 988 and 978 cm-1 and weak intensity at 947 cm-1 as 
well as the υas(CN) and the υas(CN) attached to the quaternary carbon bands at 916 and 
840 cm-1 respectively.  Lower in wavenumber, we expect to find the υ(C-C-O) band at 
780 cm-1 in the Raman spectrum and at 773 cm-1 in the IR spectrum and the CH 
wagging bands at 648 cm-1 in the Raman spectrum and at 668 and 647 cm-1 in the IR 
spectrum.  
     Finally, the complex ring modes of CCC and CCN deformations in the range 
between 300 and 550 cm-1 occur. The very weak feature in the Raman spectrum at 404 
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cm-1 can be assigned on the basis of quantum chemical calculations to δ(OH). The 
methyl torsional band is observed in the Raman spectrum at 264 cm-1 of weak intensity. 
The skeletal mode extends over the region of 80 to 150 cm-1 in the Raman spectrum. 
 
 Figure 4.22. FT-Raman and IR spectral stack plot of SB in the 50 – 1100 cm-1 
region. 
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     The key Raman spectral features of SB are the υ(NH) band at 3160 cm-1, the υ(CH2) 
and υ(CH3)  bands  at 3062 cm-1, the υas(CH3) band at 2985 cm-1,the υ(CH) attached to 
aliphatic (OH) band at 2927 cm-1, the υ(CH2) attached to aliphatic (OH) band at 2899 
cm-1, the  υ(CH3) band at 2880 cm-1, the υ(C=C) band at 1616 cm-1, the δ(CH2-N) band 
at 1466 cm-1, the δ(CH) band at 1255 cm-1,  the υas(C-OH) band at 978 cm-1, the υ(C-C-
O) band at 780 cm-1 and the skeletal mode bands at 150, 101 and 81 cm-1 , while its  key 
IR spectral features are the υ(OH) band at 3474 cm-1, the υ(NH) bands at 3272 and 3162 
cm-1, the υas(CH2) attached to (OH) band at 3025 cm-1, the υas(CH3) bands at 2982 and 
2954 cm-1, the υ(C=C) band at 1616 cm-1, the δ(CH2)(sciss.) band at 1507 cm-1, the mixed 
modes associated with δ(NH2+), δ(CH2) and δ(CHOH) at 1386 and 1379 cm-1, the 
 95
hydrogen bonded C-OH angle coupled to phenyl ring vibration bands at 1205 and 1112 
cm-1 , the hydrogen bonded CH-OH & CH2OH angle coupled to phenyl ring vibration 
band at 1084 cm-1 ,  the r(CH3) band at 1029 cm-1 , the υas (C-OH) bands of the three 
(OH) groups at 988, 978 and 947 cm-1 and the υas(CN) attached to the quaternary carbon 
band at 840 cm -1   
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Table 4.3. The observed and calculated vibrational wavenumbers/cm-1 of SB. The 
calculated IR intensities (IIR) are relative to that of δ(COH) and δ(CH2OH) at 1187 
cm-1. The calculated Raman intensities (IRaman) are relative to that of υas(CH3) at 
2997 cm-1.  
 
Observed 
 
 
Calculated 
Raman 
(cm-1) 
IR 
(cm-1) 
 
υ 
 
IRaman 
 
IIR 
 
 
Proposed Assignment 
 3474 ms 3573 0.450 0.250 υ(OH)  
 3272 s 3344 0.158 0.141 υ(NH) 
3190 vw     υ(NH)  
3177 vw     υ(NH) 
3160 vs 3162 s 3208 0.345 0.452 υ(NH) 
3127 w  3120 0.384 0.504 υ(CH)ring 
3107 vw  3103 0.255 0.335 υ(CH)ring 
3093 vw  3091 0.400 0.057 υ(CH)ring 
3062 m  3058 0.261 0.342 υ(CH2)& υ(CH3) 
3027 w 3025 ms 3037 0.235 0.308 υas(CH2) attached to (OH) 
2985 ms 2982 ms 2997 1.000 0.010 υas(CH3) 
2973 m,sh  2992 0.115 0.046 υas(CH3) 
 2954 m 2984 0.202 0.048 υas(CH3) 
2927 br,m  2925 0.216 0.161 υ(CH) attached to aliphatic (OH) 
2899 m  2920 0.622 0.237 υ(CH2) attached to aliphatic (OH) 
2880 m     υ(CH3) 
2854 w      
2833 vw      
2821 vw      
2808 w,br      
 2793 ms,br     
2760 w      
2745 w,br      
2728 vw 2726 m     
2711 vw      
2702 w,br      
 2691 m     
2676 w      
2659 w      
2641 vw      
2623 w     υ(CC)ring 
 2584 mw     
 2560 mw     
 2483 w     
 2457 mw     
 2360 mw     
 2341 w     
  1643 0.032 0.219 δ(NH2+) 
1616 ms 1616 ms 1625 0.259 0.177 Hydrogen bonded C-OH angle 
coupled to phenyl ring vibration & 
(C=C) 
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Table 4.3. (Continued) 
 
 
Observed 
 
 
Calculated 
Raman 
(cm-1) 
IR 
(cm-1) 
 
υ 
 
IRaman 
 
IIR 
 
 
Proposed Assignment 
 1558 vw 1580 0.111 0.059 Hydrogen bonded C-OH angle 
coupled to phenyl ring vibration 
  1569 0.036 0.052 δ(CH3) 
  1563 0.069 0.172 δ(CH3) 
  1552 0.033 0.027 δ(CH3) 
 1539 vw 1527 0.014 0.391 υ(CC)ring 
 1507 ms    δ(CH2)(sciss.) 
1494 mw  1489 0.062 0.031  
1468 m 1468 mw 1475 0.052 0.064 δ(CH2-N)  
 1455 mw 1456 0.052 0.054  
 1438 m 1429 0.083 0.049 Ring stretch 
 1409 mw 1419 0.029 0.183 Hydrogen bonded C-OH angle 
coupled to phenyl ring vibration 
1395 vw 1395 m 1395 0.016 0.919  
 1386 m 1376 0.085 0.167 Mixed modes associated with 
δ(NH2+), δ(CH2) and δ(CHOH) 
 1379 m 1371 0.009 0.135 Mixed modes associated with 
δ(NH2+), δ(CH2) and δ(CHOH) 
1360 w 1362 mw 1355 0.076 0.038 Mixed modes associated with 
CH2 and CH-OH vibrations 
 1340 w 1344 0.006 0.290 Ring stretch 
1331 vw     In-plane δ(CH)  
 1309 vw 1299 0.028 0.014  
1283 vw  1290 0.009 0.119 υ(C-C) of  the t- Butyl group 
1255 m 1261 m,sh 1268 0.017 0.327 δ(CH) 
 1244 m 1249 0.018 0.129  
1205 w 1205 m 1219 0.065 0.032 Hydrogen bonded C-OH angle 
coupled to phenyl ring vibration 
1187 w      
1156 vw     υ(S=O) 
 1126 ms,sh 1187 0.029 1.000 δ(COH) and δ(CH2OH) 
 1112 vs 1106 0.031 0.141 Hydrogen bonded CH-OH angle 
coupled to phenyl ring vibration 
1080 w 1084 s 1097 0.007 0.418 Hydrogen bonded CH-OH & 
CH2OH angle coupled to phenyl 
ring vibration 
1062 w 1060 ms 1067 0.017 0.008  
1034 vw 1029 vs 1033 0.014 0.124 r(CH3) 
1011 w 988 m 1012 0.060 0.446 υas(C-OH) 
978 s 978 m 965 0.010 0.188 υas(C-OH) 
 947 w 944 0.040 0.076 υas(C-OH) 
937 mw 
 
 924 0.026 0.008 Out-of-plane δ(CH)  
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Table 4.3. (Continued) 
 
 
Observed 
 
 
Calculated 
Raman 
(cm-1) 
IR 
(cm-1) 
 
υ 
 
IRaman 
 
IIR 
 
 
Proposed Assignment 
917 vw 916 mw 912 0.137 0.376 υas(CN)  
881 w 882 w 910 0.073 0.102 δ(CH)ring 
859 vw  869 0.026 0.074 δ(CC)ring 
841 vw 840 m 835 0.041 0.121 υas(CN) attached to the quaternary 
carbon 
 792 vw 796 0.013 0.137 Out-of-plane δ(CH)ring 
780 ms 773 w 775 0.010 0.020 υ(C-C-O) 
747 m 747 w 750 0.092 0.022 Ring vibration 
729 vw  728 0.005 0.026 Out-of-plane δ(CC)ring 
 668 w 670 0.003 0.006 CH wagging 
648 w 647 w 651 0.006 0.006 CH wagging 
609 vw 616 mw,sh 635 0.006 0.091 δ(CCC) 
 610 m 593 0.006 0.066 Ring deformation 
589 w  577 0.010 0.071 Out-of-plane δ(CCC)ring 
569 vw 575 vw    In-plane δ(CCN)  
533 w 534 w 520 0.033 0.011 Out-of-plane δ(CC) 
487 mw 487 vw 472 0.009 0.014  
465 vw 464 w 457 0.002 0.124 δ(CC)chain 
404 vw  409 0.017 0.664 δ(OH) 
360 w  362 0.006 0.008 Out-of-plane (CCC) skeletal 
deformation 
338 vw  333 0.004 0.126 Out-of-plane (CCC) skeletal 
deformation 
312 w  318 0.013 0.250 In-plane (CCC) skeletal 
deformation 
264 w  257 0.004 0.016 CH3τ 
193 m  203 0.013 0.032  
165 ms  165 0.007 0.010  
150 ms  142 0.017 0.010 Skeletal mode 
101 s  101 0.004 0.015 Skeletal mode 
81 vs 
 
 92 0.001 0.015 Skeletal mode 
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4.3.4. Terbutaline hemisulfate 
     The PXRD pattern of TBS is presented in Figure. 4.23. The diffraction pattern of 
TBS has been used to establish the solid-phase identity of the sample under 
investigation. All peaks in the pattern coincided with the theoretical patterns for 
terbutaline hemisulfate sesquihydrate as appears in CSD, under code BECVIO (Figure 
4.24). The calculations were performed on the terbutaline cation. 
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Figure 4.23. The PXRD pattern of TBS. 
 
Figure 4.24. The crystal structure of terbutaline hemisulfate sesquihydrate (code 
BECVIO).     
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     The observed IR and Raman spectroscopic wavenumbers are listed in Table 4.4 
along with the calculated values; assignment of the major experimental vibrational 
features was carried out in the light of the theoretical results performed and the 
spectroscopic Raman data and the previously reported IR data (Agatonovic-Kustrin and 
Alany, 2001; FDM). Several calculated modes have been matched with experimentally 
observed bands in the IR and Raman spectra, and these modes have been described; 
only very weak features in the observed spectra cannot be reliably assigned on the basis 
of the quantum chemical calculations.   
 
4.3.4.1. 3800 – 2100 cm-1 region 
     The υ (OH) stretching band (Figure 4.25) in the IR spectrum at 3527 cm-1 suggests 
that hydrogen bonding occurs in the crystalline TBS. The υ (NH) stretching bands are 
observed in the IR spectrum in the range 3500 – 3100 cm-1 (Figure 4.25) which are 
much more broader than the υ (OH) band. The CH stretching region comprises several 
features in the wavenumber range 3100 – 2800 cm-1 (Figure 4.25) for the IR and Raman 
spectra; the CH stretching bands of the aromatic component of TBS are shown in both 
the Raman and IR spectra (Table 4.4) and can be assigned to the bands at 3057 and 
3069 cm-1 in the Raman and IR spectra respectively. The CH aliphatic stretching bands 
of CH3 symmetric and asymmetric stretching modes are more clearly shown in the 
Raman spectrum rather than the IR spectrum and can be assigned to the medium feature 
at 2978 cm-1 and to the medium weak feature at 2881 cm-1. 
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Figure 4.25. FT-Raman and IR spectral stackplot of TBS in the 2100 – 3800 cm-1 
region. 
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4.3.4.2. 1800 – 1100 cm-1 region 
     This is a very important spectroscopic region for structural studies, particularly for 
the C=C group in this molecule. Expanded wavenumber regions of the IR and Raman 
spectra are shown in Figure 4.26. A comparison between the experimental and 
calculated IR and Raman spectra (Figures 4.27 and 4.28) are also presented to show the 
overall agreement between them as a representative example. The IR spectral region 
comprises a rich spectrum from the C=C functionality, along with several bands of 
medium and strong intensities, whereas the Raman spectrum consists mainly of the 
strong C=C features and several other weaker features. The υ(C=C) band occurs at 1604 
cm-1, of medium intensity in the Raman spectrum and strong intensity in the IR 
spectrum. It is worth noting that , the calculated methyl deformation vibrational bands at 
1549, 1558 and 1568 cm-1 have not been observed in the experimental spectra that is 
due to the presence of sulfate anion may hinder some of the methyl deformation 
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features. The δ (NH+2) band is observed at 1624 cm-1 of medium intensity in the Raman 
spectrum and medium strong intensity in the IR spectrum. In the range 1490 – 1300 cm-
1, we expect CH3, CH2 and CH aliphatic bending vibrations bands to occur. Lower in 
wavenumber we expect to find the υ(C-C) and υ(C-N) bands of weak intensities in the 
Raman spectrum at 1292 and 1195 cm-1 respectively and the υ(C-OH) band at around 
1235 cm-1 of medium intensity in the IR spectrum and weak intensity in the Raman 
spectrum. The υ(S=O) band is observed at around 1155 cm-1 of strong intensity in the 
IR spectrum and weak intensity in the Raman spectrum.  
 
Figure 4.26.  FT-Raman and IR spectral stackplot of TBS in the 1100 – 1800 cm-1 
region. 
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 Figure 4.27. A comparison between the calculated and experimental Raman 
spectra of TBS 1100 – 1800 cm-1 region. 
 
 
Figure 4.28. A comparison between the calculated and experimental IR spectra of 
TBS 1100 – 1800 cm-1 region. 
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4.3.4.3. 1100 – 100 cm-1 region 
     Raman and IR spectra over this wavenumber range are presented in Figure 4.29.  
In the 973 – 997 cm-1 region we can expect modes arising from υas(C-OH). Lower in 
wavenumber we expect to find the CH wagging bands at 759 and 784 cm-1 in the 
Raman spectrum and at 760 and 689 cm-1 in the IR  spectrum.  
     Finally, the complex ring modes of CCC deformations in the range between 400 and 
550 cm-1 occur. The methyl torsional band is observed in the Raman spectrum at 271 
cm-1 of weak intensity. 
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Figure 4.29. FT-Raman and IR spectral stackplot of TBS in the 100 – 1100 cm-1 
region. 
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     The key Raman spectral features of TBS are the υas (CH3) band at 2978 cm-1, the 
υ(CH) attached to the aliphatic (OH) band at 2922 cm-1, The δ(NH+2) band at 1624 cm-1, 
the   υ(C=C) band at 1604 cm-1, the δ(CH3) band at 1450 cm-1, the δ(CH) band at 1341  
cm-1, the (C-OH) stretching bands of the three (OH) groups at 1232, 992 and 973 cm-1,  
and the out of plane (CH) wagging band at 759 cm-1 while its  key IR spectral features 
are the υ(OH) band at 3527 cm-1, the υ(NH) bands at 3332 and 3171 cm-1, the aliphatic 
υ(CH) band at 3069 cm-1, the υas(CH3) band at 2983 cm-1, the δ (NH+2) band at 1624 
cm-1, the υ(C=C) band at 1605 cm-1, the δ(CH3) band at 1458 cm-1, the (CH2)&(NH2) 
and (CH) deformation bands at 1380 and 1346 cm-1,respectively, the (C-OH) stretching 
bands of the three (OH) groups at 1237, 997 and 982 cm-1 and the υ(S=O) band at 1154 
cm-1.  
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Table 4.4. The observed and calculated vibrational wavenumbers/cm-1 of TBS. The 
calculated IR intensities (IIR) are relative to that of δ (NH+2) at 1396 cm-1 The 
calculated Raman intensities (IRaman) are relative to that of υ (CH) at 3075 cm-1.  
 
 
Observed 
 
 
Calculated 
Raman 
(cm-1) 
IR 
(cm-1) 
 
υ 
 
IRaman 
 
IIR 
 
 
Proposed Assignment 
 3527 m 3583 0.805 0.026 υ(OH)  
 3332 m 3326 0.272 0.030 υ(NH) 
 3171 m 3229 0.889 0.059 υ(NH)  
3057 mw 3069 m 3075 1.000 0.103 Aromatic υ(CH)  
2978 m 2983 m 2979 0.225 0.102 υas (CH3) 
2922 m  2908 0.379 0.069 υ(CH) attached to the aliphatic OH 
2881 mw 2878 mw   0.133 υ (CH3) 
2802 w 2819 mw   0.087  
2749 w    0.040  
 2653 w   0.449  
 2510 w   0.856  
 2461 w   0.133  
 2153 vw     
 2078 vw   0.033  
1624 m 1624 ms 1639 0.039 0.016 δ(NH+2)  
1604 m 1604 s 1608 0.107 0.049 υ(C=C) 
  1593 0.180 0.021 υ(CC)ring 
  1569 0.031 0.015 δ(CH3) 
  1558 0.033 0.038 δ(CH3) 
  1549 0.120 0.002 δ(CH3) 
 1518 w 1505 0.117 0.029  
1472 m,sh 1485 m 1486 0.104 0.051 δ(CH3) 
1450 m 1458 m 1463 0.036 0.063 δ(CH3) 
1409 w 1402 m 1391 0.014 0.047 Ring stretch 
  1396 0.024 1.000 υ(NH+2) 
1371 w 1380 m 1378 0.119 0.052 δ(CH2)& δ(NH2) 
1341 m 1346 m 1349 0.149 0.045 δ(CH) 
 1304 m 1327 0.031 0.019 In-plane δ(CH) 
1292 w  1299 0.007 0.340 υ(C-C) 
1266 w  1258 0.018 0.039 δ(CH) 
1232 w 1237 m 1212 0.057 0.014 υ(C-OH) 
1213 w      
1195 w 1195 m 1195 0.005 0.077 υ(C-N) 
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Table 4.4. (Continued) 
 
 
Observed 
 
 
Calculated 
Raman 
(cm-1) 
IR 
(cm-1) 
 
υ 
 
IRaman 
 
IIR 
 
 
Proposed Assignment 
1157 w 1154 s    υ(S=O) 
1131 w 1113 s 1139 0.063 0.168  
1097 w 1087 s 1110 0.043 0.045  
1067 w 1064 s 1066 0.006 0.220  
1056 mw    0.106 υ(CC) aromatic 
1030 w  1026 0.026 0.183  
992 s 997 m 1004 0.029 0.317 υas(C-OH) 
973 m 982 m 986 0.023 0.112 υas(C-OH) 
932 mw 921 w 943 0.017 0.136  
891 w 895 w 912 0.192 0.327  
872 w  873 0.028 0.110  
842 w 846 m 822 0.012 0.039  
759 ms 760 mw 766 0.010 0.102 Out of plane(CH) wagging 
703 w 707 mw 721 0.063 0.039  
684 w 689 mw 674 0.002 0.026 CH wagging 
620 w  632 0.014 0.002  
581 w  548 0.021 0.028  
541 m  561 0.006 0.002 In-plane δ(CCN)  
519 mw  532 0.076 0.005 Out-of-plane δ(CC)  
505 w  509 0.027 0.007  
475 w  475 0.004 0.041  
439 w  450 0.047 0.024 Out-of-plane δ (CC)chain 
373 w  384 0.023 0.389  
342 w  352 0.004 0.028  
271 w  265 0.005 0.074 CH3τ 
236 ms  233 0.017 0.056  
222 mw  220 0.015 0.021  
152 mw 
 
 161 0.007 0.040  
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4.3.5. Ipratropium bromide 
     Calculations were performed on the IPRA cation (Figure 4.30). Two conformations 
of the IPRA cation were investigated. As can be seen in Figure 4.30, the hydroxyl group 
is able to form an intramolecular hydrogen bond (conformer IPRA2).  This 
conformation would be expected to be the most stable in the gas phase. In the solid sate 
the hydroxyl group is able to form intramolecular hydrogen bonds and the conformation 
depicted in Figure 4.30 (conformer IPRA1) may be important.  For both conformers full 
geometry optimisation was carried out, followed by the determination of the predicted 
vibrational frequencies. 
 
IPRA2           IPRA1 
 
Figure 4.30. The calculated conformations of the IPRA cation; IPRA1 has no 
intramolecular hydrogen bond and IPRA2 with an intramolecular hydrogen bond. 
 
4.3.5.1. Computational studies 
     The predicted IR spectra of the conformations IPRA1 and IPRA2 over the region 0-
2000 cm-1 are compared in Figure 4.31. The simulated spectra were generated by using 
the computed frequencies and intensities and applying a Gaussian broadening to each 
transition of 10 cm-1. There is a clear shift in the C=O stretching at 1743 cm-1 (IPRA1) 
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to 1716 cm-1 (IPRA2) resulting from the intramolecular hydrogen bonding. The strong 
absorption at 1134 cm-1 (IPRA1) shifts to 1110 cm-1 (IPRA2) corresponds to a coupled 
stretching of the C-O and C=O of the ester linkage.  
 
Figure 4.31. The calculated IPRA cation IR conformational shifts in the region 0-
2000 cm-1. 
 
     The predicted Raman spectra of both IPRA1 and IPRA2 are dominated by the CH 
stretching bands; the region from 0-2000 cm-1 is shown in Figure 4.32. The simulated 
spectra were generated by using the computed frequencies and intensities and applying 
a Gaussian broadening to each peak of 5 cm-1. The most intense scattering, apart from 
the CH and OH region, is seen at 1595 cm-1 (IPRA1) and 1596 cm-1 (IPRA2). This is a 
stretching mode in the phenyl group. It is only seen with a very weak intensity in the 
predicted IR spectra.  The small shift in frequency between the two conformations 
reflects the small influence from the internal hydrogen bond on this vibrational mode.  
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Figure 4.32.The calculated IPRA cation Raman conformational shifts in the region 
0-2000 cm-1. 
 
     The predicted Raman spectra are complex and are difficult to interpret in terms of 
conformational changes. The shifts observed in the predicted IR spectra of the two 
conformers are more straightforward to interpret and are summarised in comparison 
with the observed bands of IPRA in Table 4.5. It can be noted that, the observed IR 
spectral features comprise the calculated IR spectral features of both IPRA1 and IPRA2. 
The very strong calculated bands at 1134 cm-1 and 1109 cm-1 of IPRA1 and IPRA2 
respectively are recorded in the observed IR spectrum at 1246 and 1228 cm-1 and the 
strong calculated bands at 1743 and 1716 cm-1 of IPRA1 and IPRA2, respectively, are 
recorded in the observed IR spectrum at 1726 and 1712 cm-1. These data suggest that the 
conformation in the solid state crystalline structure could be a mixture of IPRA1 and 
IPRA2.  
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Table 4.5. The key calculated IR spectral features of IPRA1 and IPRA2 in 
comparison with the observed bands of IPRA in the range of 600 – 1800 cm-1. 
 
Observed 
 
IPRA1 Observed IPRA2 
700 m 698 w 667 w 669 w 
741 m 745 mw  724 mw 
804 w 800 mw 804 w 802 mw 
852 w 849 w  874 w 
868 vw 869 w 894 vw 891 vw 
894 vw 891 w 934 w 936 mw 
934 w 937 mw 989 vw 991 m 
974 m 973 m 1029 w 1029 s 
1029 w 1022 s 1228 s 1109 vs 
1246 s 1134 vs 1327 w 1324 w 
1273 w 1275 w 1348 w 1347 mw 
1310 vw 1306 mw 1402 w 1397 m 
1360 vw 1355 w 1452 ms 1450 w 
1402 w 1403 m  1508 m 
1452 ms 1450 w 1601 w 1595 w 
 1508 m 1712 vs 1716 s 
1601 w 1595 w   
1726 m,sh 1743 s   
 
4.3.5.2. Vibrational spectroscopic analysis 
     The IR and Raman spectra of IPRA were shown in Figures 4.33 - 4.35. Experimental 
IR and Raman wavenumbers are listed in Table 4.6 along with the calculated values; 
assignment of the major experimental vibrational features was carried out in the light of 
the computational results and the Raman spectrum, reported for this first time in this 
study, and the IR spectroscopic data reported previously (FDM). It is shown here that 
the major features in the observed spectra can be reliably assigned on the basis of the 
quantum chemical calculations.   
 
4.3.5.2.1. 3800 – 2600 cm-1 region 
     The broad rather diffuse υ (OH) stretching band (Figure 4.33) in the IR spectrum at 
3492 cm-1 suggests that hydrogen bonding occurs in the crystalline IPRA. The CH 
stretching region comprises several features in the wavenumber range 3100 – 2800 cm-1 
 112
(Figure 4.33) for the IR and Raman spectra; the CH stretching bands of the unsaturated, 
aromatic component of IPRA are more clearly shown in the Raman spectrum rather 
than in the IR spectrum (Table 4.6) and can be assigned to the bands at 3067 and 3057 
cm-1 in the Raman spectrum. The strong bands in the Raman spectrum at 2992 and 2968 
cm-1 could be attributed to υ (CH2-O-) and υas(CH2-OH), respectively. 
 
Figure 4.33. FT-Raman and IR spectral stackplot of IPRA in the 2600 – 3800 cm-1 
region. 
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4.3.5.2.2. 1750 – 1550 cm-1 region 
     Expanded wavenumber regions of the IR and Raman spectra are shown in Figure 
4.34. The observed IR spectrum has a medium shoulder at 1726 cm-1 which can be 
assigned to υ(C=O) which is not involved in the hydrogen bonding, and a very strong 
band at 1712 cm-1, consequent upon the participation of the carbonyl group in the 
hydrogen bonding can be assigned to the carbonyl of the ester linkage. These features 
suggest that IPRA specimen could be a mixture of the two conformations, IPRA1 and 
IPRA2. The medium intensity band at 1603 cm-1 in the Raman spectrum can be 
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attributed to υ (CC) ring. There are several other features clearly seen in this wavenumber 
region at 1672, 1639, 1601, 1582 cm-1 and 1712, 1649, 1583 cm-1 in the IR and Raman 
spectra, respectively; these features can be assigned on the basis of the quantum 
chemical calculations to molecular vibrations that involve both C=C and C=O groups 
and symmetric and asymmetric ring vibrations. 
 
Figure 4.34. FT-Raman and IR spectral stackplot of IPRA in the 1550 – 1750 cm-1 
region. 
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4.3.5.2.3. 1800 – 100 cm-1 region 
     The IR and Raman spectra over this wavenumber range are presented in Figure 4.35; 
the IR spectral region comprises a rich spectrum from the C=O and C=C functionalities, 
which have already been discussed in some detail above, along with several bands of 
medium and strong intensities, whereas the Raman spectrum consists mainly of the 
strong C=C features and several other weaker features. In the range 1470 – 1300 cm-1, 
we expect CH3 and CH2 aliphatic bending vibrations to occur with υ(C-N) at around 
1310 cm-1.  
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     At lower wavenumber, there is additional indication that the IPRA sample is a 
mixture of the two conformations IPRA1 and IPRA2. The two strong calculated bands 
at 1134 and 1109 cm-1 (25 cm-1 shift) for the IR spectrum were observed in the 
experimental IR spectrum at 1246 and 1228 cm-1 (18 cm-1 shift). These two bands were 
assigned on the basis of quantum chemical calculations as the coupled stretching of the 
C-O and C=O of the ester linkage. 
     In the 1050 – 850 cm-1 region, assignment of a series of bands to modes arising from 
υ(C-OH) of the primary alcohols and CCH aromatic deformation modes near 1040 cm-1 
can be made. The υ(C-N-C) band is observed at around 850 cm-1. 
     Finally, the complex ring modes of CCC deformations in the range between 690 and 
500 cm-1 occur. The weak skeletal deformation bands are observed in the Raman 
spectrum below 440 cm-1 and the methyl torsional mode at 267 cm-1 of weak intensity 
can be noted. 
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Figure 4.35. FT-Raman and IR spectral stackplot of IPRA in the 100 – 1800 cm-1 
region. 
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     The key Raman spectral features observed  for  IPRA are: the υ(CH) bands at 3057 
and 3067 cm-1; the υ (CH2-O-) band at 2992 cm-1; the υas (CH2O-H) band at 2968 cm-1; 
the υ(CC)ring  band at 1603 cm-1; the ring vibration band at 1006 cm-1; the ring breathing 
band at 990 cm-1; the out-of-plane δ(CH)ring band at 785 cm-1 and the out-of-plane 
δ(CCC) band at 690 cm-1.  
     In contrast, key IR spectral features include: the υ(OH) band at 3492 cm-1; the 
υ(C=O) band at 1712 cm-1; the δ(CH)ring and δ(CH2)(sciss.) bands at 1492 cm-1; the 
δ(CH3) band at 1468 cm-1; the ring stretching band at 1452 cm-1; the coupled stretching 
of the C-O and C=O of the ester linkage bands at 1246 and 1228 cm-1; the υ(C-OH) 
band at 1045 cm-1; the ring vibration bands at 1006 and 741 cm-1; the out-of-plane 
δ(CH) band at 970 cm-1 and the δ(COC) band at 700 cm-1. 
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4.4. Conclusions 
 
     The Raman spectra of BUD, TBS and IPRA have been recorded for the first time 
and coupled with the predictions of quantum chemical calculations. A good overall 
agreement was obtained between the experimental and calculated frequency values for 
the all five studied drugs (Figures 4.27 and 4.28 and Tables 4.1,2,3,4 and 6); however, 
even with the support of quantum chemical calculations, it is difficult to be certain 
about the assignments of some of these molecular vibration in the mid-low wavenumber 
range because of the complexities of mode mixing of the drugs studied; nevertheless, it 
is clear that the major vibrational spectroscopic features of the all studied drugs have 
been reasonably assigned in this study.   
    
     Raman, IR and quantum chemical calculations, have been used to explain the 
presence of the observed spectroscopic complexity in the C=C and C=O stretching 
region which provide useful structural information when considering the complexation 
of BUD and FP. 
  
     Vibrational spectroscopy and quantum chemical calculations have been applied to 
the investigation of SB and TBS. As a result of the comparison of the experimental and 
calculated frequencies, the vibrational modes associated with the atoms involved in the 
hydrogen bonding were identified. As such, this study could be viable for examining the 
way in which these drugs interact with their target molecules. 
 
     The calculated vibrational modes of non-intramolecular hydrogen-bonded and 
hydrogen-bonded IPRA conformations, IPRA1 and IPRA2, provided insight into the 
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solid state analysis of IPRA. In particular it was possible to indicate that IPRA 
specimens in the solid state could be a mixture of the two conformations IPRA1 and 
IPRA2 without and with intramolecular hydrogen bonding, respectively. Quantum 
chemical calculations offer great potential to improve understanding of the structural 
properties of solid-state pharmaceuticals and these are of particular importance in the 
absence of more detailed structural information, as is the case for this system. 
 
Table 4.6.  The observed vibrational frequencies of IPRA and those calculated for IPRA cation. For calculated data, relative 
intensities for IPRA1 and IPRA2 were normalised such that the most intense band in the calculated spectra is 1. 
 
Observed 
 
 
calculated 
Raman, cm-1 IR, cm-1 IPRA1 υ (cm-1) 
(Raman, IR Int.) 
IPRA2 υ (cm-1) 
(Raman, IR Int.) 
 
 
Proposed assignment 
 3492 ms 3552 (0.201,0.045) 3589 (0.230, 0.049) υ(OH)  
 3437 ms    
 3390 s    
 3258 w    
3067 m 3073 vw 3131 (1.000, 0.037) 3137 (1.000, 0.049) Aromatic υ(CH)  
3057 m 3057 vw 3059 (0.527, 0.023) 3058 (0.157, 0.002) υ(CH) 
3038 mw 3034 vw 3043 (0.169, 0.061) 3040 (0.322, 0.045) υas (CH2) 
3017 mw 3020 w 3026 (0.155, 0.020) 3025 (0.113, 0.013) υas (CH2) 
2992 s 3007 vw 3009 (0.141, 0.018) 3004 (0.756, 0.004) υ (CH2-O-) 
 2979 w 3003 (0.014, 0.016) 2989 (0.067, 0.047) υas (CH2)& υas (CH3) 
2968 s 2968 w 2933 (0.159, 0.164) 2969 (0.285, 0.059) υas (CH2-O-H) 
2952 w 2952 w   υas (CH2) 
2938 w 2937 w   υ(CH3) 
2896 vw    υ(CH3) 
2886 w 2885 w    
 2871 sh,w   υ(CH2) 
2861 w     
 2804 vw    
2757 w     
 2723 vw    
 1726 m,sh 1743 (0.061, 0.662)  υ(C=O) 
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Table 4.6. (Continued) 
 
Observed 
 
 
calculated 
Raman, cm-1 IR, cm-1 IPRA1 υ (cm-1) 
(Raman, IR Int.) 
IPRA2 υ (cm-1) 
(Raman, IR Int.) 
 
 
Proposed assignment 
1712 mw 1712 vs  1716 (0.081, 0.360) υ(C=O) 
 1672 vw    
1649 vw    υ(C=C)chain 
 1639 mw    
1603 m 1601 w 1594 (0.120, 0.009) 1596 (0.183, 0.008) υ(CC)ring 
1583 w 1582 vw 1579 (0.024, 0.005) 1580 (0.033, 0.007)  
1493 sh,w 1492 m 1495 (0.006, 0.032) 1494 (0.049, 0.001) δ(CH)ring & δ(CH2)(sciss.) 
1481 mw  1482 (0.004, 0.071) 1482 (0.005, 0.048) δ(CH3) 
 1468 m 1478 (0.089, 0.005) 1478 (0.097, 0.004) δ(CH3) 
1456 br,m 1452 ms 1458 (0.004, 0.019) 1457 (0.003, 0.013) Ring stretch 
1431 w 1429 w 1421 (0.021, 0.035) 1421 (0.024, 0.026)  
1406 w 1408 w 1406 (0.015, 0.045) 1406 (0.018, 0.032) In-plane δ(CH3) 
 1402 w 1400 (0.026, 0.221) 1394 (0.038, 0.113) δ (OH)& δ (CH2) 
 1386 w 1391 (0.023, 0.013) 1390 (0.029, 0.048) δ(CH3) & δ(CH)chain 
1380 w 1381 w   δ(CH3) 
1370 sh,w 1372 w 1368 (0.013, 0.017) 1370 (0.029, 0.003)  
 1360 vw 1361 (0.035, 0.001) 1364 (0.011, 0.014)  
1348 w 1348 w 1355 (0.005, 0.028) 1348 (0.011, 0.009)  
1327 w 1327 w 1327 (0.006, 0.003) 1328 (0.007, 0.003) δ(CH) 
1312 w 1310 vw 1304 (0.025, 0.054) 1318 (0.018, 0.068) υ(C-N) & δ(CH3) 
1294 vw 1291 w,sh 1286 (0.016, 0.023) 1291 (0.003, 0.002) δ (OH)& δ (CH2) 
1271 w 1273 w 1273 (0.018, 0.036) 1273 (0.016, 0.008) δ(CH-N) 
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Table 4.6. (Continued) 
 
Observed 
 
 
calculated 
Raman, cm-1 IR, cm-1 IPRA1 υ (cm-1) 
(Raman, IR Int.) 
IPRA2 υ (cm-1) 
(Raman, IR Int.) 
 
 
Proposed assignment 
 1246 s 1134 (0.004, 1.000)   Coupled stretching of the C-O and C=O of the ester 
linkage 
1226 w 1228 s  1110 (0.006, 1.000) Coupled stretching of the C-O and C=O of the ester 
linkage 
1196 br,w 1199 w    
1185 w     
 1173 w    
1162 w 1161 w    
1155 w     
1137 vw 1137 m    
1110 vw 1105 vw    
1090 w 1088 w 1091 (0.017, 0.029) 1090 (0.018, 0.048)  
1063 w 1060 mw 1078 (0.022, 0.009) 1077 (0.024, 0.003)  
1040 w 1045 m 1047 (0.005, 0.161) 1032 (0.026, 0.323) υ(C-OH) 
 1029 w 1027 (0.036, 0.037) 1029 (0.031, 0.120) υ(C-OH) 
1006 ms 1006 m 1001 (0.011, 0.213) 1017 (0.008, 0.099) Ring vibration 
990 m 989 vw 988 (0.091, 0.017) 988 (0.106, 0.017) Ring breathing 
970 w 974 m 970 (0.053, 0.316) 968 (0.007, 0.011) Out-of-plane δ(CH) 
938 vw 934 w 933 (0.006, 0.113) 934 (0.001, 0.002)  
911 w 913 w 927 (0.005, 0.003) 926 (0.006, 0.002) δ(CH3) 
889 w 894 vw 897 (0.007, 0.007) 892 (0.001, 0.016) CCH aromatic deformation 
870 w 868 vw 867 (0.022, 0.033) 869 (0.002, 0.003)  
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Table 4.6. (Continued) 
 
Observed 
 
 
calculated 
Raman, cm-1 IR, cm-1 IPRA1 υ (cm-1) 
(Raman, IR Int.) 
IPRA2 υ (cm-1) 
(Raman, IR Int.) 
 
 
Proposed assignment 
854 w 852 w 858 (0.040, 0.048) 847 (0.034, 0.002) υ(C-N-C) 
828 vw 826 w 831 (0.022, 0.002) 826 (0.021, 0.011) Out-of-plane δ(CH)ring 
816 vw  819 (0.008, 0.004) 815 (0.015, 0.003) Skeletal vibrations 
805 w 804 w 802 (0.017, 0.109) 799 (0.017, 0.091) Skeletal vibrations 
785 m 783 w 790 (0.008, 0.009) 784 (5.9e-4, 0.027) Out-of-plane δ(CH)ring 
764 vw 766 mw 757 (0.040, 0.019) 758 (0.014, 0.017) Out-of-plane δ(CH)ring 
742 vw 741 m 739 (0.022, 0.079) 735 (0.029, 0.020) Ring vibration 
708 w  711 (0.016, 0.079) 719 (0.017, 0.081) Ring vibration 
 700 m   δ(COC) 
690 m 686 vw 690 (0.005, 0.051) 695 (0.002, 0.039) Out-of-plane δ(CCC)  
669 w 667 w 684 (0.022, 0.040) 665 (0.009, 0.012)  
639 vw  665 (0.009, 0.016) 656 (0.013, 0.012)  
621 w  621 (0.021, 0.023) 629 (0.036, 0.002) Ring deformation 
608 w  616 (0.018, 0.011) 614 (0.018, 0.001) δ(CCC)ring 
538 vw  554 (0.006, 0.006) 559 (0.002, 0.015) δ(C-N) 
515 vw  512 (0.009, 0.001) 514 (0.013, 0.044)  
499 vw  504 (0.003, 0.024) 510 (0.008, 0.018)  
479 sh,w  474 (0.007, 0.001) 489 (0.008, 0.009)  
470 mw  447 (0.010, 0.004) 455 (0.005, 0.031)  
438 w  439 (0.007, 0.019) 438 (0.014, 0.196) In-plane (CCC)ring skeletal deformation 
405 w  405 (0.001, 0.002) 405 (0.001, 2.3e-4) In-plane (CCC) skeletal deformation 
380 w  382 (0.015, 0.050) 380 ().005, 0.005) δ(OH) 
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Table 4.6. (Continued) 
 
Observed 
 
 
calculated 
Raman, cm-1 IR, cm-1 IPRA1 υ (cm-1) 
(Raman, IR Int.) 
IPRA2 υ (cm-1) 
(Raman, IR Int.) 
 
 
Proposed assignment 
362 vw  360 (0.003, 0.011) 359 (0.005, 5.6e-4)  
337 w  326 (0.004, 0.010) 333 (0.001, 0..003) Skeletal deformation 
285 w  276 (0.002, 0.013) 292 (0.015, 0.004)  
267 w  249 (0.002, 0.003) 260 (0.004, 0.014) (CH3)τ 
240 w  247 (0.012, 0.017) 242 (1.1e-4, 4.3e-4)  
 
5.1. Introduction 
     A major problem with the analysis of pharmaceutical compounds by Raman 
spectroscopy is the fluorescence caused by either the sample itself or by the presence of 
a small amount of impurity. The fluorescence emission of aromatic molecules such as 
salmeterol xinafoate (SX), generally occurs in the near-UV to visible region (300-700 
nm) and therefore can interfere with the Raman signal if it is located within that spectral 
region (Berlman, 1971). This type of fluorescence can usually be avoided if the Raman 
signal is located in the far UV or NIR part of the spectrum. The Raman signal is 
generally located (spectrally) near the excitation wavelength so the fluorescence can be 
avoided by choosing a laser of an appropriate wavelength. With a NIR laser, the 
fluorescence signal may be avoided or minimised as the resultant Raman spectrum is in 
a lower energy region of the electromagnetic spectrum than the emitted fluorescence. In, 
addition, the NIR laser photon generally does not have sufficient energy to excite the 
fluorophore by single photon excitation, thus reducing the total amount of fluorescence 
produced. In contrast, excitation with a UV laser can still excite visible fluorescence but 
the Raman spectrum is located in the relatively fluorescence-free UV region of the 
electromagnetic spectrum (Asher and Johnson, 1984).      
     There are two disadvantages associated with moving to NIR excitation. The Raman 
intensity is inversely proportional to the fourth power of the laser wavelength, so the 
intensity of the Raman signal is weaker than with visible excitation (McCreery, 2000). 
Hence, practically, the spectral data acquisition time is increased. In addition, the 
efficiency of the typical silicon based CCD detector falls off in the NIR region (Delhaye 
et al., 1996). The benefits of avoiding the fluorescence emission, however, often 
outweigh these disadvantages of NIR laser excitation. 
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     In this study, we describe experiments that explore the effects of using a variety of 
laser wavelengths from 488 nm to 1064 nm on the Raman spectra of SX polymorphs 
(see section 7.1.1 for details about the structure of SX). 
 
5.2. Experimental 
5.2.1. Materials 
See section 7.2.1 for details. 
5.2.2. Raman spectroscopy 
     Raman spectra were recorded using a Bruker IFS66 with an FRA106 Raman 
spectrometer module operating at 1064 nm, laser powers were maintained at 200 mW at 
the samples and a Renishaw InVia Raman microscope operating at 785, 633, 514 and 
488 nm with  approximately 25 mW  laser power at the sample (see sections 2.8.1.1 and 
2.8.1.2 for details) 
 
5.3. Results and discussion 
 
5.3.1. Characterisation of SX polymorphs 
     Different polymorphs of the same molecule each have a different crystalline form 
and, hence, a unique Raman spectrum (Yu et al., 1998). Analysis of SX polymorphs I & 
II by Raman spectroscopy yielded spectra with excellent signal to noise ratios, with the 
two polymorphs exhibiting differences in both peak positions and intensities. The 
presence of the xinafoate ion has been considered, since it is common to both 
polymorphs, hence, the spectral characteristics are due to the polymorphic forms of 
salmeterol itself. The Raman spectra of both polymorphs are shown in Figures 5.1 and 
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5.2. The wavenumbers and proposed assignments of the Raman bands are given in 
Table 5.1. 
 Figure 5.1.Raman spectra of SX (forms I and II) at 1064 and 785nm. 
 
     The main Raman spectral features common to both polymorphs studied were the 
υ(CH) band at 3060 cm-1, the υ(CH2) bands at 2998  and 2862 cm-1, the υas(CH2) band 
at 2937 cm-1, the υ(CH)ring band at 2905 cm-1, the ring stretching vibrations at 1621, 
1602 and 1581 cm-1, the (CH) deformation bands at 1466, 1434 and 1260 cm-1, the δ 
(OCH2) band at 1369 cm-1, the in-plane δ(CH) band at 1304 cm-1 , the υ(CN) band at 
1203 cm-1, the δ(CH)ring band at 1178 cm-1 , the symmetric ring stretching bands at 1021 
and 1000 cm-1 , the  skeletal stretching band at 822 cm-1 , the out-of-plane δ(CH)ring  
band at 779 cm-1 , the r(CH2) band at 726 cm-1 , the out-of-plane δ(COC) band at 538 
cm-1  and the in-plane δ(CC)chain band at 494 cm-1. 
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Figure 5.2.Raman spectra of SX (forms I and II) at 633 and 514 nm.  
 
     Despite the generally common Raman spectral features (Table 5.1), both forms under 
study were found to give rise to distinctive Raman patterns, which allow them to be 
identified through this spectroscopic technique. Form I is characterised by the υas(CH2) 
band  at 2959 cm-1 , the ring stretching bands at 1594 and 1405 cm-1 , the δ (CH) bands 
at 1457 and 1350 cm-1, the ring vibration bands at 1323, 1054 and 749 cm-1 , the 
symmetric ring stretching band at 1029 cm-1, the out-of-plane δ(CH)chain  band at 927 
cm-1, the out-of-plane δ(CH)ring bands at 829 and 796 cm-1, the in-plane δ(CCN) band at 
578 cm-1, the  δ(COC) band at 482 cm-1 ,the in-plane skeletal deformation band at 400 
cm-1, the out-of-plane skeletal deformation band at 238 cm-1  and the skeletal 
deformation bands at 220, 193 and 167 cm-1. Form II, in turn, is readily identified by the 
weak band due to υ(CH2) at 2984 cm-1 , the strong ring stretching band at 1415 cm-1 , the 
δ(CH2)chain  band at 1382 cm-1, the δ(CH) band at 1338 cm -1, the υ(CC) band at 1157  
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cm -1, the weak ring breathing band at 976 cm -1, the out-of-plane δ(CH)ring  band at 784 
cm-1, the ring vibration band at 738 cm-1   and the very weak feature at 466 cm-1 ascribed 
to out-of-plane δ(COC). These Raman differences can be attributed to the differences in 
intermolecular interactions and different modes of packing of the two crystalline 
polymorphs. 
     Several Raman peaks have been observed to be common to both forms but with 
small shifts in wavenumbers. The υas(C-NH) band at 1149 cm-1 in the spectrum of form 
I is shifted to 1143 cm-1 in the spectrum of form II with decreased intensity. The in-
plane δ (CC) bands at 1097 and 1074 cm-1 of form I are shifted to 1090 and 1079 cm-1, 
respectively in the spectrum of form II. This is due to the fact that when molecules are 
packed together in different arrangements in the crystal (i.e. polymorphism) the 
vibrational modes involving less rigid bonds will be affected more than those of rigid 
structures. Additionally, the υ(CNC), out-of-plane δ(CH)ring  and δ(C-C-C long chain) 
bands at 880, 855 and 341 cm-1 in the spectrum of the form I are shifted to 875, 848 and 
346 cm-1 , respectively,  in the spectrum of the form II. 
     The present study allowed the assignment of specific Raman spectral features, 
characteristic of each of the polymorphic form of SX investigated. Therefore, these 
results will be very useful for the identification and possible discrimination of these 
polymorphs. 
 
5.3.2. Dependence of the Raman spectra upon laser excitation wavelength 
     Figures 5.1, 5.2 and 5.3 show the Raman spectra obtained from the both polymorphs 
with the five different excitation wavelengths used (488, 514, 633, 785 and 1064 nm). 
The wavenumbers and proposed assignments of the Raman bands are given in Table 
5.1, from which, it is noted that, with decreasing the excitation wavelength from 1064 
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nm to 514 nm there is a reduction in the intensities of the Raman bands of form II 
except for the υ (CH) ring and symmetric ring stretching bands at 3079 and 1029 cm-1, 
respectively, and at 488 nm, there is very high fluorescence background and accordingly 
Raman spectra could not be obtained for both forms (Figure 5.3).  
Figure 5.3.Raman spectra of SX (forms I and II) at 488 nm.  
 
     There are several spectral features common to both polymorphs which disappear in 
the Raman spectra of form II with decreasing the excitation wavelength to both 633 and 
514 nm which are the out-of-plane δ(CC)ring, in-plane skeletal deformation and chain 
expansion bands at 648, 445 and 425 cm-1 respectively, and to 514 nm, which are the in-
plane δ(CC) bands at 1090 and 1079 cm-1, the r(CH2) band at 955 cm-1, the ring 
deformation band at 621 cm-1 and the in-plane δ(CCC) band at 605 cm-1. In turn, there 
are several distinctive patterns of form II which disappear with decreasing the excitation 
wavelength to both 633 nm and 514 nm, which is the out-of-plane δ (COC) band at 466 
cm-1, and to 514 nm, where the ring stretching band at 1415 cm-1, the ring breathing 
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band at 976 cm-1 and the out-of-plane δ (CH) ring band at 784 cm-1 are all absent from its 
Raman spectrum. From our observations, it is clear that SX form II generally has a 
higher fluorescence background level so we can conclude that, on examining the dosage 
forms containing SX by Raman spectroscopy, it is better to use NIR laser excitation, if 
available, rather than the visible excitation to avoid the higher fluorescence background 
of the form II and to ease the possible identification and discrimination of both forms 
under study. 
 
5.4. Conclusions 
     The Raman spectrum of SX polymorph II is reported for the first time. From the 
Raman spectroscopic analysis carried out in this study it is possible to identify the key 
Raman characteristic bands of SX polymorphs (I&II). The effect of using different laser 
excitation wavelengths in the range from visible to NIR when carrying out Raman 
spectroscopic analysis on these polymorphs has been studied. It can be concluded that, 
on examining the dosage forms containing SX by Raman spectroscopy, it is better to 
use NIR laser excitation if available rather than visible excitation to avoid the higher 
fluorescence background of the form II and to ease the possible identification and 
discrimination of both forms. 
   The present study clearly demonstrates that Raman spectroscopy is useful as a tool for 
assessing the polymorphic purity of SX materials and possibly other polymorphic forms 
showing similar behaviour.  
 
Table 5.1. Raman spectral wavenumbers and proposed assignments for SX polymorphs I&II at the selected wavelengths (514, 633, 
785 and 1064 nm). 
 
 
1064 nm 
 
 
785 nm 
 
633 nm 
 
514 nm 
I II I II I II I II 
 
Proposed Assignment 
3079 w,sh - 3079 w,sh - 3079 w,sh - 3079 mw 3079 m υ(CH) ring 
3060 m 3060 m 3060 m 3060 w 3060 m 3060 m 3060 m 3060 m υ(CH) 
3037 w,sh - 3037 w,sh - 3037 w,sh - 3037 w,sh - υas(CH2)chain 
2998 w 2998 w 2998 w 2998 vw 2998 w 2998 w 2998 w 2998 w υ(CH2) 
- 2984 w - 2984 vw - 2984 w - 2984 w υ(CH2) 
2959 mw - 2959 mw - 2959 mw - 2959 mw - υas(CH2) 
2937 m 2937 mw,br 2937 m 2937 vw,br 2937 m 2937 mw,br 2937 m 2937 w υas(CH2) 
2905 m 2905 mw,br 2905 m 2905 vw,br 2905 m 2905 mw,br 2905 m 2905 w υ(CH)ring 
2862 m 2862 mw 2862 m 2862 mw 2862 m 2862 w 2862 m 2862 w υ(CH2) 
- 2802 vw - 2802 w - 2802 w - 2802 vw - 
1621 m 1621 m 1621 m 1621 m 1621 m 1621 w 1621 m 1621 w Ring stretch 
1602 m 1602 m 1602 m 1602 m 1602 m 1602 w 1602 m 1602 w Ring stretch 
1594 m - 1594 m - 1594 m - 1594 m - Ring stretch 
1581 m 1581 m 1581 m 1581 m 1581 m 1581 w 1581 m 1581 w Ring stretch 
1466 s 1466 ms 1466 s 1466 ms 1466 s 1466 m 1466 s 1466 m δ (CH) 
1457 m,sh - 1457 m,sh - 1457 m,sh - 1457 m,sh - δ (CH) 
1434 s 1434 s 1434 s 1434 s 1434 s 1434 m 1434 s 1434 w δ (CH) 
- 1415 s - 1415 s - 1415 m - - Ring stretch 
1405 s - 1405 s - 1405 s - 1405 s - Ring stretch 
- 1382 w,sh - 1382 w,sh - 1382 w,sh - 1382 w,sh δ (CH2)chain 
1369 ms 1369 s 1369 ms 1369 s 1369 ms 1369 m 1369 ms 1369 w δ (OCH2) 
1350 w - 1350 w - 1350 w - 1350 w - δ (CH) 
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Table 5.1. (Continued)  
 
1064 nm 
 
 
785 nm 
 
633 nm 
 
514 nm 
I II I II I II I II 
 
Proposed Assignment 
- 1338 s - 1338 m - 1338 m - 1338 w δ (CH) 
1323 m - 1323 m - 1323 m - 1323 m - Ring vibration 
1304 m 1304 w 1304 m 1304 vw 1304 m 1304 vw 1304 m 1304 vw In-plane δ (CH) 
1266 w,sh - 1266 w,sh - 1266 w,sh - 1266 w,sh - In-plane δ (CH) 
1260 m 1260 ms 1260 m 1260 m 1260 m 1260 m 1260 m 1260 w δ (CH) 
1243 vw - 1243 vw - 1243 vw - 1243 vw - - 
1218 m,sh - 1218, m,sh - 1218 m,sh - 1218 m,sh - δ (CH)ring 
1203 s 1203 s 1203 s 1203 m 1203 s 1203 m 1203 s 1203 w υ(CN) 
1178 w 1178 w 1178 w 1178 vw 1178 w 1178 vw 1178 w 1178 vw δ(CH)ring 
- 1157 mw - 1157 w - 1157 w - 1157 vw υ(CC) 
1149 m 1143 mw 1149 m 1143 w 1149 m 1143 w 1149 m 1143 vw υas(C-NH) 
1097 w 1090 w 1097 w 1090 vw 1097 w 1090 vw 1097 w - In-plane δ(CC) 
1074 vw 1079 w 1074 vw 1079 vw 1074 vw 1079 vw 1074 vw - In-plane δ(CC) 
1054 vw - 1054 vw - 1054 vw - 1054 vw - Ring vibration 
1029 m,sh - 1029 m,sh - 1029 m,sh - 1029 m,sh 1029 w,sh Symmetric ring stretch 
1021 s 1021 ms 1021 s 1021 ms 1021 s 1021 m 1021 m 1021 w Symmetric ring stretch 
1000 s 1000 s 1000 s 1000 s 1000 s 1000 m 1000 m 1000 w Symmetric ring stretch 
- 976 w - 976 w - 976 vw - - Ring breathing 
955 vw 955 w 955 vw 955 w 955 vw 955 vw 955 vw - r (CH2) 
927 vw - 927 vw - 927 vw - 927 vw - Out-of-plane δ(CH)chain 
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Table 5.1. (Continued)  
 
1064 nm 
 
 
785 nm 
 
633 nm 
 
514 nm 
I II I II I II I II 
 
Proposed Assignment 
880 w 875 w 880 w 875 w 880 w 875 w 880 w 875 w υ(CNC) 
855 vw 848 vw 855 vw 848 vw 855 vw 848 vw 855 vw 848 vw Out-of-plane δ(CH)ring 
829 w - 829 w - 829 w - 829 vw - Out-of-plane δ(CH)ring 
822 w 822 w 822 w 822 vw 822 w 822 vw 822 vw 822 vw Skeletal stretch 
796 w - 796 w - 796 w - 796 w - Out-of-plane δ(CH)ring 
- 784 m - 784 mw - 784 w - - Out-of-plane δ(CH)ring 
779 mw 779 m 779 mw 779 mw 779 mw 779 w 779 mw 779 w Out-of-plane δ(CH)ring 
749 mw - 749 mw - 749 mw - 749 mw - Ring vibration 
- 738 mw - 738 mw - 738 w - 738 vw Ring vibration 
726 s 726 s 726 s 726 ms 726 s 726 m 726 s 726 w r(CH2) 
648 w 648 w 648 w 648 vw 648 w - 648 w - Out-of-plane δ(CC)ring 
621 mw 621 w 621 mw 621 w 621 mw 621 vw 621 mw - Ring deformation 
605 vw 605 w 605 vw 605 w 605 vw 605 vw 605 vw - In-plane δ(CCC) 
578 w - 578 w - 578 w - 578 w - In-plane δ(CCN) 
538 m 538 w 538 m 538 w 538 m 538 w 538 m 538 vw Out-of-plane δ(COC) 
494 mw 494 w 494 mw 494 w 494 mw 494 w 494 mw 494 vw In-plane δ(CC)chain 
482 w,sh - 482 w,sh - 482 w,sh - 482 w,sh - δ(COC) 
- 466 vw - 466 vw - - - - Out-of-plane δ(COC) 
445 w 445 vw 445 w 445 vw 445 w - 445 w - In-plane skeletal deformation 
425 w 425 vw 425 w 425 vw 425 w - 425 w - Chain expansion 
400 vw - 400 vw - 400 vw - 400 vw - In-plane skeletal deformation 
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Table 5.1. (Continued)  
 
1064 nm 
 
 
785 nm 
 
633 nm 
 
514 nm 
I II I II I II I II 
 
Proposed Assignment 
- 378 vw - 378 vw - 378 vw - 378 vw - 
368 vw - 368 vw - 368 vw - 368 vw - - 
341 mw 346 w 341 mw 346 w 341 mw 346 w 341 mw 346 vw δ(C-C-C long chain) 
327 w - 327 w - 327 w - 327 w - - 
284 vw 284 w 284 vw 284 w 284 vw - 284 vw - - 
269 vw - 269 vw - 269 vw - 269 vw - - 
238 w - 238 w - 238 w - 238 w - Out-of-plane skeletal deformation 
220 w - 220 w - 220 w - 220 w - Skeletal deformation 
193 vw - 193 vw - 193 vw - 193 vw - Skeletal deformation 
167 m - 167 m - 167 vw - 167 w - Skeletal deformation 
br,m, s, sh, v and w stand for broad, medium, strong, shoulder, very and weak respectively. as, r, υ, and δ stand for asymmetric, rocking, 
stretching and deformation respectively.  
 
6.1. Introduction 
     The identification of excipients is an important task in the cGMP manufacture of 
drug products within the pharmaceutical industry. A positive test is required to release 
the excipient batches for use in the production of clinical trial or commercial batches. 
The identification of excipients is performed according to the various pharmacopoeias, 
for the European Pharmacopoeia, which includes tests for identification 
(Pharmacopoeia, 1997). These tests are often wet chemical in nature, with additional 
tests required for providing evidence of functional groups such as aldehydes or ketones 
within the excipient structure. These mostly laborious compendial identification 
methods afford an opportunity to improve the analyses for both time and quality and 
one technique that meets these requirements is NIR spectroscopy. 
     NIR absorption bands in the NIR spectral region (800-2500 nm) exist because the 
vibration of a chemical bond is not a simple harmonic motion. Due to the nonideal 
nature of a chemical bond, weaker overtones of bond vibrations occur at about one-half, 
one-third, one-quarter, and one-fifth the wavelength (or twice, three times, four times, 
and five times the frequency) of the fundamental vibration. The overtones of the 
stretching vibrations are generally stronger than bending or rocking modes (Weyer and 
Lo, 2002). The overtones observed primarily in the NIR region involve small hydrogen 
atoms coupled with larger atoms. There are two main reasons of this. One is that these 
vibrations are more anharmonic than those between atoms of similar size, and therefore 
have stronger overtones. The other is that the fundamental stretching vibrations of the 
C-H, O-H and N-H bonds occur at the short-wavelength (high-frequency) end of the 
mid-IR spectrum due to lower reduced mass. The relatively high wavenumbers of these 
fundamentals means that their first overtones will occur in the NIR, while the first 
overtones of other vibrations occur within the mid-IR region.  
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     In addition to the overtone bands, the NIR region also contains groups of 
combination bands of diminished intensity. These bands involve hydrogenic vibrations 
almost exclusively, again because anharmonicity is important to both their existence 
and strength. These bands appear at frequencies that represent approxiamtely the sum of 
the two vibrations. The stronger combination bands involve good coupling between the 
two vibrations (Weyer and Lo, 2002). Good coupling is most likely to occur when the 
frequencies of the two vibrations are very similar or when they are bound together by a 
double bond or a ring. The first and strongest set of combination bands appear in the 
region of about 1900 to 2500 nm region of the NIR spectrum.      
     The low intensity of the NIR spectral features is largely compensated by the notable 
advances in the instrumentation associated with modern NIR spectrometers. The use of 
non-moving components in the construction of NIR spectrometers has also imparted the 
robustness and portability necessary for field or process operation and use in less 
restrictive ambient conditions.  
     NIR spectroscopy combined with multivariate data analysis opens many interesting 
perspectives in pharmaceutical analysis, both qualitatively and quantitatively. Fast, non 
destructive NIR measurements and their compatibility with fibre optics and glass 
containers without any sample pre-treatment being necessary have increased the 
analytical throughput significantly. The special feature of combined physical and 
chemical information allows for the assessment of a “spectral signature” of raw 
materials, intermediates and final dosage forms, which in turn offers the possibility of a 
simultaneous determination of several sample characteristics. The basic principles and 
pharmaceutical applications of NIR spectroscopy has been reviewed recently (Reich, 
2005) and several papers have been reported on the feasibility of NIR identification of 
both active ingredients and excipients (Sulub et al., 2008; Chalus et al., 2005; Roggo et 
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al., 2004; Krämer and Ebel, 2000; Beckenkamp et al., 2001; Thosar et al., 1999; 
Gustafsson et al., 2003; Burneau and Carteret, 2000; Blanco et al., 1999)      
 
     The current work was undertaken to evaluate FT-NIR spectroscopy for the in situ 
identification of solid pharmaceutical excipients inside USP vials.  
 
6.2. Experimental 
6.2.1. Materials 
     The following pharmaceutical excipients were studied: potassium sorbate, sodium 
starch glycollate, calcium ascorbate, calcium carbonate, candelilla wax, maltodextrin, 
lactose monohydrate, anhydrous and unknown lactose sample. 
     These substances are used in the manufacture of solid dosage forms as binders, 
diluents, disintegrate or lubricants. All the samples in each class (excipient) were 
obtained from the warehouse of a pharmaceutical company. The samples came from 
different excipient batches and occasionally from different suppliers. Multiple excipient 
grades within certain classes were considered, but the primary aim of this study is to 
identify the pharmaceutical excipients inside USP vials and, not their specific grades. 
 
6.2.2. FT-NIR spectroscopy 
     NIR spectra for each powder sample were collected in triplicate using a Bruker 
Optics MPA FT-NIR spectrometer (see section 2.8.2.2 for details).  Individual sample 
vials were rotated between triplicate scans to ensure representative spectra. Triplicate 
scans were averaged to obtain one spectrum for each powder sample.  
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6.3. Results and discussion 
     Common glasses (borosilicate, soda, etc.) are virtually transparent to NIR radiation 
and powdered samples may be measured in glass sample bottles using the reflectance 
mode. The effect of sampling through the transparent vials is illustrated in Figures 6.1 
to 6.8 for the studied pharmaceutical excipients as open powders and inside USP vials. 
 
6.3.1. Non-invasive in situ identification of potassium sorbate, sodium starch 
glycollate, calcium ascorbate, calcium carbonate, candelilla wax and maltodextrin. 
 
     The NIR spectra of the above pharmaceutical excipients in the range of 800 to 2500 
nm are shown in Figures 6.1-6.6 as open powders and inside USP vials. It should be 
noted that the NIR spectra obtained from specimens inside vials are almost the same as 
those obtained from open powder specimens. 
 
 
Figure 6.1. NIR spectra of potassium sorbate obtained inside a USP vial and as an 
open powder. 
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Figure 6.2. NIR spectra of sodium starch glycollate obtained inside a USP vial and 
as an open powder. 
 
 
Figure 6.3. NIR spectra of calcium ascorbate obtained inside a USP vial and as an 
open powder. 
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 Figure 6.4. NIR spectra of calcium carbonate obtained inside a USP vial and as an 
open powder. 
 
 
Figure 6.5. NIR spectra of candelilla wax obtained inside a USP vial and as an 
open powder. 
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Figure 6.6. NIR spectra of maltodextrin obtained inside a USP vial and as an open 
powder. 
 
     NIR spectral wavelengths (nm) and proposed assignments for the pharmaceutical 
excipients under study are presented in Table 6.1. From the NIR spectroscopic analysis 
carried out in the present work, it is observed that the NIR spectra of potassium sorbate 
and calcium ascorbate are much richer than the NIR spectra of sodium starch glycollate, 
calcium carbonate, candelilla wax and maltodextrin; this is due to the fact that 
compounds with long aliphatic chains, such as hydrocarbons, stearates and waxes, are 
difficult to distinguish as the spectra become dominated by the –CH2 groups. Starches 
and related compounds, such as maltodextrins, gums and other materials with 
polysaccharide groupings, are also difficult to distinguish from one another reliably. 
 
     Water is a particularly strong absorber in the NIR region, with the O-H first overtone 
of the stretching vibration occurring near 1450 nm in the case of sodium starch 
glycollate and maltodextrin (Figures 6.2 and 6.6). Sodium starch glycollate, calcium 
ascorbate and maltodextin in the NIR spectra have a very intense water absorption in the 
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region 1900 to 1940 nm assigned to the combination band between the fundamental 
stretching and deformation vibrations of the O-H bond, whereas this strong water band 
is not observed in the NIR spectra of potassium sorbate, calcium carbonate and 
candelilla wax (Figures 6.1-6.6). 
     Pharmaceutical excipients screening using NIR spectroscopy is truly a timesaving 
process, although it is not an absolute method. This approach provides an improvement 
for rapid in situ analysis of pharmaceutical excipients in the case of large number of 
samples contained in USP vials. 
 
Table 6.1. NIR spectral wavelengths, nm and proposed assignments for potassium sorbate, sodium starch glycollate, calcium 
ascorbate, calcium carbonate, candelilla wax and maltodextrin. 
 
Potassium 
sorbate 
Sodium starch 
glycollate 
Calcium 
ascorbate 
Calcium 
carbonate 
Candelilla wax Maltodextrin Proposed assignment 
888   860   Third overtone C-H stretching 
918  917  930  Third overtone C-H stretching 
 985 998  1042 996 Second overtone O-H 
stretching 
1164  1162  1190, sh  Second overtone C-H 
stretching 
1185 1197 1193   1201 Second overtone C-H 
stretching 
1199    1215  Second overtone C-H 
stretching 
1235       
  1345    Combination C-H stretching 
1335  1353 1337   Combination C-H stretching 
1337, sh  1367  1394  Combination C-H stretching 
1387  1377 1414 1416  Combination C-H stretching 
1404  1392    Combination C-H stretching 
1439 1455    1455 First overtone O-H stretching 
1457  1457    First overtone O-H stretching 
1473 1556, sh 1548  1542 1554, sh  
1582  1558     
1596  1639  1637   
1662  1690    First overtone C-H stretching 
1698  1700   1717, sh First overtone C-H stretching 
1710 1725, sh 1708  1733  First overtone C-H stretching 
1739  1733  1765  First overtone C-H stretching 
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Table 6.1. (Continued) 
 
Potassium 
sorbate 
Sodium starch 
glycollate 
Calcium 
ascorbate 
Calcium 
carbonate 
Candelilla wax Maltodextrin Proposed assignment 
1749 1773 1755 1792  1780 First overtone C-H stretching 
1780    1802  First overtone C-H stretching 
1816       
1826       
1843       
1853       
1865   1861    
1883       
1895   1899, sh    
1918       
1928       
1936 1932 1944 1954  1932  
1962  1969     
1991  2031     
2015  2037  2013  Combination O-H stretching 
2052  2048  2056  Combination O-H stretching 
2101 2102 2092   2099 Combination O-H stretching 
2109  2115  2117  Combination O-H stretching 
2141  2169  2143  Combination O-H stretching 
2167  2190  2171  Combination O-H stretching 
2186      Combination O-H stretching 
2230  2261 2208   Combination C-H stretching 
2295, sh 2285 2273   2286 Combination C-H stretching 
2332 2316, sh 2285 2344 2314 2320 Combination C-H stretching 
2371  2308  2352  Combination C-H stretching 
2401  2352 2405 2370  Combination C-H stretching 
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Table 6.1. (Continued) 
 
Potassium 
sorbate 
Sodium starch 
glycollate 
Calcium 
ascorbate 
Calcium 
carbonate 
Candelilla wax Maltodextrin Proposed assignment 
2446  2372  2387  Combination C-H stretching 
  2403    Combination C-H stretching 
  2427  2439  Combination C-H stretching 
2462 2490 2490 2462  2484  
 
6.3.2. Non-invasive in situ identification of lactose anhydrous and monohydrate 
     The NIR spectra of lactose anhydrous and monohydrate in the range of 800-2500 nm 
are shown in Figures 6.7 and 6.8 as an open powder and inside USP vials. Again, it can 
be noted that NIR spectra inside vials are almost identical with those obtained as open 
powders, with no loss of spectral quality.  
 
Figure 6.7. NIR spectra of lactose anhydrous obtained inside a USP vial and as an 
open powder. 
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 Figure 6.8. NIR spectra of lactose monohydrate obtained inside a USP vial and as 
an open powder. 
 
     An unknown lactose sample inside a USP vial was analysed using NIR spectroscopy, 
and could be identified as anhydrous lactose (Figure 6.9). NIR spectral wavelengths 
(nm) and proposed assignments for lactose anhydrous and monohydrate are presented in 
Table 6.2. 
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 Figure 6.9. NIR spectra of lactose monohydrate, anhydrous and unknown obtained 
inside a USP vial. 
 
     Despite some common spectral features between lactose anhydrous and 
momohydrate (Table 6.2), both forms were found to give rise to distinctive NIR 
patterns, which allow them to be readily and noninvasively identified inside USP vials 
through this spectroscopic technique. By careful inspection of Figures 6.7 and 6.8, it can 
be noted that the first overtone O-H stretching band at 1454 nm is characteristic of 
lactose monohydrate along with the O-H deformation combination band at 1934 nm, 
which is very strong in the lactose monohydrate NIR spectrum and weak in the lactose 
anhydrous NIR spectrum. It can be concluded that even the lactose anhydrous sample 
has absorbed some moisture, as indicated by the presence of the weak O-H deformation 
combination band at 1934 nm in the NIR spectrum of the anhydrous form; however 
NIR spectroscopy is still able to differentiate between the anhydrous and monohydrate 
forms of lactose. 
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Table 6.2. NIR spectral wavelengths, nm and proposed assignments for lactose 
anhydrous and monohydrate. 
 
Lactose 
anhydrous 
Lactose 
monohydrate 
Proposed assignment 
914 926 Third overtone C-H stretching 
1010 1040 Second overtone O-H stretching 
 1180, sh Second overtone C-H stretching 
1221 1207 Second overtone CH2 stretching 
 1268  
 1454 First overtone O-H stretching 
1475  First overtone O-H stretching 
 1536 Symmetric and antisymmetric stretching of water 
species with at least three hydrogen bonds  
1577   
1601, sh 1593  
1656  First Overtone C-H stretching 
1689 1690 First Overtone C-H stretching 
1699 1698 First Overtone C-H stretching 
1720 1719 First overtone of CH2 antisymmetric stretching 
1739 1731 First Overtone C-H stretching 
1784 1763 First Overtone C-H stretching 
1934 1934 Combination band between the fundamental stretching 
and deformation vibrations of the OH bond 
 1991  
2082, sh 2095 Combination O-H stretching 
2107 2123, sh Combination O-H stretching 
2265 2259 Combination C-H stretching 
 2280 Combination C-H stretching 
2292 2291 Combination C-H stretching 
2316 2318 Combination of  CH2 asymmetric stretching and 
bending vibrations 
2324, sh   
 2348 Combination of  CH2 symmetric stretching and bending 
vibrations 
 2361 Combination C-H stretching 
2371 2371 Combination C-H stretching 
2402  Combination C-H stretching 
2421 2421, sh Combination C-H stretching 
 2430 Combination C-H stretching 
 2479  
2489 2491  
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     NIR spectroscopy can be used in real time to follow the changes in the solid state, 
the onset of crystallization and the changes between different forms of lactose which 
accompany the onset of crystallization. The fact that NIR is non-invasive and that the 
spectra are measured in situ at room temperature in a rapid and easy manner, makes it 
very valuable tool to use in conjunction with other physical methods to study transitions 
in pharmaceuticals. There are significant advantages in the use of the NIR technique, 
which is isothermal at room temperature, over the use of differential scanning 
calorimetry where crystallization processes and transitions are induced due to heating, 
making it difficult to be certain of the properties of the starting material. 
 
6.4. Conclusions 
     The current work establishes that NIR spectra can be obtained noninvasively and 
rapidly through USP vials. Pharmaceutical excipients can be readily identified in situ by 
NIR spectroscopy, although several samples of different manufacturers and physical 
properties were studied. The discrimination of lactose anhydrous and monohydrate 
forms can be done reliably inside USP vials by studying the regions of the NIR 
spectrum corresponding to the combination and first overtone stretching frequencies of 
water. After clustering the NIR spectra of various samples, XRPD and complementary 
methods can be applied to the verification of the pharmaceuticals. This approach 
provides a timesaving improvement for the pharmaceutical analysis of excipients in the 
case of large number of samples. 
     Further studies will target to the construction of a spectral library of reference 
pharmaceutical materials using NIR spectroscopy as a rapid, non-invasive technique for 
the identification of compounds relevant to pharmaceutical preparations. 
 
7.1. Introduction 
     Polymorphism is the tendency of a substance to crystallise in different crystalline 
states. The solid forms of the same compounds are called polymorphs or crystalline 
modifications. Polymorphs show the same properties in the liquid or gaseous state but 
they behave differently in the solid state. The best known example of polymorphism is 
carbon, which can exist in the form of graphite or as diamond. 
     In the solid states, the atoms of a molecule may be arranged in one of seven 
fundamental crystalline forms: triclinic, monoclinic, orthorhombic, tetragonal, trigonal, 
hexagonal or cubic. The amorphous state is characterised by crystallisation in a non-
ordered, random system, related to the liquid state.      
     Differences in the morphological appearance of a substance do not necessarily reflect 
polymorphism. Crystallisation of the base cells may occur in three different directions. 
A compound can produce crystals with different morphologies (habits) without 
changing the crystalline structure by preferentially growing in different directions. 
     Like many other chemical compounds, however, certain hydrates (See section 3.3 for 
details) may themselves exhibit polymorphism, as in the case of fluprednisolone 
monohydrate, succinyl sulfathiazole monohydrate and nedocromil sodium monohydrate 
(Khankari and Grant, 1995). 
     Because all the physicochemical characteristics of the solid state are implied in 
polymorphism and pseudopolymorphism, the pharmaceutical industry is confronted 
with this behaviour. The main properties affected are melting and sublimation 
temperatures, heat capacity, conductivity, volume, density, viscosity, crystal hardness, 
crystal shape, colour, refractive index, solubility, dissolution rate, stability, 
hygroscopicity and solid state reactions. 
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     The effect of polymorphism on bioavailbility is the most important consequence if 
the bioavailability is mediated via the dissolution (Giron, 1995). The polymorphism of 
excipients (Giron, 1995) may also play an important role in bioavailability as 
demonstrated by the loss of bioavailability of suppositories due to polymorphic 
transformation of the excipient during storage. The process of transformation of one 
polymorph into another is a phase transition, which may occur also on storage or during 
processing. If the phase transition is reversible, the two polymorphs are enantiotropic. If 
the phase transition is irreversible, the two polymorphs are monotropic. 
     In the case of monotropy, the higher melting form is always the thermodynamically 
stable form. In the case of enantiotropy, the lower melting form is the 
thermodynamically stable form at temperatures below the transition point and the higher 
melting form is the thermodynamically stable form at temperatures above the transition 
point. 
     For enantiotropic polymorphs, the transition temperature is important since it defines 
the temperature at which the stability between the two forms becomes inverted. There 
are several methods currently available to experimentally determine or estimate this 
value (Hu et al., 2007; Zhang et al., 2002; Urakami et al., 2002; Tong et al., 2001; Gu 
and Grant, 2001; Wenslow et al., 2000; Carlton et al., 1996; Yu, 1995; Behme and 
Brooke, 1991; Lagas and Lerk, 1981; Kanke and Sekiguch, 1973). 
     The manufacture of different polymorphic forms, the determination of the stable 
modification and the knowledge of monotropy or enantiotropy are the initial studies in 
pre-formulation work.  
     Previously, simultaneous Raman spectroscopy and DSC have been used to study the 
solid state transition mechanisms of ammonium nitrate (Harju et al., 1991; Harju, 1993; 
Sprunt and Jayasooriya, 1997) and the structural polymorphs of the triglyceride 1,3-
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distearoyl-2-oleoylglyerol (Sprunt et al., 2000). However, to date, simultaneous Raman 
spectroscopy and DSC have not been used in investigations involving drug polymorphs 
and pharmaceuticals. 
     In this study, we have utilized both Raman and near IR spectroscopy to characterise 
and provide molecular structural information about salmeterol xinafoate polymorphs 
and certain sulfathiazole polymorphs (I and III) and we have monitored preliminarily 
the solid-state polymorphic conversion of salmeterol xinafoate polymorph I into 
polymorph II and sulfathiazole polymorph III into I using simultaneous in situ portable 
Raman spectroscopy and DSC to unambiguously characterise the polymorphic form of 
a sample analysed in situ. 
 
7.1.1. Salmeterol xinafoate (SX) 
     Salmeterol or [(RS)-5{1-hydroxy-2-[6-(4-phenylbutoxy)-hexylamino]ethyl}salicyl 
alcohol (Figure 7.1) is the first of a class of long acting β-adrenergic receptor agonists 
with both bronchodilator and anti-inflammatory actions. It is prepared as the 1:1 salt of 
salmeterol and 1-hydroxy-2-naphthoic acid (Martindale, 2005). 
ONH2C
OH
HO
H2
+
. OH
CO-2OH
 
 
Figure 7.1. The chemical structure of SX.  
      
     SX is known to exist in two crystalline polymorphic forms with form I being the 
stable and form II the metastable polymorph under ambient conditions (Beach et al., 
1999). These polymorphs have been characterized using differential scanning 
calorimetry, X-ray powder diffractometry,  thermogravimetric analysis and inverse gas 
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chromatography (Tong et al., 2001; Tong et al., 2003). Commercial SX is a micronized 
form with the same crystal structure as that of form I. However, the commercial drug 
can contain traces of the form II polymorph which is formed during the pharmaceutical 
manufacturing processes. 
 
7.1.2. Sulfathiazole (SZ) 
     The antibiotic drug sulfathiazole (N\-2-thiazolylsulfanilamide), Figure7.2, and its 
crystalline properties have been extensively described and studied since the 1940s 
(Apperley et al., 1999). SZ has been identified as a classic four polymorphic system by 
Burger and Dialer (Burger and Dialer, 1983). The structure of a fifth polymorph has 
only been recently determined (Hughes et al., 1997; Hughes et al., 1999). A number of 
different techniques have been used for the physical characterization of these 
polymorphic forms including thermal analysis, vibrational spectroscopy, X-ray and 
terahertz pulsed spectroscopy (Zeitler et al., 2006; Lagas and Lerk, 1981; Apperley et 
al., 1999; Burger and Dialer, 1983; Chan et al., 1999; Anwar et al., 1989; Aaltonen et 
al., 2003).   
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Figure 7.2. The chemical structure of SZ. 
 
7.2. Experimental 
7.2.1. Materials 
     SX polymorph I was obtained from Apin Chemicals Co., the polymorphic form 
being confirmed by PXRD. SX polymorph II was crystallized as a fine powder using a 
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Solution Enhanced Dispersion by Supercritical Fluids (Tong et al., 2001). Quantitative 
conversion from type I to type II polymorphic structures was confirmed by PXRD. 
     SZ form III was obtained from Alfa Aesar, Lancashire, UK. The polymorphic form 
was confirmed by PXRD. 
 
7.2.2. X- Ray powder diffractometry 
     PXRD patterns were recorded for SX and SZ samples with a Bruker D8 
diffractometer with Cu-Kα1,2 radiation (1.5418 Å) and a secondary curved graphite 
monochromator. The X-ray tube was operated at 40 kV, 30 mA. Samples were scanned 
in a vertical Bragg-Brentano (θ/2θ) geometry (flat reflection mode) from 5-40° (2θ) 
using a 0.005° step width and a 1.5 second count time at each step. The receiving slit 
was 1°and the scattering slit was 0.2°. 
 
7.2.3. Differential scanning calorimetry (DSC) 
     DSC profiles of SX and SZ were generated in the range of 0 to 150°C and 50 to 
220°C in the case of SX and SZ respectively by the use of TA instruments, DSC Q2000 
apparatus using the PCA mode with RSC90 cooling unit. Temperature calibration was 
performed using indium metal standard supplied with the instrument at the respective 
heating rate. Accurately weighed samples (1.5 – 2.5 mg) were placed in Tzero 
aluminium pans using similar empty pans as reference. A scanning speed of 10°C min.-1 
was employed. 
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7.2.4. Raman Spectroscopy 
     Raman spectra of both SX and SZ were obtained using a Renishaw portable Raman 
analyser RX210 ‘Raman-In-A-Suitcase’ (RIAS) equipped with a diode laser emitting at 
785 nm and a thermoelectrically cooled CCD detector (see section 2.8.1.2.4 for details). 
 
7.2.5. Near-infrared Spectroscopy 
     A Bruker Optics MPA FT-NIR spectrometer with an integrating sphere and auto- 
sampler along with a fibre optic powder probe was used for these measurements of both 
SX and SZ (see section 2.8.2.2 for details). 
 
7.2.6. The simultaneous in situ Raman –DSC method 
     An assembly of the fibre-optic coupled portable Raman spectrometer and DSC 
instrument was used (Figures 2.10 and 7.3) for the simultaneous in situ investigation of 
the solid-state polymorphic transformation of   SX form I to II and SZ form III to I (see  
section 2.8.5. for details). 
 
 
 
 
 
 
Figure 7.3. DSC head before optical access by the probe. 
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7.3. Results and discussion 
7.3.1. Salmeterol xinafoate  
7.3.1.1. X- Ray powder diffractometry 
     The PXRD patterns (Figure 7.4) show significant differences between the diffraction 
patterns of the two polymorphs which have been used to establish the solid-phase 
identity of these samples. 
 
Figure 7.4. The PXRD patterns of SX polymorphs I&II. 
 
7.3.1.2. Differential scanning calorimetry 
     The DSC sample arrangement has been modified to accommodate the fibre-optic 
probe; it is therefore important to compare the DSC data with and without 
encapsulation. Figure 7.5 shows that the onset melting points of 124°C for form I and 
138°C for form II are very similar for each form and agree well with the previously 
published data (Beach et al., 1999). 
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 Figure 7.5. DSC melting curves of SX, (-) for encapsulated and (- -) for 
unencapsulated specimens. 
 
7.3.1.3. Raman spectroscopy 
     Different polymorphs of the same molecule each have a different crystalline form 
and, hence, a unique Raman spectrum (Yu et al., 1998). Analysis of SX polymorphs I & 
II by Raman spectroscopy yielded spectra with excellent signal to noise ratios, with the 
two polymorphs exhibiting differences in both peak positions and intensities (see 
chapter 5 for details).  
 
7.3.1.4. Near infrared Spectroscopy 
     As NIR spectra arise, for the most part, from the overtone bands of fundamental 
groups containing C-H, O-H and N-H bonds, organic molecules with this functionality 
can be investigated using this approach. NIR spectroscopy can be an attractive option 
for the characterisation of the SX polymorphic system because of ease of sampling. The 
NIR spectra of SX polymorphs are shown in Figure 7.6. The wavelengths and proposed 
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assignments of the NIR bands are given in Table 7.1. From the NIR spectroscopic 
analysis carried out in the present work, there are several spectral bands present which 
can be used for the differentiation between polymorphic forms I and II of SX. The NIR  
spectral bands at 2393, 2364, 1743 and 1706 nm are characteristic of polymorph I, 
whereas bands at 2143, 2101, 2065, 1576 and 1501 nm are characteristic of polymorph 
II. There are several observed peak shifts from 2467, 2416, 2271, 2258, 2212, 2157, 
1757, 1723 and 1176 nm of polymorph I to 2460, 2408, 2280, 2265, 2219, 2161, 1752, 
1719 and 1181 nm of polymorph II, respectively. 
 
Figure 7.6. NIR spectra of SX (forms I and II). 
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Table 7.1. NIR spectral wavelengths/nm and proposed assignments for SX 
polymorphs I&II. 
 
 
Form I              Form II                                                   Proposed Assignment 
 
2477 m 2476 m Combination C-H stretching 
2467 m 2460 m Combination C-H stretching 
2416 w,sh 2408 w Combination C-H stretching 
2393 m - Combination C-H stretching 
2364 w - Combination C-H stretching 
2345 m 2343 m Combination C-H stretching 
2298 s 2301 s Combination C-H stretching 
2271 m,sh 2280 ms Combination C-H stretching 
2258 ms 2265 vw Combination C-H stretching 
2212 w 2219 vw Combination C-H stretching 
2188 m 2187 mw Combination N-H stretching, Combination O-H stretching 
2157 m 2161 m Combination N-H stretching, Combination O-H stretching 
- 2143 m Combination N-H stretching, Combination O-H stretching 
- 2101 w Combination N-H stretching, Combination O-H stretching 
- 2065 w Combination N-H stretching, Combination O-H stretching 
1757 w 1752 w First overtone C-H stretching 
1743 w - First overtone C-H stretching 
1723 w 1719 w First overtone C-H stretching 
1706 w,sh - First overtone C-H stretching 
1679 s 1678 s First overtone C-H stretching 
1646 w 1646 w,sh  
1634 w 1634 w,sh  
- 1576 w,br  
- 1501 w,br  
1408 w,br 1410 w,br First overtone N-H stretching, first overtone O-H 
stretching 
1389 w,br 1389 w,br Combination C-H stretching 
1199 w,br 1202 w,br Second overtone CH stretching 
1176 mw 1181 mw Second overtone CH stretching 
1142 m 1141 m Second overtone CH stretching 
 
 
7.3.1.5. The simultaneous in situ Raman –DSC method 
     The DSC melting curves for SX obtained simultaneously with the Raman spectra 
confirm the identity of each polymorph (Figure 7.5). Therefore, this provides an 
unambiguous assignment of the Raman spectrum to a certain polymorph.  
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     The polymorphic transformation from form I to form II was monitored in situ at the 
following temperatures 0, 50, 100, 110, 115°C and from 118 to 140°C at 1 degree 
interval. Typical spectral results are shown in Figures 7.7 and 7.8. Several changes in 
the collected spectra were observed during the thermal transformation of polymorph I to 
polymorph II, with the relative intensities and positions of a number of peaks changing. 
The Raman spectra of polymorph I change systemically with increasing temperature 
until the steady state is reached; at this stage the crystals are the identified as  
polymorph II. This was verified by X-ray powder diffraction patterns collected on the 
sample.  The detection of the difference can be accounted for in part by the baseline 
shifts due to the change in shape of the crystals during the conversion, as well from the 
inherent differences in polymorph I and II noted in the Raman spectral regions defined 
in Table 5.1. 
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Figure 7.7.Typical Raman spectra collected during conversion of SX polymorph I 
into polymorph II on heating at 115°C then from 118 to 130 °C at 1 degree 
interval, (500 cm-1 – 1650 cm-1). 
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     Figure 7.8.Typical Raman spectra collected during conversion of SX polymorph     
I into polymorph II on heating at 118, 119, 124 and 128°C. 
 
     The peak areas of in-plane δ (CCN) band at 578 cm-1, characteristic of form I and 
δ(CH) band at 1338 cm-1, characteristic of form II, (indicated by arrows in Figures 7.7 
and 7.8), have been plotted against the temperature degrees (Figure 7.9)  Clearly, 
Raman spectroscopy reveals that the polymorph I is the only form that presents from 0 
to 118°C, when it starts to melt and its characteristic peak at 578 cm -1 starts to 
disappear, at the same time the δ(CH) band characteristic of form II starts to appear at 
119°C  and reaches its maximum at 128°C after the complete melting of form I, then 
starts to decrease until the complete melting of form II is observed at 138 °C. Therefore, 
we can deduce that the transition temperature of the polymorphic conversion from form 
I to form II is ~119°C.  
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 Figure 7.9.Temperature dependence of the peak areas of SX polymorphs. 
 
     The two polymorphs are related enantiotropically (Tong et al., 2001), the lower 
melting form (form I) is the thermodynamically stable form at temperatures below the 
transition point and the higher melting form (form II) is the thermodynamically stable 
form at temperatures above the transition point (Giron, 1995). The transition 
temperature of this polymorphic system was previously reported using the van’t Hoff 
solubility-temperature plot as (~99°C) (Tong et al., 2001) and estimated from the DSC 
curve from a vigorously ground form I (~109°C) (Tong et al., 2001). This discrepancy 
in the estimation of the transition temperature from (~99°C) to (~119°C) is perhaps not 
surprising, considering the fact that neither technique is free from limitations or 
drawbacks. The solubility method has both experimental and theoretical constraints 
while the accuracy of the DSC technique is limited by its dynamic nature and the 
material-dependent resistance to solid-solid phase transitions at the transition 
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temperature. However, the combined approach of the current study using both DSC and 
Raman methods is the ideal complement to thermal analysis for correct interpretation of 
DSC thermal events. Changes of structure during the heating of the sample, for which 
no DSC thermal event is detectable, have been demonstrated in this combined DSC and 
Raman study as shown in Figures7.7 and 7.8. 
 
7.3.2. Sulfathiazole 
7.3.2.1. X- Ray powder diffractometry 
     The PXRD pattern (Figure 7.10) of form III has been used to establish the solid-
phase identity of the solid sample prior to the Raman/DSC experiments. 
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Figure 7.10. The PXRD pattern of SZ polymorph III. 
 
7.3.2.2. Differential scanning calorimetry 
     The onset melting points of 168°C for polymorph III and 202°C for polymorph I of 
SZ agree well with the previously published data (Anwar et al., 1989; Lagas and Lerk, 
1981; Zeitler et al., 2006) (Figure 7.11). 
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 Figure 7.11. DSC melting curve of SZ, shows the onset melting points of 168°C for 
polymorph III and 202°C for polymorph I. 
 
7.3.2.3. Raman spectroscopy 
     The Raman spectra of both polymorphs are shown in Figure 7.12. The wavenumbers 
and proposed assignments of the Raman bands are given in Table 7.2. 
     The strongest Raman bands of both polymorphs are the υ (SO2) and ring deformation 
modes at 1132, 628 and 1128, 629 cm-1 for the polymorphic forms III and I, 
respectively. Since the ring structure is relatively rigid, only a small shift was observed 
for the two different polymorphs. Polymorph I has one more strong band assigned to the 
δ (NH2) mode at 1595 cm-1. 
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 Figure 7.12. Raman spectra of SZ polymorphs III and I at 785nm. 
 
     Despite the common Raman spectral features (Table 7.2.); both forms under study 
were found to give rise to distinctive Raman spectral patterns, which allow them to be 
easily identified through this spectroscopic technique. Polymorph III is characterised by 
the in-plane δ(CH)ring band at 1290 cm-1, the δ(CH) band at 1175 cm-1, the out-of-plane 
δ(CH)chain band at 934 cm-1, the in-plane δ(CC)ring bands at 879 and 805 cm-1 and the 
out-of-plane (CCC) skeletal deformation band at 376 cm-1. Polymorph, I, in turn, is 
readily identified by the δ(NH2) band at 1630 cm-1, the υ (C=N) band at 1499 cm-1, the 
υas (SO2) band at 1317 cm-1, the in-plane δ(CC)ring band at 1007 cm-1, the in-plane 
δ(CH)chain band at 976 cm-1, the out-of-plane δ(CH)chain band at 921 cm-1, the out-of-
plane δ(CC)ring band at 780 cm-1 and the in-plane δ(CCC)ring band at 548 cm-1. These 
Raman spectral signatures can be attributed to the differences in intermolecular 
interactions and different modes of packing of the two crystalline polymorphs. 
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     Other features which exhibit the differences in the Raman spectra of the two 
polymorphic forms are bands shifts and splitting. The υas (SO2), aromatic ring vibration 
and out-of-plane δ(CH)ring bands are shifted from 1326, 1092 and 829 cm-1 in the 
spectrum of polymorph III to 1336, 1083 and 837 cm-1 in the spectrum of polymorph I, 
respectively. On the other hand, the band at 566 cm-1 in the spectrum of polymorph III 
is split into a doublet whose component bands are ~ 19 cm-1 apart in the spectrum of 
polymorph I; this feature can be attributed to the lowering of symmetry  and the 
decoupling of  a degenerate vibrational mode. 
     The low-frequency modes, arising largely from lattice vibrations, are very sensitive 
to structural changes in the solid-state. For example, the bands at 301 and 266 cm-1 in 
the spectrum of polymorph III are not observed in the spectrum of polymorph I, while 
the bands at 338, 314 and 288 cm-1 in the spectrum of polymorph I are not observed in 
the spectrum of polymorph III. In addition, the intensity of the skeletal mode band at 
213 cm-1 in the spectrum of polymorph III is substantially reduced and shifted to 207 
cm-1 in the spectrum of polymorph I. The spectral differences in this region between 
two polymorphs can be explained by the differences in the intermolecular interactions 
and differences in crystal symmetry in the two forms.  
     The present study has allowed the assignment of specific Raman features that are 
characteristic of each of the polymorphs III and I of SZ investigated. 
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Table 7.2. Raman spectral wavenumbers and proposed assignments for SZ 
polymorphs III&I. 
 
 
Polymorph III    Polymorph I                               Proposed Assignment 
 
 1630 w δ(NH2) 
1596 ms 1595 s δ(NH2) 
1569 vw 1570 sh,w Ring stretch 
1531 m 1530 mw  
 1499 w υ(C=N) 
1326 mw 1336 w υas (SO2) 
 1317 w υas (SO2) 
1290 w  In-plane δ(CH)ring 
1254 m 1250 mw In-plane δ(CH) 
1175 vw  δ(CH) 
1132 s 1128 s υ (SO2) 
1092 mw 1083 mw Aromatic ring vibration having some υ(C-S) character 
1070 mw 1072 sh,w In-plane δ(CC) 
 1007 vw In-plane δ(CC)ring 
 976 vw In-plane δ(CH)chain 
953 sh,m 959 vw  
934 m  Out-of-plane δ(CH)chain 
 921 w Out-of-plane δ(CH)chain 
879 vw  In-plane δ(CC)ring 
855 w 861 w  
829 mw 837 m Out-of-plane δ(CH)ring 
805 mw  In-plane δ(CC)ring 
 780 vw Out-of-plane δ(CC)ring 
731 m 734 mw NH wagging 
678 mw 682 m Out-of-plane δ(CCC)ring 
645 sh,ms 644 sh,w  
628 s 629 s Ring deformation 
566 mw 567 mw  
 548 mw In-plane δ(CCC)ring 
504 mw 503 w  
445 m 448 mw In-plane (CCC)chain skeletal deformation 
416 w 408 mw  
376 m  Out-of-plane (CCC) skeletal deformation 
349 m 353 w Out-of-plane (CCC) skeletal deformation 
 338 w  
 314 w  
301 ms   
 288 m  
266 w   
213 ms 207 w Skeletal mode 
179 m 
 
179 w  
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7.3.2.4. Near infrared Spectroscopy 
     The NIR spectra of both polymorphs over the wavelength range of 1100 to 2500 nm 
are shown in Figure 7.13. Both spectra appear complex, with more than 40 well-
resolved peaks being identified. The wavelengths and proposed assignments of the NIR 
bands are given in Table 7.3. NIR spectral bands at 2452, 2290, 2225, 2106, 1950, 
1928, 1911, 1865, 1644, 1562 and 1324 nm are characteristic of polymorph III, whereas 
bands at 2394, 2178, 1970, 1767, 1489, 1455, 1304, 1284, 1207 and 1184 nm are 
characteristic of polymorph I. There are several observed peak shifts from 2460, 2311, 
2197, 2141, 2092, 2035, 2013, 1818, 1743 and 1518 nm of polymorph III to 2466, 
2332, 2204, 2133, 2084, 2041, 2001, 1824, 1733 and 1524 nm of polymorph I, 
respectively. From the NIR spectroscopic analysis carried out in the present work, there 
are several spectral bands present which can be used for the differentiation between 
polymorphic forms III and I of SZ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Near-infrared spectra of sulfathiazole polymorphs III and I. 
 
 
 
 
 
 
 
 
Figure 7.13. NIR spectra of SZ polymorphs III and I. 
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Table 7.3. NIR spectral wavelengths/nm and proposed assignments for SZ 
polymorphs III&I. 
 
 
Polymorph III       Polymorph I                               Proposed Assignment 
 
2460 s 2466 s Combination C-H stretching 
2452 sh,s  Combination C-H stretching 
2397 s 2397 s Combination C-H stretching 
 2394 sh,m  
2378 ms  Combination C-H stretching 
2364 s  Combination C-H stretching 
2311 m 2332 w Combination C-H stretching 
2290 m  Combination C-H stretching 
2278 m 2281 ms Combination C-H stretching 
2258 m 2261 m Combination C-H stretching 
2225 mw  Combination C-H stretching 
2197 mw 2204 s Combination N-H stretching, combination O-H stretching 
 2178 m Combination N-H stretching, combination O-H stretching 
2165 m 2165 m Combination N-H stretching, combination O-H stretching 
2141 s 2133 ms Combination N-H stretching, combination O-H stretching 
2106 mw  Combination N-H stretching, combination O-H stretching 
2092 m 2084 ms Combination N-H stretching, combination O-H stretching 
2035 vs 2041 m Combination N-H stretching, combination O-H stretching 
2013 sh,s 2001 s Combination N-H stretching, combination O-H stretching 
 1970 vs  
1950 vw   
1928 vw   
1911 vw   
1882 vw 1885 vw  
1865 vw   
1818 w 1824 w  
1783 vw 1786 w First overtone C-H stretching 
 1767 vw First overtone C-H stretching 
1743 vw 1733 vw First overtone C-H stretching 
1709 w 1706 w First overtone C-H stretching 
1666 ms 1664 s First overtone C-H stretching 
1644 ms   
1637 s 1641 s  
 1629 s  
1562 s   
1518 mw 1524 s  
1503 mw 1502 s First overtone N-H stretching, first overtone O-H stretching 
 1489 sh,s First overtone N-H stretching, first overtone O-H stretching 
 1455 s First overtone N-H stretching, first overtone O-H stretching 
1395 w 1394 w Combination C-H stretching 
1324 w  Combination C-H stretching 
 1304 w Combination C-H stretching 
 1284 w  
 1207 w Second overtone C-H stretching 
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Table 7.3. (Continued) 
 
Polymorph III        Polymorph I                Proposed Assignment 
 
 1184 w Second overtone C-H stretching 
1135 w 1138 w Second overtone C-H stretching 
1115 w 1113 w Second overtone C-H stretching 
 
 
7.3.2.5. The simultaneous in situ Raman –DSC method 
     The polymorphic transformation from form III to form I was monitored in situ at the 
following temperatures 20, 50, 100, 150, 155°C,  160-178°C at 1 degree interval, 180, 
185, 190, and 195-205 °C also at 1 degree interval. Typical spectral results are shown in 
Figures 7.14 and 7.15. Several changes in the collected spectra were observed during 
the thermal transformation of polymorph III to polymorph I, with observed changes to 
the relative intensities and positions of a number of peaks. The Raman spectra of 
polymorph III change systematically with increasing temperature until the steady state 
is reached; at this stage the crystals are the identified as  polymorph I. This was verified 
by X-ray powder diffraction patterns collected from the sample.  The detection of the 
difference depends upon the inherent differences in polymorphs III and I noted in the 
Raman spectral regions defined in Table 7.2. 
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Figure7.14. Typical Raman spectra collected during conversion of SZ polymorph 
III into polymorph I on heating at 150, 155°C then from 160 to 176 °C at 1 degree 
interval, (250cm-1 – 1700 cm-1). 
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Figure7.15. Typical Raman spectra collected during conversion of SZ polymorph 
III into polymorph I on heating at 150, 168 and 170°C. 
 
     The main differences between the polymorphs of SZ lie in the hydrogen bonding and 
its effects on the arrangement of the molecules in the crystals (Kruger and Gafner, 
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1972). Single crystal structures (Kruger and Gafner, 1972) show the hydrogen bonding 
schemes for SZ polymorphs III and I, imine nitrogen (C7=N) is not involved in the 
hydrogen bonding of polymorph III but it is in that of polymorph I. The appearance of 
the band at 1499 cm-1 in polymorph I is attributed to a shift to lower wavenumber (from 
1531 cm-1 in polymorph III) of the υ (C7=N) bond (Lin-Vien et al., 1991) 
corresponding with this change in the hydrogen bonding for polymorph I (Figure  7.12). 
  
     The peak areas of the out-of-plane (CCC) skeletal deformation band at 376 cm -1, 
characteristic of polymorph III and the υ(C7=N)  band at 1499 cm-1, characteristic of 
polymorph  I, (indicated by arrows in Figures 7.14 and 7.15), have been plotted against 
the temperature degrees (Figure 7.16). Clearly, Raman spectroscopy reveals that 
polymorph III is the only form that presents from 20 to 150°C, when it starts to melt and 
its characteristic peak at 376 cm -1 starts to disappear; at the same time, the υ (C7=N) 
band characteristic of polymorph I then starts to appear and reaches its maximum at 
170°C after the complete melting of polymorph III, then starts to decrease gradually 
until the complete melting of polymorph I is observed at 202 °C. Therefore, we can 
deduce that the transition temperature of the polymorphic conversion from form III to 
form I is ~160°C.  
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Figure 7.16. Temperature dependence of the peak areas of SZ polymorphs III and 
I. 
 
     The two polymorphs are related enantiotropically (Lagas and Lerk, 1981). The 
transition temperature of polymorph III to I was previously reported using dissolution 
studies as (~103°C) (Lagas and Lerk, 1981) and estimated from the DSC curve as 
between (105-170°C) (Lagas and Lerk, 1981). Again, this discrepancy in the estimation 
of the transition temperature from (~103°C) to (~170°C) is perhaps not surprising as 
mentioned earlier. However, the combined approach of the current study using both 
DSC and Raman methods is the ideal complement to thermal analysis alone, so it is 
possible to obtain a complete picture of the chemical and physical changes occurring in 
the thermal process of conversion from polymorph III to polymorph I, as shown in 
Figures 7.14 and 7.15. 
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7.4. Conclusions 
     From the Raman and NIR spectroscopic analysis carried out in the present work it is 
possible to identify the characteristic spectral bands of SX polymorphs (I and II) and SZ 
polymorphs (III and I). The combination of the two techniques removes ambiguity from 
the data collected from the two separate techniques. This is due to the complementary 
nature of the two spectroscopies, which allows for the production of a complete 
characterisation of the chemical composition of pharmaceutical materials.  
 
     At the same time, the methodology described here provides a simple easy-to-use 
technique for on-line monitoring and determination of the transition temperature when a 
polymorphic conversion in the solid state is complete. An unambiguous assignment of 
the SX and SZ spectra to the appropriate form is thus facilitated. This system will also 
be of utility when there are several phase changes within a wide temperature interval. 
Use of the fibre-optic probe improves the versatility of the system by allowing 
conventional DSC analysis. Further use for the method could be demonstrated in other 
pharmaceutical and polymer research, where samples in some cases are unique, and 
parallel measurements do not give reliable results. The minimum need for sample 
preparation in Raman spectroscopy also makes it suitable for measurements where the 
high purity of the samples is essential. 
 
     The advantage of Raman spectroscopy over other analytical techniques lies in its 
ability to monitor in situ the progress of the phase transformation between polymorphs 
which can allow a better understanding of such transformations and so enabled 
improved control of processes such as the isolation and drying of crystalline 
pharmaceutical materials. In situ measurements avoid running the reaction separately 
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from an off-line analytical evaluation and having to transport the reacting samples for 
analysis, during which samples may undergo further phase transformation. On the basis 
of the insight provided by Raman spectroscopy coupled with an in situ immersion probe 
and DSC, we are able to efficiently monitor the polymorphic transformation of SX and 
SZ over a relatively wide range of temperature degrees in the solid state. 
 
     Further studies should address the methodology of the quantitative investigation of 
the polymorphic transformation of SX polymorphs and qualitative and quantitative 
investigation of the all other known polymorphic forms of SZ using simultaneous in situ 
Raman spectroscopy and DSC. This aspect could be examined using the Raman data of 
this study.    
 
8.1. Conclusions 
     The main goal of this research project was the evaluation of the potential and 
suitability of vibrational spectroscopic techniques (Raman, FT-IR and FT-NIR 
spectroscopy) as tools for the solid-state characterisation of several drugs used in the 
management of certain respiratory disorders. The Raman spectra of budesonide, 
terbutaline hemisulphate, ipratropium bromide and salmeterol xinafoate polymorph II 
were reported for the first time. The results have highlighted the power of these 
techniques to generate reproducible low noise spectra. However, the spectra produced 
are complicated for certain drugs owing to their chemical composition. Spectral and 
structural characteristics are not readily apparent upon simple visual examination. 
Quantum chemical calculations have been shown to offer the potential to improve 
understanding of the structural properties of solid-state pharmaceuticals and be a vital 
aspect of a fundamental spectral assignment approach. In this way it should be possible 
for quantum chemistry to assist quality control development in the same way that it has 
facilitated drug discovery for many years. The dependence of the Raman spectra of 
salmeterol xinafoate polymorphs upon the laser excitation wavelength was highlighted. 
It has been shown that NIR spectra can be obtained noninvasively and rapidly through 
USP vials. Pharmaceutical excipients can be readily identified in situ by NIR 
spectroscopy, although several samples from different manufacturers and materials with 
different physical properties were used. NIR spectroscopy has been shown to be an 
effective tool for the characterisation and differentiation of salmeterol xinafoate 
polymorphs and two polymorphic forms of sulfathiazole. The use of simultaneous in 
situ Raman spectroscopy and differential scanning calorimetry for the preliminary 
investigation of the solid-state polymorphic transformation of certain pharmaceutical 
systems has been presented, thus providing a new method for the solid-state estimation 
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of the transition temperature of the enantiotropically related pharmaceutical 
polymorphs. This methodology represents the first analytical record reported for the 
simultaneous in situ use of portable Raman spectroscopy and differential scanning 
calorimetry for the investigation of pharmaceutical polymorphic systems.  
 
8.2. Further work   
     The use of vibrational spectroscopy in conjunction with quantum chemical 
calculations for the solid-state characterisation of pharmaceuticals has considered a 
limited number of drugs used in the management of certain respiratory disorders but 
from different chemical entities, therefore, further work should be carried out to include 
a larger volume of pharmaceutical compounds from different chemical and 
pharmacological groups to allow a better understanding of relevant pharmaceutical 
systems.   
     The combined approach of the current study using both DSC and Raman methods is 
the ideal complement to thermal analysis alone for the correct interpretation of the DSC 
thermal events and provides a simple easy-to-use technique for on-line monitoring and 
determination of the completion of polymorphic conversion in the solid state. Changes 
of structure during the heating of the sample, for which no apparent  DSC thermal event 
is detectable, have been demonstrated in this combined DSC and Raman study so it is 
possible to obtain a complete picture of the chemical and physical changes occurring in 
the thermal process of conversion of the polymorphic forms of specified drugs. An 
unambiguous assignment of the drug spectra to the appropriate form is thus facilitated. 
This system will also be of use for structural studies when there are several phase 
changes occurring within a wide temperature interval. Further use for the method could 
be demonstrated in pharmaceutical and polymer research, where samples in some cases 
 179
 180
are unique, and parallel measurements do not give reliable results. Current work has 
only concentrated upon a qualitative polymorphic conversion and in the future, 
quantitative investigation of the polymorphic conversion should be considered. This 
approach is recommended for further work regarding pharmaceutical polymorphic 
systems since it is non-destructive and for which minimal or no sample preparation is 
required, particularly where maintenance of high sample purity is essential. 
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